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Chapter 1. General Introduction 
Introduction to the Problem 
Bovine respiratory syncytial virus (BRSV) is a common and economically important 
agent of respiratory disease in cattle. Infection with BRSV alone can induce acute 
respiratory disease, and it is one of several pathogens that can be involved in the bovine 
respiratory disease complex; others include bovine herpesvirus 1, bovine viral diarrhea virus, 
parainfluenza virus 3, bovine coronavirus, Mannheimia haemolytica, Pasteurella multocida, 
and Hemophilus somnus. Young calves are particularly susceptible to such respiratory 
infections. Vaccines against BRSV and the other pathogens have been routinely used in beef 
and dairy herds for decades, but large economic costs are still associated with respiratory 
diseases of calves. The study of BRSV has added significance because of the virus' strong 
similarities with human respiratory syncytial virus (HRSV), a prevalent pathogen of infants. 
Immunization against HRSV presents significant problems because of disease-causing 
tendencies of early vaccines, and it has been proposed that BRSV infection in cattle can serve 
as a valuable research model for HRSV. 
Immunological studies of bovine viruses and vaccines have traditionally concentrated 
on the humoral immune response. Assays for antibodies are relatively simple and cost-
effective by nature, whereas analysis of adaptive cell-mediated immune responses is 
complicated by the biology of T cells and other leukocytes. New methods of testing cell-
mediated responses have been adapted in recent years for use in veterinary species. As a 
result, there is now a greater appreciation for the importance of T cells in immunity against 
viral pathogens of cattle, such as BRSV. However, there is much room for improvement in 
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the availability of efficient, informative assays of T cell activity, both for basic research and 
for designing and evaluating vaccines. 
Aims of the Present Studies 
A broad goal of the work presented in this dissertation was to gain a fuller 
understanding of how different subsets of T cells can be primed against BRSV and a 
candidate vaccine vector for recombinant BRSV vaccines. An assay was previously 
developed in our laboratory that measured recall responses to viral antigens in vitro by using 
flow cytometry to detect CD25 upregulation on major T cell subsets. This technique was 
used and refined extensively during the studies described here. The first experiment 
described in this dissertation addressed whether or not T cell memory against BRSV can 
exist in calves that do not have detectable titers of antibody to the virus. The second 
experiment described in the dissertation tested the hypothesis that modified-live and 
inactivated BRSV vaccines from commercial sources differ in their ability to prime CD4, 
CDS, and yd T cells against the virus. A third project was carried out to characterize the T 
cell stimulatory properties of modified vaccinia virus Ankara (MVA), a candidate vector for 
recombinant BRSV vaccines. In the fourth project, the hypothesis from experiment 2 was 
revisited in greater depth by further analyzing T cell responses to BRSV in seropositive 
calves receiving polyvalent modified-live virus or inactivated virus vaccines. This was 
facilitated by improvements to the flow cytometry assay that enabled more precise 
determination of cell phenotypes, and by using an enzyme-linked immunoassay (ELISA) for 
interferon-Y production. 
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Dissertation Organization 
Chapter 2 of the dissertation is a literature review of prior BRSV research and of 
relevant T cell biology. Characteristics of the virus, pathogenesis of BRSV-induced disease, 
immune responses to infection, and immune responses to vaccines are discussed in the 
review. Chapter 3 is a paper submitted to the Journal of the American Veterinary Medical 
Association. It is an extension of the literature review, written for an audience of veterinary 
researchers and professionals. The Ph.D. candidate was primarily responsible for gathering 
references and writing the review paper, and the major professor was the author for 
correspondence. Chapter 4 is a paper that was published in Veterinary Immunology and 
Immunopathology (84: 111-123). The Ph.D. candidate was the primary researcher and 
author, and the major professor was the author for correspondence. Chapter 5 is a paper that 
has been accepted for publication in Veterinary Immunology and Immunopathology. The 
Ph.D. candidate was the primary researcher and author, and the major professor was the 
author for correspondence. Chapter 6 is a paper submitted to Viral Immunology. The Ph.D. 
candidate was primarily responsible for performing experiments and authoring the 
manuscript. The second author participated in the preparation of viruses and in the 
development of the flow cytometry assays that were utilized. The major professor was the 
author for correspondence. Chapter 7 is a paper that will be submitted to Veterinary 
Immunology and Immunopathology. The Ph.D. candidate was the primary researcher and 
author, and the major professor was the author for correspondence. 
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Chapter 2: Literature Review of Bovine Respiratory Syncytial Virus 
Characteristics of the Virus and the Disease 
Bovine respiratory syncytial virus (BRSV), a pneumoviras of the Paramyxoviridae 
family, is one etiologic agent of the bovine respiratory disease complex \ As a 
paramyxovirus, BRSV is enveloped and has a negative-sense RNA genome. Human 
respiratory syncytial virus (HRSV) is a closely related virus2, also classified in the 
Pneumovirus genus. Infections by BRSV and HRSV are similar with respect to epidemiology 
and disease3. 
Attachment of respiratory syncytial viruses to respiratory tract epithelial cells is 
thought to be mediated by the major glycoprotein (G), which is located in the viral envelope. 
Cellular heparin molecules were shown to be essential receptors for G-mediated attachment 
of HRSV 4. Additionally, Tripp et al reported that a cysteine signature motif (CX3C) in G 
facilitates virus binding through its interaction with chemokine receptor CX3CR15. Since 
chemokine receptors are not normally expressed on epithelial cells, this interaction is more 
likely to be significant in leukocyte activity during the immune response than in the infection 
of respiratory tract epithelial cells. The fusion glycoprotein (F) facilitates fusion of an RSV 
envelope with the host cell and formation of syncytia among adjacent cells6'7. The small 
hydrophobic (SH) glycoprotein is another constituent of the envelope. Recent reports have 
added complexity to the known roles of the envelope glycoproteins in the infection process. 
An HRSV deletion mutant lacking G and SH replicated well in vitro, though it was 
attenuated in vivo according to human clinical experiments 8. BRSV mutants in which G or 
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SH were deleted by reverse genetics also proved competent to replicate in cell culture 9. It 
was further shown that F glycoprotein, in both HRSV and BRSV, binds to 
glycosaminoglycans, such as heparin, indicating that F participates in the attachment of 
virions to cells. For BRSV it was also reported that F-mediated cell fusion is optimized in the 
presence of G and SH1. 
BRSV infects respiratory tissues, and severe disease typically coincides with viral 
replication in the lower respiratory tract. In situ hybridization demonstrated BRSV 
replication in tracheal, bronchial, bronchiolar, and alveolar epithelial cells of naturally 
infected calves 10. The same study reported extensive syncytia in the bronchiolar epithelium 
and alveolar epithelium, but this contradicts a larger study of 32 naturally infected calves, in 
which syncytial cells were rare 11. New insight into RSV life cycle and tropism may be taken 
from an HRSV study that utilized a primary airway epithelial cell culture system that 
supports growth of a well-differentiated pseudostratified mucociliary epithelium u. In this 
system, inoculation on the apical surface was essential for infection, and epithelial cells were 
susceptible only after having differentiated to a ciliated form. Virus was shed exclusively 
from the apical surface, then spread with the aid of cilial beating. 
Ten genes, each encoding a unique protein product, occur in the BRSV genome 13. 
The functions of these genes in the life cycle of BRSV are thought to contribute to a 
replication program that is characteristic of negative-sense RNA viruses in general13. The 
genes encoding non-structural proteins 1 and 2 (NS1 and NS2) are unique to respiratory 
syncytial viruses, and may have special relevance to BRSV immunity. It was shown that the 
two gene products cooperatively suppress the antiviral effects of type I interferons, and the 
deletion of either gene causes attenuation in MDBK cell culture 14. 
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Genetic and antigenic diversity are important factors in understanding BRSV 
evolution and transmission, and in the effective design of immunization strategies. The 
subject has been explored in several studies. The attachment protein (G) displays more 
genetic variability than the other BRSV proteins 15. Its ectodomain contains two highly 
variable regions that flank a conserved, immunodominant sequence thought to be important 
for interaction with receptors 13. Other BRSV genes, such as F (fusion) and N 
(nucleoprotein), also accumulate sequence changes, but their evolution is more limited by 
structural constraints 15. Geographic clustering is a factor in sequence variability16, and there 
can also be variability from one outbreak to the next in a closed herd17. One study showed 
evidence that the evolution of G, F, and N sequences accelerates in countries where BRSV 
vaccination is widely adopted 15. Researchers have studied whether the global BRSV 
phytogeny splits into major subgroups, as is seen with HRSV subgroups A and B. Nucleotide 
sequences in BRSV isolates fall into distinct phylogenetic branches, distinguishable mostly 
by the divergent properties of their G proteins 15'16. The variation among these branches is 
similar to that within each HRSV subgroup, leading at least one research group to conclude 
that all BRSV strains belong to a single genetic and antigenic group 16. It remains to be 
determined how well divergent strains of BRSV can cross protect against one another. One 
BRSV strain primed partial protection against challenge by a strain with significant genetic 
and antigenic differences in G, and a secondary antibody response to the dissimilar region 
was observed 18. 
BRSV can cause a broad range of disease severity. Cattle frequently undergo 
subclinical infection, but severe pneumonia also occurs, sometimes causing death 19. 
Characteristic signs of the acute disease include nasal and ocular discharge, fever, cough, and 
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shortness of breath 19. Young calves are particularly susceptible to BRSV outbreaks, which 
typically arise in the winter months2. Cattle with past exposure to the virus gain a measure of 
resistance, but it is common for individuals to have subclinical or mild re-infections20. 
Primary BRSV lung lesions in calves are often secondarily infected with bacteria, such as 
Hemophilus somnus and Mannheimia hemolytica, which typically enhance clinical disease 21. 
Gross examination of BRSV -infected lungs typically reveals interstitial pneumonia 
and widely distributed edema and emphysema20. At the histologic level, the usual pattern 
involves bronchointerstitial pneumonia, bronchiolitis, syncytial cell formation, and viral 
antigen in the cranioventral region. Viral antigen can be detected by immunohistochemistry 
20 or immunofluorescence 11. Necrosis and hyperplasia of the airway epithelium are common 
20
. Alveolar edema and interstitial emphysema occur throughout the lung, and are most 
prominent in the dorsal lobes, where virus replication is not usually evident. This points to a 
significant role for inflammatory mediators in BRSV pathogenesis, and some studies have 
provided clues as to host factors that may be involved. There is evidence that complement is 
activated by BRSV-infected cells (independently of specific antibody)22, and that 
complement component C3 is deposited in infected portions of lungs from naturally infected 
calves23. Signs of mast cell degranulation and of histamine release, extending outside the 
virus-positive areas, were associated with C3 detection in the same lungs. Another study 
revealed high levels of TNF-a in BAL fluids of experimentally infected calves at days 6 and 
7 post-infection24. Lesion severity and virus titers also peaked near that time, making it 
unclear whether the net effect of TNF-a was protective or pathogenic. 
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BRSV Immunity 
Innate Immune Response 
Surfactant proteins (SP) are early respiratory tract defenses against respiratory 
syncytial viruses. These molecules are produced by airway and alveolar epithelial cells. 
Recent genetic studies showed the importance of SP-A and SP-D in the outcome of human 
infection with HRSV 25,26. In vitro experiments demonstrated that SP-A can neutralize HRSV 
by binding to F 27 and opsonize HRSV uptake by phagocytes28. 
Respiratory syncytial virus infection of epithelial cells induces expression of 
numerous genes that encode pro-inflammatory mediators. The finding that BRSV's NS1 and 
NS2 gene products cooperatively suppress IFN-a and -j3 activity (mentioned above)14 
indicates that type I interferons (IFN) are potent enough to exert evolutionary pressure on 
BRSV, and suggests that infected cells of the bovine respiratory tract cannot use the antiviral 
activity of type I IFN efficiently. However there is evidence from mouse experiments that 
type I IFN signaling through STAT-1 is vital to the formation of a protective, Thl-biased 
immune response to HRSV29. Also in mouse models, HRSV infection has been shown to 
induce the expression of IL-8 and RANTES by pulmonary epithelial cells30"34. These are 
turned on by signaling pathways that lead to nuclear factor-xB (NF- KB) and activator 
protein-1 (AP-1) translocation. 
Non-adaptive recognition via CD 14 and toll-like receptors (TLR) was reported with 
HRSV before any other virus 35. Gene knockout experiments demonstrated that CD14 and 
TLR-4 were required for mouse macrophages to release IL-6 in response to HRSV F protein 
(as was also true for the response to lipopolysaccharide). Virus clearance in TLR-4-deficient 
mice was delayed significantly. In another study, TLR-4 function was associated with several 
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parameters of innate immunity in the murine response to HRSV36. TLR-4-deficient mice had 
impaired natural killer (NK) cell and CD14+ cell trafficking to the lung, diminished NK cell 
cytotoxity, and diminished IL-12 expression by BAL cells. None of these deficiencies were 
apparent in identical mice responding to influenza virus infection. 
There is evidence that several types of innate immune cells are important in the 
response to respiratory syncytial viruses. Alveolar macrophages in lavage fluids from HRSV-
infected children expressed interleukin-1/3 and tumor necrosis factor37. TNF-a inhibits 
HRSV replication38. These facts seem consistent with the restricted BRSV replication 
reported in bovine alveolar macrophages39, but it has also been reported that BRSV inhibits 
alveolar macrophage functions 40. During the course of experimental BRSV infection in 
calves, there was evidence of neutrophils playing a major role in clearing virus from the 
lumen of the respiratory tract41. As early as day 2 post-infection, neutrophils were seen 
migrating across the bronchial epithelium, into the lumen. Substantial amounts of BRSV 
antigen could be detected in neutrophils on several subsequent days. It has recently been 
theorized that eosinophils supply innate defenses against single-stranded RNA viruses 42. The 
proposed defense mechanism is attributed to ribonucleases like eosinophil-derived 
neurotoxin (EDN) and eosinophil cationic protein, which have undergone evolutionary 
diversification that might correspond to the evolution of RNA viruses. Experiments with 
HRSV lent support to this theory. Human eosinophils, as well as recombinant EDN alone, 
reduced HRSV infectivity in vitro except when ribonuclease activity was inhibited. 
NK cells play critical direct and indirect roles in protecting mice against HRSV. At an 
early stage in infection (day 4), NK cells were the most prominent EFN-y-producing cell 
population in the lungs 43. Strong cytotoxicity toward infected cells was also observed in the 
same cell population. NK cells probably exerted another direct effect on virus replication 
because IFN-7 mediates antiviral activity toward HRSV in human epithelial cells via the 2'-5' 
oligoadenylate synthetase / RNAse L pathway 44. Additionally, early NK cell accumulation 
and DFN-y production in the lungs was correlated with subsequent accumulation of CD8+ T 
cells, suggesting that NK cells might modulate the adaptive immune response 43. The natural 
killer T cell population evidently has a similar role in mouse HRSV infection 45. Mice 
deficient in NK T cells had diminished CD8+ T cell recruitment to the lungs and delayed 
virus clearance. 
Humoral Immune Response 
Serological surveys have shown high percentages of BRSV-seropositive cattle in 
many areas of the globe20. Most calves receive significant levels of BRSV-specific maternal 
antibody in colostrum. Passive antibody to BRSV does not prevent infection but can lessen 
the incidence and severity of disease 46,47. Titers of passive antibody to BRSV typically 
decline to the point of being undetectable by approximately six months of age48, decaying at 
a half-life of approximately 27 days 49. 
The active humoral immune response to BRSV infection involves the production of 
both mucosal and systemic antibody50. IgA and IgM were demonstrated as the dominant 
isotypes of BRSV-specific antibody in the lung, nose, and eye of calves after primary or 
secondary infection. The same two isotypes were the first detected in serum after primary 
infection, followed by more stable titers of IgGl and IgG2. Secondary infection led to 
increases in serum IgGl and IgG2 and a new, more sustained presence of serum IgA. A 
correlation was observed between the speed of antibody appearance and virus clearance. 
Epitope mapping has identified several antibody epitopes within the F protein, including 
some that have been characterized as neutralizing and/or targets of fusion-inhibition51'52. The 
advantage of certain antibodies against F was demonstrated in gnotobiotic calves treated with 
one of three F-specific monoclonal antibodies prior to challenge53. The two neutralizing, 
fusion-inhibiting monoclonal antibodies suppressed viral replication, syncytia formation, and 
pneumonic consolidation in lungs, whereas the non-neutralizing antibody provided no 
protection. 
The fact that recovery from BRSV infection does not prevent recurrences suggests 
that adaptive immunity is induced inconsistently, immunologic memory declines over time, 
or cross-reactivity among strains is incomplete. One cause of weak active immune responses 
is the presence of passive maternal antibodies during infection at an early age. A study 
comparing antibody responses to experimental BRSV infection in colostrum-fed versus 
colostrum-deprived calves was reported50. Calves that had passive, maternal IgG titers due 
to colostrum feeding showed little or no primary antibody response. They mounted 
significant systemic and mucosal responses to secondary infection but antibody titers were 
still lower than those in colostrum-deprived calves. 
Cell-Mediated Immune Response 
Numerous studies have indicated that cell-mediated immunity is critical to BRSV 
immunity, with a particularly important role evident for CD8+ T cells 20. Early evidence for a 
cell-mediated immune (CMI) response to BRSV came from delayed-type hypersensitivity, 
lymphocyte migration inhibition, and lymphocyte blastogenesis assays performed on cells 
from experimentally infected calves 54,55. Immunoperoxidase labeling was later used to 
quantify lymphocyte subsets in the lungs of BRSV-infected calves 56,57. An influx of CD4+, 
CD8+, and gamma delta T cells was observed. T-lymphocyte subsets occurred in similar 
ratios throughout lung tissues, with CD8+ T cells typically making up a majority. In lung 
tissues of noninfected calves CD8+ T cells were a minority. Flow cytometric analysis in 
another study showed that the ratio of CD8+:CD4+ lymphocytes in calves undergoing 
infection shifted approximately from 1:1 to 3:1 in both the peripheral blood and the lung58. 
The CD8+:CD4+ ratio shifted from 1:1 to 6:1 in tracheal tissues. While the pulmonary T cell 
population increased, the proportions of CD4+ and CD8+ cells in the bronchial lymph nodes 
were somewhat diluted by the immigration of B cells. 
Expression of surface markers CD45R (high molecular weight CD45 isoform), 
CD45RO (low molecular weight isoform), and CD25 on CD8+ cells in these infected calves 
suggested a tendency for conversion to activation and memory58. In bronchial lymph nodes 
and lungs the percentage expressing CD45RO increased modestly. By day 15 post-infection, 
lung CD8+ cells expressing CD45RO outnumbered those expressing CD45R, and in some 
cases the isoforms were coexpressed. CD8+ T-cell phenotyping in cattle has shown that CTL 
precursors fall into both the CD45RO+ and CD45RCT populations59. Downregulation of L-
selectin expression on CD8+ lymphocytes was not apparent during BRSV infection, which 
agrees with earlier research showing that bovine memory T cells are predominantly L-
selectin"60. The low proportion of blood, lung, and bronchial lymph node CD8+ cells 
expressing CD25 increased with BRSV infection, so that nearly half of lung CD8+ cells 
expressed CD25 on day 5 58. 
An experiment was carried out in which monoclonal antibodies against individual 
subset markers were used to deplete calves of CD4+, CD8+, or WC1+ gamma delta T cells, 
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and results were reported in two publications 56,57. Depletion of CD8+ T cells led to more 
severe respiratory epithelial lesions upon infection56. Lesions in the CD8+-depleted 
individuals were consistent with persistent viral replication. Viral antigen was most extensive 
in these calves' lungs. 
It was also reported that MHC class I-restricted CD8+ cytotoxic T lymphocytes (CTL) 
specific for BRSV appear in the peripheral blood and lungs of calves within 10 days of 
infection61. Cross reactivity between BRSV strains was demonstrated in the CTLs. Detection 
of CTL occured at about the same time post-infection that Mclnnes et al58 observed 
increased CD8+ cells in lungs, blood, and the trachea. 
Helper T cell activation would be predicted to accompany CD8+ effector cell 
activation. The significance of the CD4+ T cell subset in immunity to BRSV was illustrated 
in the same lymphocyte depletion study that demonstrated the dominant role of CD8+ cells 
56,57
. Calves depleted of CD4+ T cells had suppressed antibody responses. The duration of 
infection in these calves was normal, but their lungs had more extensive pneumonic 
consolidation57. 
Mclnnes et al, the group that analyzed CD8+ T cell activation and migration to the 
airways after BRSV infection, also studied CD4+ lymphocytes during infection58. These data 
showed more distinct modulation of activation and memory markers in CD4+ than in CD8+ 
cells, despite a reduced influx of CD4+ cells into lungs and trachea. Previous work in cattle 
showed that the CD45RO+ population is responsible for the CD4+ subset's memory response 
59
. Evidence for this included the detection of antigen-specific proliferation, IFN-y and IL-4 
transcription, and IFN-y production solely in the CD45RO+ population. In lungs and 
bronchial lymph nodes following BRSV infection, the number of CD4+ cells expressing 
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CD45R decreased, while CD45RO expression increased significantly by day 10 post­
infection 58. L-selectin expression was downregulated on CD4+ cells in the BLN and lungs of 
infected calves, which is interesting since work by Howard et al cast doubt on L-selectin as a 
marker of bovine CD4+ T cell memory 60. Expression of CD25 in CD4+ cells, similar to that 
in CD8+ cells, was upregulated in infected calves and peaked by day five post-infection in the 
lungs and BLN. Together, these findings illustrate the involvement of CD4+ T cells in the 
CMI response to BRSV, and fit within the helper role. 
CD4+ T-cell epitopes were identified in the F and G proteins of BRSV, using an assay 
in which PBMC were stimulated with synthetic peptides62. Lymphocyte proliferation was 
assayed in response to these stimuli. Multiple epitopes in the F1 region of F protein could be 
recognized in the context of diverse MHC class II haplotypes, and some of these 
corresponded with HRSV epitopes recognized by human T cells. Proliferative responses to 
epitopes from BRSV G protein were weak, with the only detectable responses directed 
toward sequences from the more conserved cytoplasmic region. 
T helper responses influence important events such as isotype switching, macrophage 
activation, and the induction of CTL activity. These are critical not only in promoting 
clearance of a pathogen, but also in numerous pathogenic mechanisms such as IgE-mediated 
and delayed-type hypersensitivity. Immunity and immune-mediated disease are often 
sensitive to the differential activation of T helper subsets 1 and 2. Thus the activity of the 
CD4+ T cell subset is probably an important determinant in the outcome of BRSV infection 
or vaccination. The following studies were undertaken to characterize cytokine patterns in 
cattle infected with the BRSV. 
Several key cytokines (IFN-y, IL-2, IL-4, and IL-10) were assayed by RT-PCR in 
mononuclear cells from BRSV-infected and control calves63. This study was aimed at 
characterizing the helper T cell response to BRSV seven days after infection. Messenger 
RNA for IFN-y was observed in pulmonary mononuclear cells from most animals, whether 
infected or not. In PBMC, infection was a distinct factor, i.e. all infected animals were 
positive, whereas most control animals were negative. IL-2, IL-4, and IL-10 messages were 
each detected in mononuclear cells from the blood and lungs of some infected calves. Cells 
from the control calves did not express any of these transcripts. IL-2 and IL-4 mRNA 
generally were not expressed together. Most interestingly, calves expressing IL-4 and IL-10 
mRNA had more extensive pneumonic lesions at necropsy. 
Gershwin et al examined IgE production and cytokine gene expression in pulmonary 
lymph from conventionally-reared calves infected with BRSV64. These data also presumably 
reflect CD4+ helper T-cell activity. Lymph was sampled repeatedly from thoracic lymph 
fistulas. The concentration of BRSV-specific IgE in the lymph of infected calves increased 
significantly from baseline to day nine, and this factor correlated with clinical disease 
severity. Results of RT-PCR assays for IL-4 and IFN-y messages in lymphocytes did not 
demonstrate a strong bias toward a Thl or Th2 immune response. However, the IgE response 
is consistent with helper T cell activity that potentially drives class switching in this direction 
and contributes to BRSV pathogenesis. 
Another study, in which calves were infected with non-cell-culture-passaged BRSV, 
demonstrated BRSV-specific IFN-y synthesis in the blood of infected calves 65. Heparinized 
blood from infected and mock-infected calves was stimulated in vitro with BRSV, and IFN-y 
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was measured by ELIS A. At day seven most infected calves were producing IFN-y in 
response to in vitro stimulus. By day 21 statistically significant IFN-y synthesis was induced 
in five of the six infected animals, but none of the six mock-infected calves' cells showed a 
significant gain in IFN-y production. Similar data have been reported for naïve calves 
challenged with BRSV in subsequent studies 66,67. Collins et al characterized the relative 
capacity of bovine T-cell subsets to produce IFN-y in response to in vitro restimulation with 
BRSV. Bovine peripheral blood mononuclear cells (PBMC) stimulated by BRSV and IL-12 
produced IFN-y. Flow cytometric analysis of intracellular cytokine expression indicated that 
IFN-y synthesis is largely by the CD4+ population, in small part by CD8+ cells, and not by 
gamma delta T cells 68. 
Experimental data on the role of bovine gamma delta T lymphocytes in response to 
BRSV and other viruses is limited. Depletion of yô T cells did not appear to make calves 
more susceptible to lesions following BRSV challenge 56. However, the depletion of this cell 
subset was associated with higher titers of BRSV-specific IgM and IgA in postmortem lung 
washes57. Mclnnes et al showed no significant change in yô T cells' phenotype during BRSV 
infection58. Given the high number of yô T lymphocytes in calves 69 and their influx to the 
lungs after BRSV infection56, they could be influential sometime in the course of infection. 
T lymphocyte activity in response to HRSV infection has been the focus of numerous 
studies in humans and mice. It was demonstrated that infants and children acquire HRSV-
specific CTL activity in the CD8+ T cell population70. CTL activity declined from one 
HRSV season to the next, but the development of CTL responses in the first year was 
associated with a lower incidence of lower respiratory tract disease the following year. In the 
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same study, CTL activity was directly correlated with in vitro HRSV-specific IFN-Y 
production, but inversely proportional to IL-4 production. Another recent study examined the 
cytokine profiles of PBMC taken from HRSV patients and stimulated with virus71. 
Compared with non-HRSV patients, the levels of both Thl and Th2 cytokines were increased 
in cells from HRSV patients, and there was an increase in the ratio of IFN-Y to IL-4. 
However, an earlier report indicated that PBMC from infants with HRSV were biased toward 
a Th2 cytokine response when stimulated with mitogens72. Ostler et al used the mouse 
infection model to investigate the activation and function of pulmonary CD8+ T cells during 
and after HRSV infection73. They showed that a sizeable population of HRSV -specific CD8+ 
T cells persist in the lungs even fifty days after the influx brought on by acute infection. 
These cells retained a memory phenotype (CD69hl CD62L10), but cytolytic activity was no 
longer detectable in them at fifty days. Reinfection elicited a fresh accumulation of 
pulmonary CD8+ T cells. These appeared to have been supplied from rapidly dividing 
memory cells in the mediastinal lymph node. This suggests that CD8+ T-cell memory in 
humans and cattle may involve cooperation between lung-resident cells and others induced in 
secondary lymphoid tissues. 
Summary: Protective BRSV Immunity 
Studies of BRSV immunity collectively indicate that a multifaceted response to this 
virus is ideal. The following points are important to consider: 
• Neutralizing antibody can contribute a significant, though incomplete, level of 
protection when present at a sufficient levels. 
• The CD8+ T-cell subset plays a critical role in mediating virus clearance from 
infected calves, which is consistent with findings in other RSV hosts. 
• BRSV-specific IFN-y production is typically primed in PBMC during infection. This 
may be an important correlate of protection since there is evidence linking elevated 
IL-4 and IL-10 expression with increased lesion severity. 
• It is reasonable to hypothesize that BRSV-specific mucosal antibody and T cells in 
respiratory tract of previously infected cattle cooperate with systemic memory cells 
and IgG in the formation of a secondary response. Nonetheless, repeated infections 
are common. 
BRSV Vaccines 
The humoral response to BRSV immunization was analyzed in early work by 
Kimman et al14. Parenteral administration of live virus to seronegative calves stimulated the 
production of BRSV-specific IgG in the serum. The same treatment primed the animals for 
mucosal IgM and IgA responses following a subsequent respiratory tract challenge. In that 
study, inactivated BRSV injection did not prime for detectable immune responses. In 
contrast, an early study by Howard et al showed significant humoral responses to an 
adjuvanted vaccine in which a BRSV-infected cell line was fixed with glutaraldehyde75. 
Subsequently, there were a number of studies of antibody responses in cattle vaccinated with 
commercially available modified-live or inactivated BRSV. In two of these, Ellis et al 
compared antibody titers, specificities, and neutralization properties in serum from calves 
treated with commercial MLV or inactivated vaccines 76,77. Both classes of vaccine induced 
BRSV-specific antibodies, some of which bound the F protein. However, MLV vaccines 
induced significantly stronger neutralizing antibody responses than inactivated viruses. An 
extensive set of serological assays was performed more recently with sera from treatment 
groups receiving commercial MLV or inactivated polyvalent vaccines78. Again neutralizing 
antibody was generated more efficiently in response to MLV than to any of the inactivated 
vaccines, although one inactivated vaccine did induce a significant increase in neutralizing 
antibody titers. In addition, MLV-induced antibodies were superior in terms of fusion 
inhibition, further suggesting that commercial inactivation processes affect viral epitopes and 
weaken the function of resulting antibodies. Sera from all treatment groups had increases in 
antibody dependent complement mediated cytotoxicity following immunization. 
Immunization with an experimental inactivated BRSV vaccine led to antibody 
responses biased toward different epitopes than in naturally infected cattle51. Following 
natural infection, most F-specific antibody was directed against epitope A, and this was 
associated with virus neutralization. Animals that received inactivated vaccine made similar 
amounts of antibody to epitope A, but also made significantly more antibody to epitopes B 
and C than did the infected cattle. Nonetheless, virus neutralization titers were significantly 
lower in cattle that received the vaccine. 
The mucosal antibody response to BRSV vaccination and challenge was revisited in a 
study by West et al19. IgA and IgM titers in the bronchoalveolar lavage and nasal secretions 
were not significant following vaccination with MLV until after challenge with virulent 
BRSV. From that point mucosal antibody detection was accelerated in vaccinated animals, 
with a 1-3 day delay before the nonvaccinated calves began elaborating antigen-specific 
antibodies at those sites. 
Cell-mediated responses to various BRSV vaccines have also been assessed in a 
number of studies. In one of these, commercial MLV and inactivated vaccines were 
compared by monitoring in vitro correlates of CMI, and responses were distinctly different 
80
. Antigen-specific lymphocyte proliferation was detected seven days after primary 
immunization with the adjuvanted, inactivated vaccine and seven days after secondary 
immunization with the MLV. Proliferation values of the MLV group surpassed the 
inactivated group following the third dosages. In vitro IL-2 production correlated with 
lymphocyte proliferative responses, and CD4 T cells were the predominant proliferating 
population. The strong cellular response in cattle given inactivated BRSV was consistent 
with previous lymphocyte proliferation data induced by glutaraldehyde-fixed, whole-cell 
vaccines formulated with Freund's incomplete55 and Quil A adjuvants15. In contrast, a later 
study of several commercial vaccines showed that MLV vaccines stimulated superior overall 
immunity11. Lymphocyte proliferative responses were statistically significant only in the 
MLV treatment group. 
Two more recent reports added insight into the practical efficacy of MLV and 
inactivated vaccines by including virus challenges. In one, the effects of glutaraldehyde-
fixed, cell-associated BRSV and heat-inactivated, cell-free BRSV vaccines were tested in 
lambs81. Both vaccines limited virus shedding and induced humoral and cellular immunity, 
as assessed by virus neutralization, virus-specific cytotoxicity, and lymphocyte blastogenesis. 
The glutaraldehyde-fixed vaccine gave superior protection and immune responses. A similar 
set of experiments in calves was performed with two commercial, polyvalent MLV vaccines 
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. After challenge, clinical disease, virus shedding, and pulmonary lesions were reduced in 
calves receiving either vaccine. Protection was correlated with pre-challenge in vitro cellular 
responses, as measured by antigen specific lymphocyte proliferation and interferon gamma 
(IFN-y) production. Virus clearance in vaccinated and control calves coincided with the 
detection of BRSV-specific CTL in the lungs. Thus, while inactivated and modified-live 
BRS V vaccines both have the potential to stimulate the humoral and cellular immune 
responses of calves, the literature suggests that these responses differ to some degree. One 
study with particular relevance to this issue showed that incubation of bovine dendritic cells 
with live versus inactivated BRSV results in different transcription levels for three key 
cytokines82. According to real-time RT-PCR assays, live BRSV stimulated significantly 
more production of IL-10 mRNA, while inactivated virus stimulated significantly more 
IL-12p40 and IL-15 messages. 
There is evidence that an inactivated BRSV vaccine primes CD4+ T cells to 
proliferate in response to numerous peptide targets derived from the F glycoprotein62. These 
targets did not differ greatly from those which were identified following experimental and 
natural BRSV infections. 
Several recombinant BRSV vaccines have been constructed and tested 
experimentally. Glycoprotein F, vectored in baculovirus and adjuvanted with Quil-A, was 
effective in priming lambs for a response to BRSV83. This response entailed antigen-specific 
lymphocyte proliferation and cytotoxicity and virus neutralizing antibody. Reduced virus 
shedding following BRSV challenge was reported for vaccinated animals. Two studies 
examined the immunogenic properties of recombinant bovine herpesvirus-1 expressing 
BRSV's G glycoprotein 84,85. This approach was shown to protect calves in terms of both 
virus shedding and pneumonic lesions, and this was associated with antibody and 
lymphocyte proliferative responses to immunization. However, the recombinant virus -
which was administered via the upper respiratory tract - was virulent85. Limited protection 
was also seen following vaccination with DNA plasmids encoding G84. In another study, 
vaccinia virus was used as a vector for F, G, N, and M2 genes from BRSV86. Immunization 
with F, G, and N all conferred significant protection, but the immune responses differed 
among the four treatments. Calves primed with F developed higher titers of total antibody to 
BRSV than G or N, and no BRSV-specific antibody was detected in calves receiving M2. 
Only F induced detectable neutralizing antibody. Immunization with F favored IgGl 
production over IgG2 in serum. BRSV-specific lymphocyte proliferation was observed in 
response to F and N. 
Few field trials for BRSV vaccine efficacy have been published. Two commercial 
modified-live BRSV vaccines were tested for field efficacy in calves pre- or post-weaning or 
in cattle arriving at feedlot87. In general, there was a trend toward reduced treatment for 
respiratory disease in immunized cattle. However, only two of eight vaccine treatment groups 
had statistically significant reductions in treatment rate compared with intermingled control 
animals, including a group that received vaccine upon arrival at feedlot and a group that were 
immunized before weaning. Other studies showed that an inactivated, whole-cell BRSV 
vaccine with Quil A adjuvant could provide significant protection from BRSV-associated 
respiratory disease in the field 75,88. In several published cases, commercial BRSV vaccines 
failed in field situations. Two large herds of beef calves experienced severe respiratory 
disease outbreaks weeks after having been immunized twice with a commercial inactivated 
BRSV vaccine 89. Antigen detection and serological results linked the outbreaks to BRSV. 
Maternal antibody blocking of the active immune response was suspected as the cause for 
this vaccine failure. In another outbreak, circumstantial evidence suggested that disease 
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severity was actually enhanced by the commercial inactivated BRSV vaccine that had been 
given to part of the herd90. Pulmonary eosinophilia was associated with this severe form of 
disease. MLV vaccine has also been implicated in the enhancement of a BRSV outbreak 91. 
Subclinical BRSV infection had apparently been spreading in this particular herd when a 
portion of the calves were immunized, and severe disease arose in the vaccinated subset. 
Difficulties with Vaccines for BRSV and Other RSVs 
As mentioned previously, one difficulty in effective immunization against BRSV is 
blockade by maternal antibody (IgGl) in young calves. One study examined several 
components of the humoral response in calves primed with BRSV by different methods74. 
Maternal antibody to BRSV severely suppressed the primary antibody response to live or 
inactivated BRSV administered by either parenteral or mucosal routes. Passive antibody also 
suppresses antibody responses to HRSV immunization in animal models92. Maternal 
antibody blocking is generally thought to result from immunoglobulins masking the antigen 
from the immune system. Another relevant mechanism may be the suppression of naïve B 
cell activation that occurs when immune complexes cross-link surface antigen receptor with 
FcyRIIb 93. Work done in calves by Aldridge et al raises another possibility 94. They 
examined the expression of surface immunoglobulins on B cells in the lymph nodes of fetal 
and neonatal calves. Surface IgGl and IgG2 were readily detectable in cells from fetuses and 
colostrum deprived calves, but expression in colostrum-fed calves was absent at 36 h of age. 
This implied that a non-antigen-specific factor in colostrum could modulate calves' antibody 
production. 
There is evidence that exposure to viruses in the face of antigen-specific maternal 
antibody can prime some facets of immunity. Some studies have indicated that virus 
infection or vaccination in calves95'96, infants91, and mice 98 with high maternal antibody 
titers may prime a T cell response despite the lack of an active antibody response. In 
addition, passively immunized calves that failed to mount primary antibody responses to 
bovine herpesvirus 1 (BHV-1)99 and BRSV74 did have memory-type antibody responses 
following secondary exposure. Thus, while maternal antibody-mediated inhibition of active 
immunity to BRSV is well documented, many of the details are unresolved. Some areas of 
ambiguity include the mechanisms of inhibition, how comprehensively a calf s immune 
response is suppressed, and how the problem might be circumvented. 
A vaccine trial with human infants demonstrated substantial risks associated with 
formalin-inactivated HRSV (FI-HRSV). Vaccinated children suffered more severe disease 
after natural infection with RSV than did their nonvaccinated counterparts, which led to 
longer hospital stays 10°. This outcome has greatly slowed progress in developing HRSV 
vaccines for humans. It has also stimulated research in rodent, primate, and bovine disease 
models to discover the mechanisms underlying this disease enhancement. 
Sera from children vaccinated with the FI-HRSV vaccine had low ratios of 
neutralizing to total antibody101. Similarly, non-neutralizing antibodies to HRSV proteins F 
and G were prevalent in cotton rats that received formalin-inactivated HRSV (FI-HRSV) 
vaccines 102. Vaccinated rats developed much lower neutralizing antibody titers to surface 
glycoproteins F and G than rats which were infected with live virus. The predominance of 
nonneutralizing antibody in the rats was associated with enhanced pulmonary disease after 
challenge. It was theorized that the abundant nonneutralizing antibody is the basis for 
enhanced disease upon infection of FI-HRSV vaccinated subjects. When rats were vaccinated 
with purified F protein, it induced antibodies capable of preventing syncytia. In contrast, FI-
HRSV did not prevent syncytia or induce substantial levels of neutralizing antibody, 
suggesting that formalin treatment changed critical epitopes on the glycoproteins 101. It was 
proposed that nonneutralizing antibody forms immune complexes with the replicating virus 
and causes a type III hypersensitivity reaction 101. Neutrophilia in the initial lung infiltrate of 
vaccinated, infected rats was consistent with this notion. A recent study provided further 
validation for this concept103. The absence of either mature B cells or complement 
component C3 abrogated a mouse model of FI-HRSV enhanced disease. In addition, the 
authors detected C4d deposition in lung sections from infant patients who died of FI-HRSV 
enhanced disease in the 1960's vaccine trial. 
Most of the recent research on this subject has focused on another hypothesis, that 
RS V immunity in animals receiving formalin-inactivated vaccine is skewed toward a Th2 
response. One study measured cytokine mRNA expression in groups of mice that were 
primed with inactivated HRSV, subunit F glycoprotein, or modified-live HRSV and 
challenged with live virus 104. Inactivated virus and F induced relative increases in IL-4 
mRNA transcripts, whereas MLV led to an increased IFN-y to IL-4 mRNA ratio. Other work 
showed that mouse RS V disease enhancement after challenge could be eliminated by 
depleting CD4+ T cells at the time of challenge 105. A subsequent study tested the effects of 
depleting IFN-y, IL-2, IL-4, and IL-10 from FI-vaccinated mice immediately before 
challenge I06. Mice depleted of IL-4 had partially reduced histologic lesions. Depletion of 
both IL-4 and IL-10 completely prevented lesions. Mice depleted of IFN-y and/or IL-2 
appeared to have the same enhanced pulmonary inflammation post-challenge as control 
vaccinates. Another study examined cells from bronchoalveolar lavage after challenging 
mice that were vaccinated with formalin-inactivated HRSV 107. Total cell, granulocyte, 
eosinophil, and CD4+ counts were increased in the BAL of FI-vaccinated mice, but the CD8+ 
count declined. Messenger RNA for several Th2-type cytokines also increased, but IFN-y 
expression dropped. These results support the hypothesis that polarized immune regulation 
enhances RSV disease in mice immunized with FI-HRSV vaccine. 
A study by de Swart et al108 provided evidence that similar Th2-driven pathogenic 
processes can take place in primates as well. Macaques that received FI-HRSV vaccine 
responded with a strong T cell response that included virus-specific proliferation and the 
production of IL-5 and IL-13. Following challenge with species-adapted HRSV there was 
significant eosinophil infiltration in the lungs of most vaccinated animals, in addition to the 
bronchointerstitial pneumonia that was also present in non-vaccinated animals. 
It is not well established why FI-HRSV vaccine is linked to a Th2-polarized immune 
response. Several unique properties of G glycoprotein, e.g. chemokine mimicry and bias 
toward class II-restricted T cell priming, led researchers to investigate whether the 
glycoprotein inherently favors Th2 cytokine production and enhanced disease (reviewed by 
Graham et al109). Vaccinia-vectored G can prime mice for enhanced disease after challenge, 
similarly to FI-RSV. However, the FI vaccine-induced version of disease enhancement 
requires a more complex Th2 cytokine milieu than the G-induced form. Therefore it is 
doubtful that G glycoprotein alone accounts for the disease complications. Other contributors 
to the association between FI-RSV and a Th2 response might include the obligatory use of 
endocytic antigen processing and RSV's antagonism toward type I interferon. As for 
mechanisms to link Th2 cytokines with enhanced disease, there are a few strong possibilities. 
The recruitment of eosinophils by IL-5 from Th2 memory cells in the airways is thought to 
be a key step in immunopathogenesis 109. There is also evidence that IL-4 reduces the 
cytolytic activity of CD8+ T cells in ways that promote inflammation110,11 Specifically, IL-
4 increases the expression of Fas ligand (FasL) and TNF-a in CD8+ T cells. Upregulation of 
FasL shifts the balance of cytolytic activity from the very targeted perforin-mediated 
mechanism to the more promiscuous Fas-mediated mechanism, which is prone to killing 
uninfected cells. By comparing HRSV infection in perforin knock-out and wild type mice, it 
was shown that HRSV clearance is delayed and illness is lengthened when perforin is 
disabled and other defense mechanisms (e.g. Fas-mediated killing) are used instead m. 
Some efforts have been made to determine whether inactivated BRSV vaccines cause 
enhanced subsequent disease in cattle. Gershwin et al performed an experiment in which 
calves were either vaccinated with FI-BRSV or mock-vaccinated, followed by challenge with 
BRSV 113. Virus clearance was less efficient and pulmonary disease was enhanced in FI-
BRSV vaccinated calves. After challenge, IFN-y production was significantly lower in 
PBMC from the vaccinated calves than in cells from control calves 66. These data appear to 
be consistent with results from HRSV studies in mice. Weak IFN-y responses in FI-BRSV 
vaccinates may account for the inefficient clearance of virus and enhanced pulmonary 
disease. Another noteworthy finding from this work was that FI-BRSV induced only non-
neutralizing antibodies, which also mirrors the data from HRSV studies in humans and 
rodents. It is noteworthy that another group tested a similar FI-BRSV vaccine in calves, with 
different results. They reported an overall reduction in clinical disease after challenge, except 
that disease onset was more rapid when calves had been vaccinated with FI-BRSV 114. It is 
not clear whether the licensed inactivated BRSV vaccines used routinely in the field can 
drive a disease-enhancing response, but at least one field case was consistent with that 
• 90 scenario . 
A consensus about the pathogenesis of vaccine-enhanced RS V disease has still not 
been reached. There is substantial evidence for both cytokine-mediated and antibody-
mediated mechanisms, but no solid link between the two seems to have been demonstrated. 
There was a report that Th2-like responses are favored when specific antibody targets an 
antigen to APC via Fc receptors, even reversing the Thl bias of activated macrophages 115. 
This could point to the high level of FI-RSV-induced nonneutralizing antibodies as the 
fundamental problem. Conversely, one could speculate that a Th2-like cytokine milieu 
diminishes neutralizing properties, perhaps by changing the balance of antibody isotypes. It 
is also possible that these two mechanisms are independently driven by exposure to FI-RSV, 
and perhaps their impact can be synergistic. 
MLV and inactivated RSV vaccines each pose potential risks to bovine and human 
recipients. Both forms are also prone to blocking by passive maternal antibody. In order to 
provide safer and more reliable prophylaxis for bovine and human RSV, a more thorough 
understanding of host immune responses to vaccines is needed. It will be valuable to develop 
and test new generation RSV vaccines, such as subunit antigens vectored in avirulent viruses 
or encoded in DNA. These are likely to be useful tools for research, helping to identify 
critical targets for immunization, but such strategies also hold out promise to make 
immunization more effective. 
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Characteristics and functions of bovine T cells 
Antigen receptors on classical T lymphocytes recognize viral peptides from proteins 
processed in the cell and presented on major histocompatibility complex (MHC). Classical 
CD8+ CTLs recognize peptides presented on MHC class I molecules. Class I presentation 
has generally been associated with antigen processing by the endogenous pathway, in which 
peptide loading takes place in the endoplasmic reticulum. CD4+ T cells ordinarily recognize 
viral peptides in the context of MHC II complexes on the surface of an antigen presenting 
cell (APC). Class II presentation has usually been associated with ingestion of antigen and 
antigen processing in the exogenous pathway. On a given 00 T cell, the ICR and the CD4 or 
CDS co-receptor are matched for binding to the same class II or class I molecule. The 
cytoplasmic domains of CD4 or CDS participate with the TCR-associated CD3 in extensive 
cell signaling. Co-stimulatory signals are also necessary for activation of a T cell. This 
interaction is classically carried out between CD28 from the T cell and B7 molecules from 
the APC. Antigen recognition in the absence of co-stimulation results in T-cell anergy.116 
Because the ability to drive a primary CD8+ T cell response is unique to professional 
APC, and because many intracellular pathogens do not infect professional APC, it is 
important that there be a special route for CD8+ T cell sensitization to these invaders. 
Professional APC can prime CD8+ T cells with exogenous antigens by a mechanism - or set 
of mechanisms - termed "cross presentation"117. Dendritic cells (DC) were shown to be 
sufficient for this activity 118, and they are more efficient in cross presentation than 
macrophages 119. In this system, DC located throughout peripheral tissues can ingest various 
materials, such as debris from infected cells that may be undergoing apoptosis or necrosis U9. 
The maturation of these DC likely depends on Toll-like receptor-mediated signaling 
triggered by heat shock proteins (especially in viral infection) or by numerous bacterial 
constituents, such as lipopolysaccharide. The DC can then migrate to secondary lymphoid 
tissues and present antigen to naïve CD8+ T cells. There are thought to be two routes for DC 
to present peptides from an exogenous antigen in the context of MHC class I. By one of these 
routes, peptide loading on MHC class I occurs in the endosomal-lysosomal system or directly 
on the cell surface. The other route uses a property unique to DC that allows antigens to pass 
from endosomes into the cytosol. From this point, the exogenous antigen can be processed 
and presented in the same manner as an endogenous antigen. 
Gamma delta T cells express a set of antigen receptor genes distinct from those of the 
0)3 T cells. This cell subset is a small portion of the circulating lymphocyte population in 
humans and rodent species 120, but large numbers of 7Ô TCR+ cells, such as intraepithelial 
lymphocytes (IEL), localize in various non-lymphoid tissues 121. In ruminants the 7Ô T cells 
are also a major lymphocyte subset in the circulation 122. Many aspects of 7Ô T cell biology 
are either poorly understood or difficult to generalize because there are major differences 
between species and there are heterogeneous subsets within species 123. Functional subsets 
have been distinguished using several parameters, including anatomical location, receptor 
specificity, and phase of immune response. The receptor diversity of yô T cells is quite 
limited in humans and rodents 120,124. Many of the observed functions and activities of this 
population are consistent with a niche in the innate immune response. Endogenous 
molecules, such as heat-shock proteins, phosphoantigens, and non-classical class I molecules, 
can be upregulated on host cells (e.g. epithelial cells) in response to stresses like infection 
and transformation 123. Certain y<5 T cells recognize these molecules, either through a 
31 
canonical TCR arrangement or a non-TCR receptor, and respond with a variety of activities. 
Gamma delta T cell functions have been shown to include cytotoxicity, cytokine production, 
and secretion of growth factors such as keratinocyte growth factor121. Through the 
production of cytokines like TNF-a and IFN-y, these cells probably favor the activation of 
macrophages, natural killer cells, and a(3 T cells early in an infection123. Later, during the 
resolution of some immune responses, certain yô T cells release cytokines that dampen 
inflammation and growth factors to aid in healing lesions. 
WC1, also known as T19, is a marker unique to ruminant yô cells. It is a surface 
heterodimer with a large extracellular domain and a small intracellular tail, and can 
contribute to yô T cell activation 125. WC1 helps to differentiate two major yÔ T cell subsets 
126
. One subset is WC1-, CD2+, and CD8+ and the other is WC1+, CD2~, and CDS". Many 
WC1~ yô T cells are found in the intestinal tract and splenic red pulp. WC1+cells can be 
detected in peripheral blood, the splenic marginal zone, skin, and gut lamina propria. 
Although the WC r population's high expression of CDS suggests that they might bind MHC 
I, no such restriction requirement has been demonstrated. Analysis of cytokine production by 
WC1+ cells has indicated that they tend toward a Thl profile 127. 
Ruminant species appear to have diverse gamma delta receptor genes and joining 
patterns, suggesting that they have sophisticated antigen recognition capabilities and a 
significant role in adaptive immunity124. Consistent with that idea, yô T cells comprise a 
large fraction of the circulating bovine T cell population: sometimes nearly half of the PBMC 
in young calves 69,128. However ruminant yô T cells are quite rare in the conventional T cell 
zones of secondary lymphoid organs 122. Studies in cattle have shown important roles for yô 
T cells in immune responses to a number of microorganisms. Gamma delta T cells from the 
peripheral blood of Mycobacterium &ovis-infected cattle give specific responses in vitro to 
mycobacterial antigens 129,13°. In one instance it was shown that the in vitro proliferative 
response by OjST cells was higher when yô T cells were removed, suggesting an 
immunomodulatory role for the latter130. Gamma delta T cells were important for the 
formation of granulomas in a SCED-bovine chimera model of M. bovis infection 131. 
Vaccination of cattle against Leptospira borgpetersenii primed for antigen-specific in vitro 
IFN-y production by yô T cells 132. Virus-specific in vitro yô T-cell responses were also 
acquired by cattle that were infected with bovine viral diarrhea virus 133 or vaccinated for 
bovine herpesvirus 1 134. 
Some activities of bovine yô T cells appear to fall in the category of innate immune 
responses. Peripheral blood yô T cells proliferate in response to autologous monocytes that 
are metabolically inactivated or stimulated with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) 135,136. They do not respond to normal monocytes, which secrete a specific 
inhibitor of this activity. The proliferative response requires contact with the yô TCR 137. It is 
hypothesized that this mechanism directs a yô T cell response specifically to altered 
monocytes, which may have been transformed, infected, irradiated, or activated. In addition, 
peripheral blood yô T cells exhibited natural killer cell-like activity toward several viruses 
after isolation from foot-and-mouth disease vaccinated cattle 138. 
Bovine T lymphocyte populations undergo changes in distribution during the early 
months of life. In a study of these dynamics, maximal concentrations of circulating CD4+ and 
CD8+ T cells were observed in fetal calves (tested at 8 months gestation)69. Subsequently, 
33 
both subsets dropped below adult levels from parturition until after 120 days of age, with 
CD4+ cell counts changing most significantly. Gamma delta T cell numbers peaked near the 
time of birth and then declined to adult level at around 120 days. The numbers of CD4+ and 
CD8+ T cells were significantly greater in the lymph nodes of fetal calves than in adults. A 
similar trend was seen for CD4+ T cells in the spleen. These patterns of cellular traffic in fetal 
and neonatal calves suggest that a functional repertoire of T cells develops in prenatal calves. 
In a study of longer term lymphocyte population dynamics, the frequencies of CD4+, CD8+, 
and yô T cells were lower in the peripheral blood and spleen of a group of cattle >five years 
of age than in a group of two-year-old animals 139. Fluctuations in the number of circulating 
WC1+ y<5 T cells have also been associated with a change in environment121. 
Mechanisms of T Cell Activation 
Activation of T cells can be detected by analysis of several surface marker 
phenotypes, such as downregulation of CD45RA and L-selectin, and upregulation of 
CD45RO, MHC II, and the a-subunit of high-affinity IL-2 receptor. High-affinity IL-2 
receptor (IL-2R) is a trimer composed of the a, (3, and yc chains (CD25 is an alternate name 
for IL-2Ra). The critical function of IL-2 signaling in T cells is to induce the cell cycle 
transition from Gr to S-phase, thus driving proliferation during a response to antigen or 
mitogen. Resting T cells express undetectable or low levels of a (CD25), p, and yc chains. 
Signaling that is initiated by TCR engagement with peptide and MHC leads to transactivation 
of the IL-2 and CD25 genes. CD25 expression permits the assembly of high-affinity IL-2R, 
which tends to localize in membrane microdomains 140. This initiates a positive feedback 
loop in which IL-2 signal drives further expression of CD25 in a manner dependent on signal 
transducers and activators of transcription (STAT) 3 and STATSa140. CD25 expression is 
more rapid on antigen-primed cells than on naïve cells 141,142. In contrast, the ability of naïve 
T cells to engage TCR was shown to be equal to that of effector cells 141. This suggests that 
efficient CD25 expression by effector T cells contributes to their superior responsiveness to 
antigen. 
Recent studies in mice have identified a numerically small subpopulation of CD4+ 
regulatory T cells that constitutively express CD25 and demonstrate suppressive activity 
toward pathogenic, self-reactive T cells in vivo 143,144. CD25+CD4+ regulatory T cells are able 
to suppress the activation, IL-2 production, and proliferation of CD25~CD4+ and CD25~CD8+ 
T cells in response to antigen in vitro. It is thought that the regulatory T cells recognize and 
respond to self antigens, allowing them to suppress potentially pathogenic self-reactive T 
cells while both are interacting with antigen presenting cells. The mechanisms of this 
suppression are unclear. These regulatory T cells should not be confused with ordinary 
activated CD4+ T cells that upregulate CD25 in response to antigenic stimulation. No 
published studies concerning CD25+CD4+ regulatory T cells in cattle are known to the 
author. 
There are quantitative and qualitative reasons that effector/memory T cells respond 
more rapidly and efficiently than naïve cells of the same specificity. One key to the 
effectiveness of CD4+ and CD8+ memory T cells is numerical superiority over equivalent 
naïve cells in non-exposed individuals 142,145. There are also critical qualitative differences in 
the antigen-driven responses of naïve and memory T cells, which is reflected in the above-
mentioned fact that CD25 is more readily expressed on primed T cells. Qualitative factors 
that allow memory CD8+ T cells to respond more vigorously include a lower activation 
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threshold in terms of peptide concentration and co-stimulation, more direct migration to 
peripheral sites of inflammation, and more immediate induction of effector functions, such as 
cytotoxicity 142,146. One reason for those qualitative differences is that memory cells are 
programmed for a different pattern of gene expression, due to their remodeled chromatin 
structure and the constitutive presence of mRNA transcripts that encode key effector 
molecules 147. 
Different subsets of naïve T cells behave in unique ways during antigen-driven 
responses, which is potentially significant in the development of vaccines. In studies of mice 
with deficiencies in costimulatory molecules, it was shown that CD4+ and CD8+ T cells have 
distinct requirements for costimulatory signals 147. The kinetics of a proliferative response are 
also different between these two subsets. It was reported that CD4+ T cells stimulated with 
immobilized anti-TCR monoclonal antibody and B7-1 proliferated and expanded well 
beyond the 3-4 days at which CD8+ T cell activity (including lytic effector function) peaked 
and cell death began 148. These data fit the current understanding that CD4+ T cells are slower 
to begin proliferating after engaging viral antigen 147. For CD8+ T cells, the rapid 
proliferative burst is tightly correlated with the subsequent acquisition of effector functions 
147
. In contrast, CD4+ T cells must engage antigen for a longer time, in the presence of proper 
cytokines, in order to be differentiated into effector cells. It would be valuable to learn more 
about the antigen-driven activation of yô T cells, especially in ruminants, since they seem to 
span the innate and acquired branches of immunity, yô T cells in sheep upregulate activation 
markers CD25 and MHC II in response to concanavalin A within just eight hours of 
stimulation, whereas CD4+ and CD8+ cells require 24 hours to do the same 149. 
There have been reports that a great majority of CD8+ T cells proliferating during an 
acute anti-viral response are non-antigen-specific 150. Limiting dilution analysis was used in 
these studies to count antigen-specific CTLs. Those conclusions were contradicted by more 
recent data obtained with peptide-MHC I tetramer assays, intracellular IFN-y staining, and 
single cell IFN-y ELISPOT assays. These assays were used in one study to analyze responses 
to lymphocytic choriomeningitis virus (LCMV) and heterologous viruses in LCMV-immune 
mice 151. All three assays indicated that 50-70% of activated CD8+ cells were specific for the 
infecting virus. Few cells from naïve mice were stained by LCM-derived tetramers or 
responded to its peptides; nor did lymphocytes from mice immunized with vaccinia. Another 
approach used to quantify specific versus "bystander" CD8+ T cell activation involved 
adoptive transfer of polyclonal, virus-primed T cells 152. Tracer cells from Thy 1.2+ mice were 
transferred into Thyl.2+Thyl.l+ recipients. Donor cells taken from LCMV immune mice or 
vaccinia immune mice made up 60-80% of proliferating CD8+ T cells upon infection of the 
recipients with the respective virus. Meanwhile, there was no evidence that donor cells from 
naïve mice or mice primed with the irrelevant virus contributed to expansion. Thus, several 
lines of evidence suggest that a primary anti-viral response stimulates mainly antigen-
specific T cells. It has been suggested that activation-induced cell death caused 
underestimation of antigen-specific cells in limiting dilution assays 151. 
The maintenance and re-stimulation of memory T cells are influenced by cytokine 
stimulation 153. In murine systems, type I interferon, IL-12, IL-15, IL-18, and IFN-y have 
been shown to promote proliferation of memory CD8+ T cells, even independently of TCR 
stimulation. IL-15 appears unique among these in its ability to directly stimulate memory 
CD8+ T cell turnover. Evidence suggests that the other cytokines act indirectly by helping 
37 
drive IL-15 synthesis by cells such as macrophages. The proliferation of memory CD4+ T 
cells can be driven by IL-12, and to a lesser extent, DL-18 153. One study examined the 
stimulation requirements for bovine CD8+ T cells responding to Theileria parva in vitro 154. 
Naïve CD8+ cells required contact with antigen-stimulated CD4+ cells for development into 
parasite-specific CTL. Primed CD8+ cells could develop into CTL under less stringent 
conditions, such as the presence of T cell growth factors, recombinant bovine IL-2, or CD4+ 
T cells responding to another antigen. The authors reported no data concerning proliferation 
or activation marker expression. The fact that there are means of non-antigen-specific T-cell 
stimulation suggests that in vitro assays for antigen recall must be interpreted with some 
caution. 
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Chapter 3. Methods for Analysis of Cell-Mediated Immunity 
in Domestic Animal Species 
A review paper submitted to the Journal of the American Veterinary Medical Association 
Matthew R. Sandbulte and James A. Roth 
Introduction 
Past efforts to evaluate immune responses in domestic animals typically focused on 
humoral immunity. One reason for this is the relative ease with which serum antibody 
responses can be monitored, using assays such as virus neutralization, hemagglutination, and 
enzyme-linked immunosorbent assays (ELIS A). The many facets of cell-mediated immunity 
(CMI) in response to infectious agents have been explored and appreciated more thoroughly 
in recent years. This has accentuated the importance of examining CMI in any thorough 
effort to characterize an immune response to infection or vaccine. When evaluating 
veterinary vaccines antibody titer is often cited as an important measure of vaccine efficacy. 
Yet, there are several realistic scenarios in which these data are insufficient to predict a 
positive or negative outcome. 
• For many infectious agents, specific antibodies do not adequately protect the host. 
• Antibodies to certain infectious agents enhance disease. One mechanism for this is 
antibody-dependent enhancement (ADE), where immunoglobulin-bound pathogens 
rely on Fc receptor-mediated phagocytosis for entry to host cells. Immune complexes 
can also contribute to the pathogenesis of infectious diseases by triggering 
complement activation and driving a type III hypersensitivity response. 
• Antibodies may not always be evident following an adaptive immune response. It has 
been documented with several viral agents that adaptive CMI responses can be 
mounted in the face of passive maternal antibody even while humoral responses are 
suppressed l'2. This can result in animals with no detectable antibody titers being fully 
resistant to challenge. 
CMI is a rather simple label for a broad and complex set of mechanisms that require 
T-cell activity. Cytotoxic T lymphocytes (CTL), which express CDS on their surface, are 
important weapons against many intracellular pathogens. CTL are programmed to destroy 
infected cells when they recognize pathogen-derived peptides that have been processed and 
presented in the context of MHC class I via the endogenous pathway. Antigen-activated 
CD4+ helper T cells coordinate the overall adaptive immune response. They recognize 
peptides presented in the context of MHC class II by the exogenous pathway. Helper T cells 
influence the activities of many other immune cells through cytokine production and direct 
cell-cell contact (e.g. CD40-CD40 ligand signaling). For instance, both types of signal are 
used by T helper 2 (Th2) cells to induce antibody class switching and maturation of B cells. 
The T helper 1 (Thl) cells facilitate CTL activation and drive the inflammatory immune 
response. During an inflammatory response, signals from antigen-specific Thl cells aid the 
rapid recruitment and activation of macrophages and neutrophils. Gamma delta (yô) cells are 
the other major T-cell subset (reviewed by Hayday3). The structure of yô TCR is different 
from that of the 0)3 T cells (CD4 and CDS), and antigen recognition by yd T cells is not 
usually MHC-restricted. Certain host cell markers, such as stress-induced heat-shock 
proteins, can activate yô T-cell activity. The functions of yô T cells in response to pathogens 
are not well understood, but their prominent distribution in mucosal surfaces is consistent 
with a role in surveillance and rapid response to invaders. There is also a body of evidence 
that yô T cells modulate inflammatory responses and promote tissue repair 4. 
The balance of immune regulation has been one of the foremost topics in 
immunology in recent years. The Thl versus Th2 paradigm has been used to explain striking 
divergences between protection and disease in several human and rodent infections, such as 
leprosy and leishmaniasis. There is some ambiguity as to the Thl/Th2 paradigm's relevance 
in other animal hosts, such as cattle5, but there is evidence from several species to support it 
6-8
. The induction of cytokine activity promises to be a useful measure of vaccine efficacy for 
infectious agents of animals. 
In this review, we briefly discuss strengths and drawbacks of the classical CMI 
assays. This is followed by a survey of contemporary methods for CMI assessment, with 
emphasis on those which are practical for studies in outbred animals. The assays monitor 
four categories of immune parameters: (1) antigen-specific in vitro activation and 
proliferation of distinct T-cell subsets, (2) antigen-specific cytokine production, (3) 
production of non-cytokine effector molecules, and (4) direct detection of peptide-specific 
receptors. 
To set the context for this discussion, it is important to point out that there are two 
different reasons to assay for T cell activity. One is to examine basic immunologic 
mechanisms involved in an immune response, and the roles of these mechanisms in 
protection. This can be done with in-depth, molecular analysis on small numbers of 
specialized animals (such as gene-knockout mice or NIH mini-pigs). The second reason is to 
monitor T-cell responses to vaccines in populations of animals over time. This requires 
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assays that can be performed on large numbers of outbred animals. Some assays are very 
cumbersome to use for this purpose (e.g. CTL assays, discussed below). Other CMI assays 
are inherently more practical for this research aim (e.g. in vitro tests for antigen-specific 
lymphocyte activation, proliferation, or cytokine production, also discussed below). Ideally, 
some of these CMI methods will be enhanced to a point where they match the efficiency of 
serological assays for immunologic monitoring of domestic animals. 
Classical CMI methods 
The oldest technique for monitoring the cell-mediated response to an antigen is the 
delayed-type hypersensitivity (DTH) assay. This method involves observation of the swelling 
that results from leukocyte recruitment to a site of intradermal antigen injection in an 
immune animal. Therefore it permits in vivo detection of cell-mediated responses to a wide 
variety of infectious agents. Another advantage is that the test can be performed without 
expensive equipment. Among its drawbacks, the results are difficult to quantify and the test 
may only be valid the first time it is performed in an individual, if the test itself induces T 
cell responsiveness. 
Antigen-specific lymphocyte proliferation has been used widely to assess antigen 
recall responses in vitro. High proliferation to an antigen reflects the expansion of antigen-
specific lymphocytes in the course of immunization or infection, as well as the superior recall 
responses of memory cells in immune individuals. Lymphocyte proliferation has typically 
been assessed by cellular uptake of tritiated thymidine that is added during the final 24 hours 
of culture with antigen. This technique offers a quantitative read-out via scintillation counter, 
and it can be repeated routinely with peripheral blood mononuclear cells (PBMC) from an 
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individual animal. Data from the assay do not indicate which lymphocyte populations are 
responding to a given antigen. The assay only provides information about proliferation 
during the time period when tritiated thymidine is present. The hazards and restrictions of 
handling radioactive material are significant disadvantages. 
Cytotoxic T lymphocytes (CTL), known to be a crucial component of many immune 
responses, have long been assayed by an in vitro method that measures the lysis of antigen-
loaded autologous target cells. In the conventional chromium release format for this 
technique, 51Cr is loaded in the target cells, and its release is read as the indicator of target 
cell lysis. Several controls are necessary to demonstrate antigen-specificity and MHC 
restriction. One of the difficulties with this technique is handling radioactive material. Many 
related techniques that use non-radioactive labeling for target cells have been reported, but 
none of them seem to have been widely adopted. The major disadvantage when using this 
method for outbred animals is that autologous target cell lines susceptible to infection with 
the agent being studied must be maintained for each individual tested. 
Contemporary CMI methods 
Monitoring the sensitivity of T lymphocytes to recall antigens in vitro 
Many of today's prevalent methods for CMI assessment are akin to the traditional 
lymphocyte proliferation assay, in that they are based on in vitro culture of PBMC with 
antigen. Lymphocyte proliferation is still a very widely used parameter for antigen-driven 
cellular activity in these systems, but significant efforts have been made to develop 
alternative proliferation assays that use non-radioactive signals and provide more information 
about the responding cell populations. Several colorimetric assays were evaluated as tests for 
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proliferation. Two indicator reagents which proved effective in domestic animal studies were 
alamar blue and the tetrazolium salt MTT (see Table 1). Both of these reagents undergo color 
changes under the metabolic conditions of proliferating lymphocytes, which can be 
quantified by standard spectrophotometry. 
Flow cytometry-based proliferation assays have gained widespread acceptance in 
recent years. With these techniques, markers are incorporated into cells during culture, and 
precise measurements of antigen-driven proliferation can be derived from changes in marker 
intensity. Reagents that have been used for this purpose include 5-bromo-deoxyuridine 
(BrdU), the PKH series of dyes, and carboxyfluorescein diacetate succinimidyl ester 
(generally referred to as CFSE, though technically, CFSE is the fluorescent molecule derived 
when intracellular esterases remove two acetate side chains from the original molecule). All 
three of these have been used successfully in immunological studies of domestic animal 
species (see Table 1). BrdU is a nucleotide analog that is added to cells late in culture for 
incorporation into replicating DNA. Before flow cytometric analysis, BrdU-specific antibody 
must be applied for fluorescence labeling. Both PKH and CFSE are typically used to stain 
cells before culture with antigen, and no further reagents are required to achieve 
fluorescence. PKH dyes stain cells by integrating into the membrane, whereas CFSE is a 
membrane-permeant dye that binds covalently to cytoplasmic proteins. With either type of 
dye, each cell division results in two daughter cells with half the fluorescence intensity of the 
parent cell. This allows one to determine the proportion of cells that have undergone division 
and the number of generations that have occurred. Cells undergoing as many as eight rounds 
of division are routinely differentiated with these protocols. Another advantage of flow 
cytometric proliferation techniques is the capacity to phenotype the proliferating and non-
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Table 1. 
Contemporary methods for analysis of lymphocyte activation and proliferation 
utilized in domestic animal species 
Technique Host Species 
CD25 flow cytometry Bovine 9,10 
Goat11 
Pig 12,13 
MHC II flow cytometry Bovine 9 
Pig 12'14 
MTT proliferation Dog15 
Chicken 16 
Alamar blue proliferation Cat17 
Chicken 18 
BrdU flow cytometry Bovine 19 
Dog15 
Chicken20 
PKH flow cytometry Pig21 
Bovine 22 
CFSE flow cytometry Bovine 19 
proliferating cells. Fluorescent antibody conjugates are used directly or indirectly to label T 
lymphocyte subset markers, such as CD4, CDS, WC1, and yô TCR. 
There are potential weaknesses to the flow cytometry-based proliferation assays. As 
is the case in a traditional radioactivity-based lymphocyte proliferation assay, these 
techniques do not specify or prove effector functions of the responding cells. In addition, the 
dyes tend to be somewhat toxic to cells, and this complicates the interpretation of results, 
particularly negative data. 
Along similar lines, lymphocyte responses to in vitro antigens can be detected by 
flow cytometric analysis of activation-induced cell surface markers. Fluorescent antibodies 
can be used to label these molecules. Activation markers that have been used for the purpose 
of detecting recall responses include CD25 (IL-2 receptor a subunit), CD69, and MHC class 
II11,23'24 (also see Table 1). The expression of such markers can be analyzed in parallel with 
T lymphocyte subset markers in order to assess the level of responses by distinct cell 
populations, such as CD4, CDS, and yô T cells. Levels of activation marker expression in a 
cell population can be measured in terms of two statistics: the percentage of cells expressing 
the marker and the mean fluorescence intensity (MFI) of staining for the marker. Monoclonal 
antibodies to subset markers and activation markers are commercially available for a number 
of animal species, which makes this approach a practical tool for veterinary researchers. 
Under some circumstances, antigen-stimulated cells express activation markers but do not 
proliferate, suggesting that activation marker-based assays should detect some T cell 
responses that proliferation assays miss 25. There are some important considerations 
regarding the interpretation of data from these assays. 
As with proliferation, the demonstration of lymphocyte activation in response to 
antigen does not prove any particular effector function. If one subset of lymphocytes is better 
adapted to survive and proliferate in vitro, then the relative levels of antigen-driven activation 
across subsets may be skewed in favor of that subset. In addition, it is possible that antigen-
specific cytokine production by one T-cell population in an in vitro system might drive non­
specific "bystander activation" of other T cells. Ordinarily, the activation of a T cell depends 
on antigen recognition by the TCR, and further stimulation by cytokines serves to amplify 
that antigen-specific response. Memory T cells, however, can be sensitive to stimulation by 
certain cytokines in the absence of antigen26. Thus, it is plausible that an antigen-specific T-
cell response in vitro might lead to the activation of accompanying memory T cells that do 
not share the same specificity. It has not been shown conclusively whether this causes 
measurements of antigen-specific T-cell activity to be inflated. Regardless, even bystander T-
cell activation presumably depends on antigen-specific cells having made a recall response in 
the first place. 
There are important choices to be made in terms of the population of leukocytes to 
test for antigen-specific priming. The most convenient source of cells for repeated assays of a 
systemic immune response is the peripheral blood, and PBMC are therefore used very 
frequently. Cells from lymphoid organs can arguably give a more direct indication of 
immune induction, especially in the early stages. Responses to systemic infections or 
parenteral vaccination are typically initiated in draining lymph nodes or the spleen. Infections 
of the respiratory tract or the gut (or intranasal immunization) will likely lead to immune 
responses in mucosal lymphoid tissues, e.g. tonsils or Peyer's patch. In some animal studies, 
draining lymph nodes can be biopsied, and in other instances cells are collected from 
lymphoid tissues at necropsy. One technically demanding, but commendable approach used 
in bovine studies was to sample pulmonary lymph from cannulated lymphatics over an 
extended time 27. 
It is sometimes desirable to examine fractionated lymphocyte populations for antigen-
specific responses. For instance, if a flow cytometry assay reveals CDS T cell proliferation 
or activation in response to antigen, it can be useful to test a purified CDS T cell population 
for dependence on CD4 T cell help. Separation of subsets before antigen stimulation also 
enables one to measure the contribution of each subset to cytokine production, using 
techniques like reverse transcriptase PCR (RT-PCR), ELIS A, or ELISPOT (which are 
discussed in the next section). Several antibody-mediated techniques are available to either 
isolate one subset of T cells or deplete a given subset from the mixed population. These 
techniques include fluorescence activated cell sorting (FACS), magnetically activated cell 
sorting (MACS), and complement-mediated subset depletion. Homogenous lymphocyte 
subset populations may be inferior to mixed PBMCs in terms of creating an in vitro 
environment where antigen presentation, cognate T cell help, and the cytokine milieu can 
support T cell activation. 
Researchers have utilized several approaches to culturing lymphocytes for antigen 
stimulation. In some studies antigens are simply added to a suspension of mononuclear cells 
in media. Alternatively, T-cell activation is often facilitated with differentiated antigen 
presenting cells (APC) prepared in advance. Mitomycin C-treated PBMC and adherent cells 
from peripheral blood monocyte culture have both been used as renewable sources of 
syngeneic APC 28'29. Recall antigens utilized in published studies include whole viruses (live 
and inactivated), recombinant viruses, protein extracts from bacterial culture, individual 
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proteins, and peptides. The more complex antigens may be better at provoking APC activity. 
They are also likely to contain more diverse epitopes for the stimulation of polyclonal T cell 
responses. According to dogma, live intracellular pathogens have optimal access to the 
endogenous antigen presentation pathway. This suggests that viable microorganisms may be 
ideal antigens for testing recall responses by CD8 T cells. Synthetic peptide libraries 
containing arrays of short sequences from within antigenic proteins are useful to screen for 
prominent T cell epitopes (reviewed by Rodda30). Libraries tailored for analysis of CTL 
epitopes usually consist of peptides around 8-11 residues in length, whereas libraries for Th 
cell epitopes often have peptide lengths of 13-25 residues. A library of 16mer peptides 
representing two proteins from bovine respiratory syncytial virus was one example of a 
CD4+ T cell epitope library used in veterinary research31. 
Monitoring antigen-driven cytokine production 
A variety of methods are used to analyze T cells' capacity for antigen-specific 
cytokine expression, and like the previously mentioned methods, most of these involve the 
incubation of cells with antigens. Some of the most frequently studied cytokines are Thl 
mediators IFN-y and TNF-a, and Th2 mediators IL-4, IL-5, and IL-10. One approach to 
analyzing cytokine production is to perform "bioassays." In these assays, supematants - such 
as from antigen-stimulated lymphocytes - are tested for biological effects upon a specific 
type of cell in culture. For instance, B cell proliferation can be associated with the presence 
of IL-4. Bioassays have been utilized for studies of domestic animals (see Table 2), 
especially in cases of limited reagent availability. One clear disadvantage to these methods is 
that a particular cytokine is typically not the only factor capable of causing a particular 
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biological effect. More confidence in the presence of a cytokine can be gained if the activity 
is blocked in the presence of cytokine-specific antibody. Because of this subjectivity in 
bioassays, direct detection of cytokines or the transcripts that encode them is generally 
considered to be more accurate and reliable. 
Starting at the level of gene transcription, the first approach is to detect shifts in the 
level of cytokine mRNA after exposing cells to antigen. Methods of analyzing cytokine gene 
transcription include Northern hybridization, ribonuclease protection assays, and several 
variations of RT-PCR. Total RNA can be isolated for any of these methods with a number of 
commercially available kits. Because there are published genetic sequences for many of the 
key cytokines in domestic animal species, the development of probes or primers suited for 
these techniques is generally quite feasible. In their basic forms, the mRNA-based assays 
yield data that are qualitative or semi-quantitative, but adaptations with better quantitative 
readouts have been developed; some of these are mentioned below. 
A ribonuclease protection assay for cytokine transcription relies on the construction 
of a radioactively labeled antisense RNA probe derived from the gene sequence. The probe is 
incubated with total RNA so that it may hybridize with target mRNA. Next the RNA mixture 
is treated with ribonuclease enzyme so that single-stranded RNA is digested, whereas the 
dsRNA complexes are protected. The sample is separated in a denaturing polyacrylamide gel. 
Radioactive signals are measured from the dried gel; intensity of signal is proportional to the 
amount of mRNA. RNA messages for multiple cytokines can be analyzed in a single assay, 
provided that probe sizes are differentiate on the gel32'33. 
RT-PCR offers the advantages of a partially automated assay that requires no 
radioactive isotopes. Total RNA is reverse transcribed into DNA by standard procedures that 
Table 2. 
Cytokine detection methods utilized in domestic animal species 
Technique Host Species 
Bioassay Bovine34 
Chicken35 
Pig" 
RNase protection Bovine33 
Standard RT-PCR Bovine37 
Chicken38 
Competitive RT-PCR Bovine33,39 
Pig40 
Cat41 
Sheep 42 
Real-time RT-PCR Chicken 43,44 
Bovine 45 
Horse 46 
Sandwich ELISA Bovine8 
Chicken 47 
Pig" 
Sheep 49 
ELISPOT Bovine 45 
pig 50,51 
Intracellular staining Bovine52,53 
utilize heat-stable reverse transcriptase enzyme. A pair of PCR primers derived from the 
cytokine sequence are used to amplify the specific signal of interest. In the conventional 
technique, product is electrophoresed on an agarose gel so that the target band can be 
visualized with ethidium bromide under UV light. Densitometry techniques can be used to 
compare band intensities. 
Competitive RT-PCR is a modified version of the assay designed to make results 
somewhat more quantifiable, and it has been used often for the measurement of cytokines 
from domestic animals (see Table 2). This technique requires the construction of a 
competitor template which is recognized by the same two primers that target the cytokine 
mRNA. Amplification of the cDNA template and the competitor template yield products of 
distinct sizes. In a set of parallel reactions, the quantity of competitor template is reduced by 
serial dilutions. The key concept is that greater initial quantities of mRNA-derived template 
will outnumber the competitor template, and thus deliver signal, earlier in the series of 
competitor dilutions. PCR products are separated and visualized on agarose gels. The 
concentration of cDNA can be estimated by identifying the concentration of competitor 
template DNA in the particular lane where the two bands have equal intensity. 
A major advance in this area is real-time RT-PCR, which enables the researcher to 
quantify cytokine transcripts with high sensitivity and accuracy. The read-out from this assay 
is derived from fluorescence signals that correspond with the synthesis of PCR product. The 
accumulation of signal is monitored in real-time from one PCR cycle to the next. One 
strategy is to use a dye in the reaction mixture that specifically labels double-stranded DNA. 
Greater specificity is attainable with fluorescently labeled DNA probes. These 
oligonucleotide probes, such as TaqMan® reagents, have a reporter dye at one end and a 
62 
quencher at the other. Fluorescence is quenched unless the probe is cleaved. The probe is 
specific to the DNA sequence of the target gene, and enough of it must be present to tag all 
amplified DNA strands. During the next primer elongation step, the 5' exonuclease activity 
of Taq polymerase cleaves the probe and unquenches the reporter fluorochrome. A 
fluorimeter built into the thermocycler measures this signal. The number of cycles required to 
achieve detectable signal and the kinetics of signal amplification are used to quantify the 
mRNA template, typically with the help of computer software. 
Generally speaking, the key advantage of mRNA sequence-based tools for studying 
cytokine expression is their versatility in settings where monoclonal antibody reagents are 
not available, as is common in domestic animal research. Several disadvantages must be 
taken into account. First, the transcription of genes does not always correlate with synthesis 
of the respective proteins. Second, the expenses and labor required to perform RNA isolation, 
reverse transcription, and PCR, in addition to the initial cell culture, may be prohibitive in 
experiments where a large number of samples must be tested. Real-time PCR requires 
specialized equipment, which represents another significant expense. 
Cytokines are often measured in supernatants from antigen-stimulated cells using 
ELISA analysis. The sandwich ELISA is preferred for this purpose due to its high specificity 
and sensitivity. This technique requires a pair of antibodies to a given cytokine, which ideally 
should bind to different epitopes. The detection antibody is frequently conjugated to biotin, 
so that an enzyme-streptavidin conjugate can be added in the next step, followed by addition 
of the enzyme substrate. Alternatively, an unlabeled detection antibody can be followed by 
indirect labeling with an isotype-specific antibody-enzyme conjugate. ELISA kits for many 
human and murine cytokines are marketed commercially, but there are only a few kits 
available for domestic animal species. In some cases where kits do not exist, pairs of 
monoclonal antibodies can be purchased in order to develop ELISA assays in-house. One of 
the advantages to using ELISA in detection of cytokines is that many samples can be 
collected and frozen for storage, then tested efficiently at one time. Equipment suitable for 
this technique is available in most research laboratories. Quantitative results can be obtained 
using a standard curve based on purified or recombinant cytokine. Drawbacks to 
conventional ELISA assays are that they do not identify the cell populations producing a 
cytokine or indicate the frequency of cells that express it. Also, detection of a cytokine 
protein does not ensure that the protein is in its biologically active form. Cytokines that are 
characteristically produced at low protein concentrations, such as IL-4, can be difficult to 
detect by sandwich ELISA. 
The frequency of cytokine-secreting cells can be determined with the ELISPOT 
assay, which is a variation on the sandwich ELISA. In this method, capture antibody is 
coated on the bottom of plastic wells before media, cells, and antigen are incubated in them. 
At each locus in the well where a cytokine-secreting cell lies, that cytokine will bind to 
capture antibodies within a small radius. At the completion of the culture period, 
approximately the same detection steps are carried out that would be employed in a 
conventional sandwich ELISA. The result is a pattern of "spots" that corresponds with the 
distribution of cytokine-secreting cells. These spots are examined by microscopy and 
quantified either manually or by computer, which leads to a straight-forward calculation of 
the frequency of cytokine secreting cells. This approach is often used to count effector cells 
after only one or two day of ex vivo incubation, though the detection of memory cells can 
require more time54. Limitations to the ELISPOT method include the lack of information 
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about cytokine quantities and the identity of secretor cells. The latter can be dealt with if cells 
are sorted by phenotype before beginning the assay. Reagent availability for domestic animal 
species is likely to be the same as for conventional ELISA formats. 
Cytokine-producing activity can be measured in different T-cell subsets using 
intracellular cytokine staining techniques and multi-parameter flow cytometry. Two key 
requirements for the success of this approach are that cells retain the cytokine molecules they 
produce and that cells be permeable to antibody during the staining steps. The first 
requirement is met by treating cells with an inhibitor of the golgi complex, such as brefeldin 
A, during culture. The second requirement is met by fixing cells and permeabilizing their 
membranes with a detergent solution before labeling. All of the reagents necessary for 
blocking secretion, fixing, and permeabilizing can be purchased together in a kit. Data are 
acquired and analyzed by much the same approach as the above-mentioned flow cytometric 
assays for T-cell activation. Antigen-specific cytokine-producing cells are often present at 
rather low frequencies, making assay sensitivity a potential problem. One approach to 
overcoming this problem is to amplify the responding cells by adding PMA-ionomycin to the 
cell culture near the end of incubation. Clearly, it is essential with this approach to run 
controls for non-specific T-cell activation. The main advantage of intracellular staining is its 
powerful capacity to trace cytokine production to specific populations of effector 
lymphocytes. However, the assay is complicated by the special requirements for inhibition of 
protein secretion and cell membrane permeabilization. Altered cellular activity may distort 
normal antigen-driven processes, and cell labeling procedures inevitably allows some 
leakage of cytokines. In addition, the technique is more time-consuming than flow cytometric 
assays for T-cell activation markers. 
It was reported that highly sensitive labeling can detect certain cytokines (IL-10 and 
IFN-y, but not IL-2 or IL-4) on the membranes of lymphocytes that secrete them55. The key 
to this high assay sensitivity was a labeling reagent containing several thousand 
fluorochromes per particle, which was achieved with magnetofluorescent liposomes that 
incorporate carboxyfluorescein and specific antibody. Since the detection antibodies are able 
to block the biological activity of the cytokines they bind, it is unlikely that the staining 
technique labeled receptor-bound cytokines. The authors did not demonstrate a mechanism 
for the phenomenon of surface cytokine localization, but it was observed in human, murine, 
and hamster cell lines. This raises the possibility that the production of IL-10, IFN-y, and 
perhaps other cytokines could be assessed by surface labeling in conjunction with 
lymphocyte subset markers without having to block secretion. 
Assays for molecules involved in lytic function 
Effector lymphocytes, such as CD8+ CTL, express distinctive molecules. Some of 
these have been utilized as markers for immunity, and these methods are potentially very 
useful, though they have been little-used in veterinary research to this point. Effector 
molecules originating in the granules of CTL, most notably perforin, granzyme A, and 
granzyme B, are of particular interest. The synthesis of these proteins is induced upon 
activation of the naïve CTL precursor56. When an armed effector CTL recognizes an 
infected cell it releases perforin in a polarized fashion. Perforin facilitates the delivery of 
other granule contents, including the granzymes, which are serine proteases that trigger 
apoptosis pathways. An ELISPOT assay designed to directly measure granzyme B secretion 
was used to detect peptide-specific CTL in PBMC from human patients51. An alternative 
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approach, which probably requires less investment in the development of reagents, is to 
measure granzyme activity with serine protease substrates as indicators. Strong correlations 
have been observed between enzymatic activity and target cell killing 58,59. Influenza-specific 
CMI responses were analyzed in humans using parallel assays for 51Cr release and granzyme 
activity60. Granzyme protease activity was detected in PBMC by measuring digestion of a 
substrate specific to granzyme B. Data obtained by the two methods were well-correlated. 
Techniques aimed at monitoring granzyme production or activity would appear to offer better 
efficiency and fewer difficulties with radioactivity and target cell preparation than 
conventional51 Cr release assays. 
Tetramer labeling of T cell receptors 
A major breakthrough in immunology in the past five years has been the development 
of reagents and techniques that allow the direct identification of peptide-specific CDS T cells. 
The key concept is that peptide-specific COS T cells can be identified from within a 
polyclonal T cell population by staining the cells with a fluorescently labeled complex of 
peptide and autologous MHC class I. This is a powerful tool for identifying critical epitopes 
and measuring the dynamics of a complex immune response. In order to achieve high enough 
avidity to label T cells, multimers of MHC-peptide must be constructed. Typically, four 
MHC-peptide units are combined in a tetramer. "Tetramer" has become shorthand for this 
class of labeling reagents. Since there are typically many peptide targets in a given protein, a 
large set of tetramers is often necessary to characterize the CDS T cell response to an antigen. 
It is much easier to prepare the necessary tetramers when working with a strain of inbred 
mice than with outbred groups of individuals because the MHC genotype is uniform, well-
defined, and shared amongst mice in many different laboratories. This technology has been 
used to analyze murine immune responses to many pathogens and tumor antigens. There are 
a significant number of human studies utilizing tetramers that are matched to the HLA 
genotypes of test subjects. A helpful factor for some of this work is the high prevalence of 
HLA-A*0201 in humans (>95% of US population)13. It is difficult to predict if or when 
sufficient resources might become available for the practical use of tetramer technology in 
veterinary research. Even if it eventually proves feasible, there are limitations to the 
technique. It would be rather cumbersome in studies aimed at assessing the overall T cell 
response to a pathogen because of the many peptides that would have to be tested in each of 
the six MHC I or II types in each individual. Also, tetramer labeling by itself does not 
characterize any functions of cells that it identifies, so other assays would often need to be 
performed with tetramer-positive cells. 
Considerations for experimental design 
CMI assays are inherently more complex than serological assays because they 
measure the in vitro functions and activities of live cells. Therefore, considerable day to day 
variability is typical in experiments that incorporate these assays. This makes it essential that 
statistical analysis be designed to test for diffences between a control group and treatment 
groups that are vaccinated or infected, as opposed to differences across time. Valid statistical 
comparisons are only possible if cells from control and subject animals are tested in parallel 
on the same day. 
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Conclusion 
Many of today's experimental vaccines for veterinary pathogens are designed to 
target critical epitopes by utilizing recombinant gene technology. In these sophisticated 
approaches, genes are more and more routinely being deleted from wild-type 
microorganisms, vectored in heterologous viruses or bacteria, or inserted into plasmids for 
DNA vaccination. In order for these cutting edge vaccines to be thoroughly evaluated and 
optimized for practical use, it is important that researchers and regulatory professionals 
utilize effective and comprehensive tests of immunity. There is also a strong trend toward 
methods for evaluating vaccines and therapeutics that minimize the use of challenge 
infections in animal subjects. Modern assays for cell-mediated immunity will very likely be 
essential for accomplishing all of these goals. 
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Chapter 4. T Cell Populations Responsive to Bovine Respiratory 
Syncytial Virus in Seronegative Calves 
A paper published in Veterinary Immunology and Immunopathology * 
Matthew R. Sandbulte and James A. Roth 
Abstract 
Calves lacking detectable serum antibodies against bovine respiratory syncytial virus 
(BRSV) were screened for virus-specific T cell memory. Peripheral blood mononuclear cells 
were cultured in vitro with live BRSV and analyzed by dual-color flow cytometry for surface 
expression of CD25 on CD4+, CD8+, and 76 T cells. Significant recall responses were 
detected in some of the seronegative calves. Modified-live BRSV vaccine was administered 
to these and to a group of non-responding calves. Following vaccination, virus-specific IgG, 
virus neutralizing antibody, and T cell recall responses were all elevated more rapidly in the 
group with BRSV-sensitive T cells than in the T cell-negative group, which suggested that 
calves in the first group were previously exposed to BRSV. This demonstrates that exposure 
to BRSV can induce T and B cell memory in young calves without causing seroconversion. 
The calves were presumably exposed to BRSV while they had maternal antibody, which 
inhibited the calves from developing an antibody response. 
Keywords: Bovine respiratory syncytial virus; maternal antibody inhibition; T cells; 
modified-live virus; anamnestic immune response 
* Reprinted from volume 84, pages 111-123, © 2002, with permission from Elsevier. 
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Abbreviations: BHV1, bovine herpesvirus 1; BRSV, bovine respiratory syncytial virus; 
BVDV, bovine viral diarrhea virus; E.I., expression index; HBSS, Hanks' balanced salt 
solution; BFN-7, interferon gamma; LSD, least significant difference; PBS% phosphate-
buffered saline with 0.5% bovine serum albumin and 0.1% sodium azide; PE, phycoerythrin; 
PI3, parainfluenza 3; SVN, serum virus neutralization 
1. Introduction 
Various characteristics of bovine immune response to infection and vaccination with 
bovine respiratory syncytial virus (BRSV) have been reported. Seronegative calves produce 
systemic (Kimman et al., 1987a; West and Ellis, 1997; Uttenthal et al., 2000) and mucosal 
(Kimman et al., 1987b; Kimman et al., 1989) antibodies to the virus following primary 
exposure. Cattle in the United States and many other countries are predominantly 
seropositive for BRSV (Ames, 1993; Uttenthal et al., 2000). Correlations between humoral 
responses and protection from secondary challenge have been inconsistent (Kimman et al., 
1989; West et al., 1999a; West et al., 1999b). However, the capacity for a secondary mucosal 
IgA response has been noted as a predictor of protection (Kimman et al., 1987b; West et al., 
1999b). Vaccines vary in their potential to induce neutralizing and fusion-inhibiting 
antibodies to the virus; higher ratios of both parameters (compared to ELIS A titers) are 
induced by modified-live viruses than by inactivated viruses (Ellis et al., 1995; West and 
Ellis, 1997). Substantial BRSV-specific maternal antibody titers can partially protect young 
calves (Kimman et al., 1988; Belknap et al., 1991). Maternal antibody decays at a half-life 
estimated between 23 and 27 days (Kimman et al., 1987a; Uttenthal et al., 2000). 
Results of several studies have demonstrated the importance of a cell-mediated immune 
response to BRSV. In one study, lymphocytes from the respiratory tract, bronchial lymph 
nodes, and peripheral blood all progressed toward an activation phenotype (as measured by 
CD45R, CD45RO, L-selectin, and CD25 expression) following infection with BRSV 
(Mclnnes et al., 1999). CD8+ T cell recruitment to the respiratory tract has been observed in 
the same time frame (Thomas et al., 1996; Mclnnes et al., 1999). In one set of experiments, 
monoclonal antibodies were used to deplete T cell subsets from cattle before and during 
infection with BRSV (Taylor et al., 1995). Virus shedding was prolonged and pathologic 
lesions were most severe in the group lacking CD8+ T cells. Antigen-specific lymphocyte 
proliferation, interferon gamma (IFN-7) production, and chromium-release cytotoxicity 
assays have been used to demonstrate T cell-mediated immune responses to various whole 
BRSV vaccines (Ellis et al., 1992; Ellis et al., 1995; Ellis et al., 1996; Keles et al., 1998; 
West et al., 1999b). In calves immunized with commercial modified-live vaccines and later 
challenged, virus specific proliferation and IFN-7 responses before challenge correlated 
better with rapid virus clearance than did serum antibody titers (West et al., 1999b). 
Passive antibody has been shown to suppress the active humoral response to infection or 
vaccination (Kimman et al., 1987a; Kimman et al., 1987b; Kimman et al., 1989). In the latter 
two studies, live virus administered to maternal antibody-positive calves via the respiratory 
tract did, however, appear to prime for memory antibody responses upon secondary 
challenge after maternal antibody was lost. This suggests that the immune system did 
respond to BRSV in some fashion in the face of maternal antibody. The effect of maternal 
antibody on T lymphocyte priming is uncertain, but there is evidence that viruses can prime 
T cells of passively immune cattle. For example, lymphocyte proliferative responses to 
BRSV were detected in seropositive neonatal calves following a single vaccine dose (Ellis et 
al., 1996). 
In preparation for another study, we tested sixteen beef calves that lacked BRSV-specific 
IgG and serum virus neutralizing (SVN) antibody for T-cell mediated immunity to the virus. 
A flow cytometric assay measuring in vitro virus-specific upregulation of surface CD25 (the 
alpha chain of the interleukin-2 receptor) was used to analyze the sensitivity of CD4+, CD8+, 
and y<5 T cells to live BRSV. These animals were assumed to be immunologically naïve to 
BRSV, but for three calves the assay repeatedly detected T cells responding to BRSV. This 
suggested that the animals had previously been infected with BRSV. In response to the 
conflicting serological and cellular data, and given the evidence cited above that a cell-
mediated immune response may be activated in calves with antigen-specific maternal 
antibody, we hypothesized that these calves had been infected while maternal antibody was 
still present. The antibody-negative, T-cell-positive animals and a group of the naïve calves 
were immunized with a commercial modified-live vaccine in order to compare their 
functional immune responses and to clarify the unconventional immune status of the first 
group. If the hypothesis was correct, this would be a secondary exposure for the T-cell 
positive calves, and the subsequent humoral and cell-mediated responses would be expected 
to reflect immunologic memory. 
2. Materials and methods 
2.1. Animals 
Sixteen mixed breed beef calves, which had tested negative for serum virus neutralizing 
(SVN) antibody to BRSV, were purchased. All calves were from the same herd and had an 
average body weight of approximately 180 kg. Additional serum samples were collected 
(weeks -4 and 0) to test for SVN activity and ELISA antibody against BRSV. Peripheral 
blood mononuclear cells were isolated three times (weeks -4, -2, and 0) and cultured in vitro 
to test for recall responses to BRSV using flow cytometry and CD25 as an activation marker. 
Upon finding that all calves were seronegative by virus neutralization, and that three of them 
consistently had BRSV -responsive T cells, treatment groups were formed. Eight of the naïve 
calves with negative T cell responses and all three of those with positive T cell responses 
were vaccinated (on day 0) intramuscularly with 2 ml of modified-live vaccine containing 
BHV1, types I and II bovine viral diarrhea virus (BVDV), parainfluenza virus 3 (PI3), and 
BRSV (Titanium™ 5, Agri Laboratories, Ltd., St. Joseph, MO). At week four post-
vaccination, these calves received a second, identical dose of Titanium™ 5. The other five 
naïve calves were not vaccinated, and composed a negative control group. In one of these 
individuals, the T cell assay was unreliable, due to high background expression of CD25. The 
data from this animal was not included. 
2.2. Viruses 
Modified-live BRSV from Bovi-Shield™ BRSV vaccine (Pfizer Animal Health, Exton, 
PA) was used for in vitro stimulation of peripheral blood mononuclear cells (PBMC). The 
vaccine was reconstituted with the manufacturer's diluent, aliquotted into small volumes, and 
stored at -70°C. The optimal dilution of virus for stimulation of T cells was determined by 
titrating with PBMC from a separate group of positive control animals. 
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2.3. Antibodies 
Primary and secondary antibodies used to label PBMC for flow cytometry were the same 
as listed previously (Quade and Roth, 1999), except that two fluorochrome-conj ugated 
secondary antibodies were purchased from Southern Biotechnology Associates 
(Birmingham, AL). These were goat anti-mouse IgGl-fluorescein isothiocyanate (FITC) and 
goat anti-mouse IgG2a-phycoerythrin (PE). A peroxidase-labeled goat anti-bovine IgG (with 
specificity for heavy and light chains) was purchased from Kirkegaard & Perry Laboratories 
(Gaithersburg, MD) for detection of BRSV-specific IgG in an ELIS A assay. 
2.4. Isolation and culture of PBMC 
Blood samples were collected from calves in tubes containing 60 U.S.P. units heparin per 
ml blood at weeks -4, -2, 0,2,4, and 6. PBMC were isolated for in vitro culture. The 
samples were kept on ice until being centrifuged at 800g for 20 minutes at 4°C. The buffy 
coat was collected and diluted at least 2-fold in Hanks' balanced salt solution without Ca2+ 
and Mg2+ (HBSS), and layered onto an equal volume of Histopaque 1077 (Sigma, St. Louis, 
MO). This was centrifuged as before, and the mononuclear cell layer was washed in HBSS. 
Contaminating erythrocytes were lysed by hypotonic flash lysis. PBMC were counted and 
resuspended to 1.6 X 107/ml in HBSS. Then the cells were cultured with or without virus in 
96-well, round-bottomed plates. Wells received 200 (j.1 of growth medium (RPMI^), 
consisting of RPMI1640 with 25mM HEPES and L-glutamine (Life Technologies, 
Gaithersburg, MD), plus 10% fetal bovine serum (PBS) (Atlanta Biologicals, Norcross, GA) 
and 0.1% tissue culture penicillin/ streptomycin (Sigma, St. Louis, MO). The FBS tested 
negative for BVDV by five blind passages in cell culture, followed by immunocytochemistry 
using bovine antiserum to BVDV. Each well received 4 X 105 PBMC in 25 p.1 volume and 
25 pi of either BRSV suspended in RPMI"" (104 TCID50 / ml) or control RPMI"" alone. Cells 
with each stimulus (BRSV and control RPM1"H~) were dispensed in triplicate wells. Plates 
were incubated in a humidified 5% CO2 atmosphere at 39°C for 5 days. 
2.5. Fluorescent labeling and flow cytometry 
Following culture, PBMC underwent washing and antibody labeling. This was carried out 
as follows: Plates of PBMC were initially chilled on ice, then washed four times, twice with 
cold phosphate-buffered saline (PBS) and twice with cold PBS with 0.5% BSA and 0.1% 
sodium azide (PBS"1-1"). Cells were incubated with two primary monoclonal antibodies: one 
against CD25 and another against CD4, CDS, or 7Ô TCR. Each well received a 50-jxl PBS4™1" 
suspension of its two antibodies. In these mixtures the concentrations of anti-CD4 and -CDS 
were 3.3 pg/ml and the concentrations of anti-yô TCR and anti-CD25 were 1.67 pg/ml. In 
isotype control wells, mouse IgG2A, IgGl, and IgG2b were used in place of anti-CD25, anti-
CD4 and anti-CDS, and anti-yô TCR, respectively. Cells were incubated with the primary 
antibodies at 4°C for 30 minutes, followed by four washes with cold PBS++. Appropriate 
secondary antibodies were added to all wells. Each one received anti-IgG^-PE conjugate 
(0.17 ng/ml) and either anti-IgGi-FITC (1.0 ng/ml) or anti-IgG^-FITC (0.33 ng/ml) 
conjugate. Four washes with PBS followed. Cells were fixed with 1% formaldehyde in 
HBSS, and the contents of triplicate wells were pooled in tubes. A FACScan flow cytometer 
(Becton-Dickinson) was used to acquire raw data from samples. Excitation was by a 488 nm 
laser. FITC fluorescence was measured in the FLl channel and PE fluorescence was 
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measured in the FL2 channel. Forward and side scatter parameters were also acquired, and an 
acquisition gate was set around the lymphocyte populations. Enough cells were analyzed to 
accumulate 5000 gated events for each sample. 
2.6. Serology 
At weekly intervals, blood samples were collected in evacuated serum separator tubes. 
After centrifuging tubes for 30 minutes at 1200g, aliquots of serum were removed and saved 
at -20°C until submission for testing. Samples were submitted to the Iowa State University 
Veterinary Diagnostic Laboratory for measurement of BRSV serum neutralizing antibody 
titers. Neutralization titers were defined as the reciprocal of the highest serum dilution that 
inhibited 100% of BRSV cytopathic effects in cell culture. 
An indirect ELIS A protocol was used to detect BRSV-specific IgG in frozen serum 
samples, using a protocol adapted from Bruckova et al. (1981). Briefly, BRSV antigen was 
partially purified from BRSV-infected bovine turbinate cell monolayers, and negative control 
antigen was prepared from noninfected cells. Lysates from freeze-thawed and sonicated cells 
were ultracentrifuged, resuspended in BBSS (pH 8.5), and coated onto ELISA plates. Serum 
samples from weeks -4 and 0-6 were diluted 1:5 and dispensed into duplicate BRSV antigen-
coated and control antigen-coated wells. Plates were incubated at room temperature, washed, 
and treated with peroxidase-labeled goat anti-bovine IgG, diluted 1:500. After application of 
substrate, absorbance was read at 405 nm. Final optical density (OD) values were tabulated 
for BRSV-coated wells receiving serum by subtracting the background OD level in wells 
without serum added. 
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2.7. Data analysis 
Analysis of CD25 expression index data was performed as described previously (Quade & 
Roth 1999). Gates were set on the basis of side-scatter versus forward-scatter to include most 
lymphocytes. Quadrant markers were selected by comparing staining with specific antibodies 
versus isotype controls. For each combination of T-cell subset and stimulant, the percentage 
of cells expressing CD25 and the geometric mean fluorescence intensity of CD25-specific 
staining among these cells were tabulated. CD25 expression indices (E.I.) were calculated by 
the following formula for each combination of animal, stimulant, and subset: 
(% of subset CD25+')x(geometric mean intensity of CD25 staining) for cells cultured with BRSV 
(% of subset CD25+)x(geometric mean intensity of CD25 staining) for cells cultured with medium 
For statistical tests, a log(2) transformation was performed on all CD25 expression index 
values and SVN titers. All SVN titers of <2 were defined to be 1 prior to log(2) 
transformation. Differences in mean log2(CD25 E.I.) and mean log^(SVN titer) among 
groups at each time point were determined by Analysis of Variance in the SAS program 
(SAS Institute Inc., Cary, NC) with P < 0.05. Pairwise comparisons between treatment 
effects in the three groups were made by Least Significant Difference tests (LSD). 
3. Results 
3.1. Baseline immunity 
T cells from group 3 cattle responded to BRSV in vitro at all three pre-vaccination time 
points. At two of these samplings, the log^(GD25 EI) for CD4+, CD8+, and yô T cells in 
group 3 were all significantly greater than corresponding values in groups 1 and 2 (P < 0.05) 
(Figures 1-3). SVN titers were also assayed three times prior to vaccination. Negative titers 
were recorded consistently for most calves in every group (Figure 4). The exceptions were 
titers of 2 for three calves (one in group 1 and two in group 3) and 4 for another (in group 2) 
at week 0. One week later, negative titers were recorded again for one of the calves that had 
registered at 2 (in group 1) and for the calf that had registered at 4 the week before. Archived 
serum samples were later assayed by ELIS A for BRSV-specific IgG in order to test whether 
T-cell positive group 3 calves had in fact seroconverted with non-neutralizing antibody 
against the virus. Among groups 1,2, and 3 there were no significant differences in OD 
values at week -4 or week 0, the only pre-vaccination time points tested. The week 0 OD 
values (± standard deviation) for groups 1, 2, and 3 were 0.109 ± 0.041,0.114 ± 0.029, and 
0.107 ± 0.015 respectively. Thus, cattle in groups 1 and 2 were naïve to BRSV with respect 
to T cells and antibody titers. The animals in group 3 had been primed for T cell responses to 
BRSV, but were antibody negative. 
3.2. Virus-specific T cell sensitivity 
Groups 2 and 3 were vaccinated with a commercial modified-live vaccine against BRSV, 
BVD types I and II, BHVl, and PI3 at week 0 and boosted with the same vaccine at week 4. 
BRSV-specific CD4+ T cells were detected in initially naïve calves (group 2) by week 4, 
when the geometric mean log(2) CD25 E.I. was significantly greater than that of control 
group 1 (P < 0.05) (Figure 1C). This was observed again at week 6. At weeks 2,4, and 6 
CD4+ T cells from group 3 calves maintained a significantly higher E.I. over their 
counterparts in the other two groups. 
Figure 1. 
BRSV-specific CD25 upregulation by CD4+ T cells from BRSV-seronegative calves 
vaccinated with modified-live vaccine. Vaccine was given to group 2 (T-cell negative, n=8) 
and group 3 (T-cell positive, n=3) at weeks 0 and 4, while group 1 (n=4) served as negative 
controls. At each sampling, PBMC were cultured with and without live BRSV for 5 days and 
analyzed for CD25 expression by two-color flow cytometry. Shown are the percentage of 
CD4+ T cells expressing surface CD25 (A), the mean fluorescence intensity of CD25 
expression among CD4+CD25+ T cells (B), and the CD25 expression index (E.I.) of CD4+ T 
cells (C). Error bars represent standard errors of the means. * Group 2 E.I. significantly 
greater than group 1, P < 0.05. f Group 3 E.I. significantly greater than group 1 ,P< 0.05. 
X Group 3 E.I. significantly greater than group 2,P< 0.05. 
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Figure 2. 
BRSV-specific CD25 upregulation by CD8+ T cells from BRSV-seronegative calves 
vaccinated with modified-live vaccine. Vaccine was given to group 2 (T-cell negative, n=8) 
and group 3 (T-cell positive, n=3) at weeks 0 and 4, while group 1 (n=4) served as negative 
controls. At each sampling, PBMC were cultured with and without live BRSV for 5 days and 
analyzed for CD25 expression by two-color flow cytometry. Shown are the percentage of 
CD8+ T cells expressing surface CD25 (A), the mean fluorescence intensity of CD25 
expression among CD8+CD25+ T cells (B), and the CD25 expression index (E.I.) of CD8+ T 
cells (C). Error bars represent standard errors of the means. * Group 2 E.I. significantly 
greater than group 1, P < 0.05. f Group 3 E.I. significantly greater than group 1 ,P< 0.05. 
X Group 3 E.I. significantly greater than group 2, P < 0.05. 
86 
% of CD8+ T Cells Expressing CD25 
A. SGrpI Unstim 
• Grp1 + BRSV 
B Grp2 Unstim 
• Grp2 + BRSV 
HGrp3 Unstim 
Week-4 Week -2 WeekO Week 2 Week 4 Week 6 
CD8+ T Cell Mean Fluorescence Intensity of CD25 
Expression 
B. 
Week-4 Week -2 WeekO Week 2 Week 4 Week 6 
CD8+ T Cell CD25 Expression Indices 
50 
45 • Group 1 
• Group 2 
• Group 3 
40 
| 35 
1 30 
§ 25 g-
UJ 20 
A 15 
10 
5 
0 
Week -4 Week-2 WeekO Week 2 Week 4 Week 6 
Figure 3. 
BRSV-specific CD25 upregulation by yô T cells from BRSV-seronegative calves vaccinated 
with modified-live vaccine. Vaccine was given to group 2 (T-cell negative, n=8) and group 3 
(T-cell positive, n=3) at weeks 0 and 4, while group 1 (n=4) served as negative controls. At 
each sampling, PBMC were cultured with and without live BRSV for 5 days and analyzed 
for CD25 expression by two-color flow cytometry. Shown are the percentage ofyô T cells 
expressing surface CD25 (A), the mean fluorescence intensity of CD25 expression among 
CD25+ yô T cells (B), and the CD25 expression index (E.I.) of yô T cells (C). Error bars 
represent standard errors of the means. * Group 2 E.I. significantly greater than group 1, P < 
0.05. t Group 3 E.I. significantly greater than group 1, P < 0.05. $ Group 3 E.I. 
significantly greater than group 2 , P <  0.05. 
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Primary vaccination did not have a large effect on the magnitude of CD8+ T cell responses 
(Figure 2C). The mean CD25 E.I. in CD8+ T cells from group 2 was elevated at week 4 to the 
point that it was not significantly different from group 3. In the only assay following 
secondary immunization (week 6), the mean CD25 E.I. in CD8+ T cells from group 2 had 
become significantly different from that of control group 1 (P < 0.05). Also at week 6, the 
mean log(2) CD25 E.I. for CD8+ T cells in group 3 was once again significantly greater than 
those in groups 1 and 2. 
yÔ T cell responses were also observed after vaccination (Figure 3C). At weeks 4 and 6, 
the mean log(2) CD25 expression indices for yô T cells in group 2 were significantly greater 
than in control group 1 (P < 0.05). At approximately the same time, an elevation in the mean 
CD25 E.I. of group 3 was evident. At weeks 4 and 6, yô T cells from group 3 once again 
showed significantly greater responses than either other group. 
Levels of CD25 expression on the different subsets of T cells appear to fall into somewhat 
different ranges following culture with and without the presence of BRSV. Variation in the 
percentages of subsets expressing CD25 probably reflects differences in their viability in 
culture and their rate of clonal expansion upon antigen recognition. 
3.3. Humoral responses to BRSV vaccine 
Serological data also suggested that group 3 calves had been primed for specific immunity 
to BRSV (Figure 4). Following immunization calves that already had BRSV-specific T cells 
(group 3) produced a strong, rapid SVN response to BRSV. In contrast with the weak 
primary antibody response in fully naïve calves (group 2), this appeared to be a memory 
response. One week after vaccines were given, the mean log(2) SVN titer of group 3 was 
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Figure 4. 
Serum virus neutralizing antibody responses of seronegative calves immunized with 
modified-live BRSV. Vaccine was administered to group 2 (T-cell negative) and group 3 (T-
cell positive) at weeks 0 and 4, while group 1 served as negative controls. Values given are 
logz(SVN titer). * Group 2 significantly greater than group 1 ,P< 0.05. f Group 3 
s i g n i f i c a n t l y  g r e a t e r  t h a n  g r o u p  1  , P <  0 . 0 5 .  J  G r o u p  3  s i g n i f i c a n t l y  g r e a t e r  t h a n  g r o u p  2 ,  P  
< 0.05. 
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statistically greater than those in groups 1 (naïve, non-vaccinated) and 2. This trend 
continued until the week after booster vaccination (week 5). At this point a statistically 
significant difference was detected in the SVN titers of control group 1 and group 2. The 
anamnestic antibody response in group 2 after secondary immunization produced titers very 
similar to those observed in group 3 after a single vaccine dose. 
4. Discussion 
A group of calves that had T cells primed to respond to BRSV, but lacked detectable titers 
of serum virus neutralizing antibody against BRSV was identified. These calves responded to 
vaccination by producing a greater antibody and T cell response than did animals without 
BRSV-specific T cells. This suggests that the animals were previously exposed to the virus, 
which enabled priming of T and B lymphocytes, but they were prevented from mounting an 
antibody response. The data are consistent with the hypothesis that these calves were infected 
with BRSV while still possessing virus-specific maternal antibody in their serum. Some 
studies have shown that virus infection or vaccination in calves (Bradshaw and Edwards, 
1996; Lemaire et al., 2000), infants (Gans et al., 1999), and mice (Siegrist et al., 1998) with 
high maternal antibody titers may induce a T cell response despite the absence of an active 
antibody response. In other studies, passively immunized calves that failed to mount primary 
antibody responses to BHV-1 (Brar et al., 1978) and BRSV (Kimman et al., 1989) did have 
memory-type antibody responses following secondary exposure. In the latter case virus 
shedding was monitored, revealing that intranasal priming conferred protection to colostrum 
fed calves. Our laboratory recently evaluated T-cell and neutralizing antibody responses in 
groups of colostrum fed and colostrum deprived calves that were challenged and later re-
challenged with bovine viral diarrhea virus (BVDV) types I and II (Endsley et al, submitted 
for publication). Colostrum fed calves, with very high passive antibody titers to BVDV I and 
II, did not produce neutralizing antibody following initial exposure. However, T cell priming 
was evident in this group of animals. Upon challenge, they mounted anamnestic antibody 
responses and were protected from disease. Other researchers vaccinated neonatal calves 
with BRSV in the face of maternal antibody and subsequently detected lymphocyte 
proliferative responses to BRSV, which demonstrated some degree of lymphocyte priming 
(Ellis et al., 1996). Therefore, our observation that T cell-mediated immunity to BRSV can 
occur without seroconversion is consistent with the reported immune responses of cattle, 
humans, and mice possessing maternal antibody to several viruses. 
The mechanisms by which maternal antibody could block antibody production by B cells 
are not clear. It is generally thought that immunosuppression by passive antibody results 
from antigen being bound and, in the case of some viruses, neutralized. It seems plausible 
that the resulting immune complexes would be readily taken up and processed by antigen 
presenting cells. This would enable naïve, antigen-specific T cells in secondary lymphoid 
tissue to recognize immunodominant epitopes and proliferate. Another relevant mechanism is 
the suppression of naïve B cell activation that occurs when immune complexes crosslink 
surface antigen receptor with FcyRIIb (Fridman, 1993). Work done in calves by Aldridge et 
al poses another possible explanation (Aldridge et al., 1998). They examined the expression 
of surface immunoglobulins on B cells in the lymph nodes of fetal and neonatal calves. 
Surface IgGl and IgG2 expression in colostrum fed calves was absent at 36 h of age, but 
readily detectable in fetuses and colostrum deprived calves. This implied that a non-antigen-
specific factor in colostrum could have a part in modulating calves' antibody production. It is 
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questionable whether any of these mechanisms would allow for B cell priming while 
suppressing antibody production. Since we did not measure B cell activation in this 
experiment, we cannot rule out the possibility that T cells were the only lymphocyte 
population to initially develop memory. In this scenario, one could speculate that the 
presence of many antigen-specific helper T cells in calves from group 3 accelerated the 
priming of B cells after vaccination. 
In conclusion, the data presented here demonstrate that cattle can acquire T cell 
responsiveness to BRSV while remaining seronegative to the virus. This agrees with findings 
in some other host-virus systems. It demonstrates that BRSV seronegative cattle should not 
be presumed to be immunologically naïve to BRSV, because the IgG ELIS A and SVN assays 
are not sufficient to identify all calves primed for a response to the virus. Seronegative calves 
with T cells primed against BRSV respond more rapidly and vigorously to vaccination than 
naïve animals. 
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Chapter 5. Priming of Multiple T Cell Subsets by Modified-Live and 
Inactivated Bovine Respiratory Syncytial Virus Vaccines 
A paper accepted for publication in Veterinary Immunology and Immunopathology 
Matthew R. Sandbulte and James A. Roth 
Abstract 
T cell activity is a critical component of immunity to bovine respiratory syncytial virus 
(BRSV). We tested the effects of immunization by modified-live and inactivated BRSV 
vaccines on cell-mediated and humoral immunity in young calves. The two forms of vaccine 
stimulated similar serum neutralizing antibody production, although the early kinetics of 
those responses differed. CD4+, CD8+, and yô T cells were analyzed before and after 
immunization for BRSV-specific in vitro recall responses, as evaluated by CD25 
upregulation measured by flow cytometry. Modified-live virus (MLV) primed each of the 
three subsets for statistically significant in vitro responses to antigen. Inactivated vaccine also 
primed each T cell population for significant antigen-driven CD25 upregulation, including 
responses by CD4+ and 70 T cells that were stronger and longer-lasting than those primed by 
MLV. Monoclonal antibody was used in additional assays to block MHC class I during 
incubation of BRSV antigen with peripheral blood mononuclear cells from an animal in the 
inactivated vaccine group. The recall response by CD8+ T cells was more inhibited by this 
treatment than the other subsets, further suggesting that the inactivated vaccine had primed 
antigen-specific CD8+ T cells. In summary, the data indicate that balanced BRSV-specific T 
cell responses can be induced by inactivated, as well as modified-live, conventional vaccines, 
which may implicate an alternative pathway of MHC class I antigen presentation. 
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Keywords: Bovine respiratory syncytial virus, vaccination, T cells, CD25 
Abbreviations: BRSV, bovine respiratory syncytial virus; IFN-y, interferon gamma; HBSS, 
Hanks' balanced salt solution without Ca2+ and Mg2+; HRSV, human respiratory syncytial 
virus; MLV, modified-live virus; PBS% phosphate-buffered saline plus BSA and sodium 
azide; PE, phycoerythrin; RPMf% RPMI1640 media plus fetal bovine serum and antibiotics 
1. Introduction 
Bovine respiratory syncytial virus (BRSV), of the Paramyxoviridae family, is an 
important etiologic agent of respiratory disease in dairy and beef cattle (Larsen, 2000). 
Calves less than one year of age are particularly susceptible to outbreaks of the virus (Van 
der Poel et al., 1994; Larsen, 2000). BRSV infects bronchiolar and alveolar epithelial tissues, 
and infected epithelial cells may fuse into syncytia (Viuff et al., 1996). Bronchiolitis and 
interstitial pneumonia in the cranioventral lung region, and alveolar edema and interstitial 
emphysema throughout the lung are typical (Kimman et al., 1989a; Baker et al., 1997). 
Human respiratory syncytial virus (HRSV) is a closely related virus that causes similar 
lesions and clinical symptoms in infants (Duncan and Potgieter, 1993; Van der Poel et al., 
1994). 
Cattle in many countries are predominantly seropositive for BRSV (Baker et al., 1997; 
Uttenthal et al., 2000). Infection with the virus does not generally induce sufficient 
immunity to prevent subsequent infection. Seroprevalence is high even in young calves, due 
to colostrum-borne maternal antibodies (Kimman and Westenbrink, 1990). Passive antibody 
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may provide partial protection from disease when titers are high (Duncan and Potgieter, 
1993), but it inhibits the humoral response to vaccine or infection, even after titers decline 
below protective levels (Kimman et al., 1989b). Another complicating factor in the 
development of RSV vaccines is the potential for immunopathologic effects. Immunization 
of infants with a formalin-inactivated HRSV vaccine enhanced subsequent disease (Kim et 
al., 1969). Therefore the quality of immunization attained in other RSV hosts, such as cattle, 
is of special interest. Calves that received an experimental formalin-inactivated BRSV 
vaccine also suffered enhanced disease following challenge (Gershwin et al., 1998). In 
addition to that work, several studies have examined the efficacy of inactivated and 
modified-live BRSV vaccines in stimulating different facets of the immune response and 
protecting against challenge. 
In one study, commercial MLV and inactivated vaccines were compared by monitoring in 
vitro parameters of cell-mediated immunity, and responses were distinctly different (Ellis et 
al., 1992a). Antigen-specific lymphocyte proliferation was detectable after one dose of 
adjuvanted, inactivated vaccine, but only after secondary immunization with MLV. The 
strong cellular response to inactivated BRSV was consistent with previous lymphocyte 
proliferation data induced by glutaraldehyde-fixed, whole-cell vaccines formulated with 
Freund's incomplete (Taylor et al., 1987) or Quil A adjuvants (Howard et al., 1987). In 
contrast, another study of several commercial vaccines showed that MLV vaccines 
stimulated superior immune responses in terms of both neutralizing antibody and lymphocyte 
proliferation (Ellis et al., 1995). 
Additional studies tested the protective effects of MLV and inactivated vaccines against 
viral challenge. Glutaraldehyde-fixed, cell-associated BRSV and heat-inactivated, cell-free 
BRSV vaccines were tested in lambs (Keles et al., 1998). Both vaccines limited virus 
shedding and induced humoral and cellular immunity, as assessed by virus neutralization, 
virus-specific cytotoxicity, and lymphocyte blastogenesis. The glutaraldehyde-fixed vaccine 
gave superior protection and immune responses. A similar set of experiments in calves was 
performed with two commercial, polyvalent MLV vaccines (West et al., 1999). After 
challenge, clinical disease, virus shedding, and pulmonary lesions were reduced in calves 
receiving either vaccine. Protection was correlated with in vitro cellular responses before 
challenge, that is, antigen specific lymphocyte proliferation and interferon gamma (IFN-7) 
production. Virus clearance in vaccinated and control calves coincided with the detection of 
BRSV-specific CTL in the lungs. Thus, while inactivated and modified-live BRSV vaccines 
can both stimulate humoral and cellular immune responses, the literature suggests 
considerable variation in these responses. It is not expected that an inactivated virus would 
prime CD8+ cytotoxic T lymphocytes because these cells recognize peptides presented on 
MHC class I, and this mode of presentation is generally thought to require virus replication in 
the cytoplasm. 
CD8+ T lymphocytes and associated virus-specific cytotoxicity are important for a 
protective immune response to BRSV (Taylor et al., 1995; Thomas et al., 1996; West et al., 
1999). CD4+ T cell responses to BRSV are of special interest due to their complex roles as 
helper cells, i.e. production of type 1 and/or type 2 cytokines. The y<5 T cells are a prominent 
cell population in cattle, and have at least an immunomodulatory role in the responses to 
numerous pathogens (Hein and Mackay, 1991; Howard et al., 1999; Rhodes et al., 2001; 
Naiman et al., 2001), possibly including BRSV (Taylor et al., 1995). Conventional 
lymphocyte proliferation assays do not distinguish activation of the CD4+, CD8+, 7Ô T cell, 
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and B-cell populations. For an improved comparison of how different BRSV vaccines prime 
the cell-mediated immune response it is important to measure the stimulation of each 
population of T cells. Dual-color flow cytometry has been used to measure in vitro 
activation of antigen-specific ruminant T cells by monitoring expression of CD25, which is 
the inducible alpha chain of IL-2 receptor (Quade and Roth, 1999; Liebana et al., 1999; 
Whist et al., 2000; Sandbulte and Roth, 2002). In the present study a similar technique was 
used to monitor T cell priming in cattle after immunization with inactivated or modified-live 
commercial BRSV vaccines. 
2. Materials and Methods 
2.1. Animals 
Holstein steers, weighing approximately 225-275 kg, were randomly divided into two 
treatment groups. Before treatment, peripheral blood mononuclear cells were isolated twice 
to assay baseline in vitro responses to BRSV and ConA (Sigma, St. Louis, MO). All calves 
were negative for BRSV serum neutralizing antibodies and negative for BRSV-specific T 
cell responses before vaccination. A group of four calves were vaccinated intramuscularly 
with 2 ml of monovalent modified-live BRSV (Bovi-Shield BRSV, Pfizer Animal Health, 
Exton, PA). The other four animals were vaccinated intramuscularly with 2 ml of 
monovalent killed BRSV with Xtend III adjuvant (Syn Shield, Grand Laboratories, Inc., 
Larchwood, IA). In accordance with both vaccine labels, vaccinated cattle were re-
vaccinated after four weeks with doses identical to their first ones. Both vaccines were 
produced from virus grown in bovine cell lines, so it is unlikely that the recipient cattle 
would have developed immunity to cell culture components. Two BRSV-negative Holstein 
steers served as negative control animals and two that had been immunized multiple times 
with polyvalent modified live vaccine (BRSV Vac 4, Miles, Inc., Shawnee Mission, KS), 
were positive controls. 
2.2. Isolation and culture of PBMC 
Calves were bled at biweekly intervals from week two to week ten. For this set of assays, 
PBMC were isolated and cultured with virus in vitro as previously described (Sandbulte and 
Roth, 2002). To summarize, heparinized blood was centrifuged, and the buffy coat was 
collected, diluted in Hanks' balanced salt solution without Ca2+ and Mg2+ (HBSS), and 
separated on Histopaque 1077 (Sigma, St. Louis, MO). Mononuclear cells were washed and 
contaminating erythrocytes were lysed by hypotonic flash lysis. Then the cells were cultured 
with and without virus in 96-well, round-bottomed plates. Wells received 200|ol of growth 
media (RPMI^), consisting ofRPMI 1640 with HEPES and L-glutamine, 10% fetal bovine 
serum FBS, and 0.1% tissue culture penicillin / streptomycin. The FBS tested negative for 
BVDV by five blind passages in cell culture, followed by immunocytochemistry. Each well 
received 4 X 105 PBMC and either 2.5 X 102 TCID50 of BRSV diluted in RPMf1"* or an equal 
volume ofRPMI^ alone, bringing the final volume to 250 pi Cells were cultured in 
triplicate wells for each treatment. The in vitro viral antigen was modified-live BRSV from 
the Bovi-Shield BRSV product (Pfizer Animal Health, Exton, PA), which was constituted 
with the manufacturer's diluent, aliquotted into small volumes, and stored at -70°C. The 
optimal virus titer for in vitro stimulation of T cells was determined by titrating the antigen 
with PBMC from the positive control animals. Plates were incubated in a humidified 5% CO2 
atmosphere at 37°C for 5 days. 
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For a subsequent experiment it was necessary to prepare PBMC suspensions in which two 
T cell subsets were depleted, in order to study the third subset of T cells in isolation. The cell 
isolation protocol described above was extended by using negative magnetic sorting. After 
the standard preparation of PBMC, the cells were resuspended in a coating buffer consisting 
of HBSS with 10% FBS and 20 mM Hepes, to 2 X 107 per ml. For samples being depleted of 
CD4+ T cells, at least 40 fxg anti-CD4 were added per ml. Samples being depleted of CD8+ T 
cells received 25 jug and those being depleted of yô TCR+ T cells received 33 /xg of the 
corresponding antibodies. Samples were incubated 30 minutes with rocking motion while on 
ice. Two washes with coating buffer followed, and then 50 [il of Dynabeads® were added per 
ml of sample. Samples were incubated 60 minutes at 4°C with gentle tumbling motion. 
Sample tubes were placed in a magnetic particle concentrator (Dynal A.S, Oslo, Norway) for 
three minutes before transferring the unbound contents to a new tube. An additional round of 
depletion was performed by adding fresh Dynabeads® and repeating the incubation and 
separation steps. Remaining cells were cultured exactly as described for nondepleted PBMC. 
Depletion efficiencies of CD4+, CD8+, and yô TCR+ T cells were 94-99%, 88-99%, and 90-
95%, respectively. 
Another experiment was designed to test T cell responses to BRSV while inhibiting MHC 
class I antigen presentation. PBMC used in this experiment did not undergo T cell subset 
depletion. Monoclonal antibody to MHC I and isotype control antibody were dispensed into 
selected wells at the beginning of culture, using antibody concentrations of 100,200, and 400 
ng/ml. 
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2.3. Antibodies 
Specific details concerning the antibodies used to label T cells for flow cytometry in this 
study were provided previously (Sandbulte and Roth, 2002). Briefly, primary monoclonal 
antibodies used to label cell surface markers CD4, CD8a, delta chain of yô TCR, and CD25 
were purchased from VMRD (Pullman, WA). Isotype control antibodies and affinity-
purified, fluorochrome-conjugated secondary antibodies were purchased from Caltag 
Laboratories (Burlingame, CA). 
The same primary antibodies to CD4, CD8a, and delta chain were used in an additional 
experiment as primary reagents for the depletion of specific T cell subsets by magnetic 
sorting. The secondary reagent for T cell depletion was a pan mouse IgG-specific 
monoclonal antibody attached to superparamagnetic beads (Dynabeads®, product number 
110.22; Dynal A.S, Oslo, Norway). For the MHC class I blocking experiment performed in 
this study, a monoclonal antibody to MHC I was purchased from VMRD (cell line H58A); an 
IgG2a isotype control antibody was purchased from Southern Biotechnology Associates, Inc. 
(Birmingham, AL). Both antibodies were dialyzed extensively in HBSS. The isotype of the 
blocking antibody (IgG2a) required that CD25 be labeled with a directly conjugated primary 
antibody. The PhycoLink® R-phycoerythrin (PE) conjugation kit from ProZyme, Inc. (San 
Leandro, CA) was used to label anti-CD25 from the original source. 
2.4. Fluorescence labeling and flow cytometry 
PBMC were prepared for flow cytometric analysis by a previously described protocol 
(Sandbulte and Roth, 2002), described here in brief. The PBMC were chilled on ice at the 
conclusion of the culture period and washed twice with cold PBS. Cold PBS with 0.5% BSA 
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and 0.1% sodium azide (PBS4-1) was used to wash cells two more times. Cell samples were 
incubated with two primary monoclonal antibodies: one against CD25 and another against 
CD4, CD8a, or yô TCR (or corresponding isotype control antibodies). Cells were incubated 
with the primary antibodies at 4°C for 30 minutes. Four washes with PBS** followed. 
Secondary antibodies were used to stain the T cell subset markers CD4, CDS, and yô with 
FITC and CD25 with PE. Cells were incubated with the secondary antibodies in the dark at 
4°C for 30 minutes, followed by four washes with PBS. Cells were fixed with 1% 
formaldehyde in PBS. A FACScan flow cytometer (Becton-Dickinson) was used to acquire 
raw data. An acquisition gate was set around the lymphocyte population, based on forward-
scatter and side-scatter parameters. Each sample was analyzed until five thousand gated 
events were collected. Flow cytometric data was analyzed similarly to that in prior studies 
(Quade and Roth, 1999). Briefly, gates were set on the basis of side-scatter versus forward-
scatter to include most lymphocytes. Quadrants were defined by comparing cell staining 
with specific antibodies versus isotype controls. For each combination of T cell subset and 
stimulant, the percentage of cells expressing CD25 was calculated. 
2.5. Virus neutralization assays 
At the same biweekly intervals, blood samples were collected in evacuated serum 
separator tubes. After centrifuging tubes for 30 minutes at 1200 x g, aliquots of serum were 
removed and saved at -20°C until submission for testing. Samples were submitted to the 
Iowa State University Veterinary Diagnostic Laboratory for measurement of BRSV serum 
neutralizing antibody titers. Neutralization titers were defined as the reciprocal of the highest 
serum dilution that inhibited 100% of BRSV cytopathic effects in cell culture. 
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2.6. Statistical Analysis 
The T cell CD25 expression data were analyzed by week and by subset. BRSV-specific 
responses were determined by calculating the difference between percent CD25 expression in 
samples receiving in vitro antigen versus control samples cultured without antigen. Within a 
treatment group, the mean of this CD25 differential (A%CD25) was determined to be 
significant if its 95% confidence interval excluded zero. Student's T test was used to test for 
significant differences between the two vaccine treatment groups at each time point, in terms 
of A%CD25. Serum virus neutralization values were also analyzed by week, using 
Wilcoxen's ranked sum test to determine significant differences between the two groups. 
Statistical significance for each test was defined as p < 0.05. 
3. Results 
3.1. Virus Neutralization 
Vaccination with MLV and inactivated BRSV vaccines stimulated serum virus 
neutralizing antibody titers that peaked at about the same level (Figure 1). However, these 
two responses developed somewhat differently. Significant neutralizing antibody was 
detected in calves from the MLV group four weeks post-vaccination (p < 0.05). Booster 
doses of both vaccines were administered at week four. There were no detectable neutralizing 
antibody titers in calves from the inactivated vaccine group until week six (p < 0.05). From 
week six until the final assay, at week ten, titers in the killed and MLV groups were very 
similar, but these appeared to be diminishing substantially by week ten. 
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Figure 1. 
Vaccine-induced BRSV neutralizing antibody levels. Serum samples collected the day of 
immunization and at biweekly intervals were tested for virus neutralizing activity in cell 
culture. Serum virus neutralization (SVN) activity was analyzed in two-fold serial dilutions. 
Titers were defined as the reciprocal of the highest serum dilution that inhibited 100% of 
BRSV cytopathic effects. Data is presented as the log2 of SVN titer. Error bars represent 
standard error of the mean (n-4). * P < 0.05; level of statistical significance of the difference 
between the two groups at the time point indicated. 
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3.2. T cell priming 
Both the MLV and inactivated vaccines primed CD4+ T cells to respond to BRSV in vitro 
(Figure 2A). Beginning at week two, the difference in CD25 expression between cells 
cultured with and without antigen was statistically significant in the inactivated vaccine 
group (p < 0.05). This was continued through the tenth week. For the MLV group, significant 
antigen-driven CD25 expression was observed at weeks 6 and 8, although the mean response 
was also higher (p > 0.05) by week 2. At weeks 8 and 10, CD4+ T cells from the inactivated 
vaccine group expressed significantly more CD25 in response to BRSV than their 
counterparts in the MLV group (p < 0.05). 
Immunization induced elevated responsiveness to BRSV by CD8+ T cells from both 
vaccine groups (Figure 2B). During the pre-immunization baseline assays there were low, but 
sometimes statistically significant, levels of CD25 expression by CD8+ T cells cultured with 
BRSV (p < 0.05). For six weeks following immunization there were steady increases in 
sensitivity to the virus by CD8+ T cells from both treatment groups. In the later weeks of the 
study, responses by the MLV group declined to nonsignificant levels, while responses by the 
inactivated vaccine group were quite steady. As a result, the in vitro CD8 response by cattle 
in the inactivated vaccine group was significantly greater than that of MLV vaccinates at 
week 10 (p < 0.05). 
yô T cell responses to in vitro BRSV antigen followed a similar kinetic pattern. For both 
groups, the difference between CD25 expression in yô T cells cultured with and without 
antigen was significant from week 2 through at least week 8 (p < 0.05) (Figure 2C). The 
responsiveness of y<5 T cells from the MLV group declined after week 6 to statistically 
nonsignificant levels at week 10. Responses in the inactivated vaccine group were stable. 
Figure 2. 
CD25 expression on CD4+ (A), CD8+ (B), and yô TCR+ (C) T cells in response to culture with 
BRSV in vitro. PBMC were isolated from cattle in the inactivated virus and MLV vaccine 
treatment groups. Cell samples were incubated with and without the presence of BRSV for 
five days, and the level of CD25 expression was determined for both conditions. Data 
presented are the percent CD25-positive for BRSV-stimulated samples minus the percent 
CD25-positive for samples without BRSV (A%CD25). Error bars represent standard error of 
the mean (n=4). * Denotes a A%CD25 that is statistically significant, i.e. its 95% confidence 
interval excludes zero, t Denotes a significant difference in BRSV-driven CD25 expression 
between cells of the two vaccine treatment groups at a given time point, as determined by 
Student's f-test (P < 0.05). 
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Consequently, there were statistically significant differences between vaccine treatment 
groups at weeks 8 and 10, regarding yô T cell sensitivity to BRSV (p < 0.05). 
Cumulative data from positive control samples during the experiment (n=13) showed 
differential CD25 expression values for CD4+, CD8+ and yô T cells of 39.1±3.0, 27.7±2.1, 
and 60.6±3.9, respectively. Equivalent data from negative control samples (n=12) showed 
differential CD25 values for CD4+, CD8+ and yô T cells of-1.6±3.1, 0.2±2.2, and 0.0±4.1. 
3.3. Roles of accompanying T cell subsets and MHC class I in in vitro activation 
Additional experiments were carried out to better understand the T cell responses to 
inactivated vaccine, with particular attention to CD8+ T cells. In the first approach, each 
subset of T cells was tested for in vitro responsiveness to BRSV after having been isolated 
from the other two subsets. Before culturing PBMC with antigen, magnetic sorting was used 
to deplete two T cell phenotypes and, in effect, enrich the third. On two occasions the three T 
cell subsets from one calf were tested under both protocols: subset isolation and ordinary 
PBMC preparation (Table 1). For CD4+ cells, isolation from the other T cells did not have a 
large influence upon the percentage expressing CD25 after culture with BRSV. In contrast, 
BRSV did not stimulate a perceptible response by isolated CD8+ T cells; these cells had 
significantly less CD25 upregulation during culture than non-isolated CD8+ T cells (p = 
0.04). The antigen-specific CD25 response by yô T cells was also reduced when CD4+ and 
CD8+ T cells were depleted, but the difference was not statistically significant. 
This raised the question of why the CD8+ T cells required the presence of other T cells to 
respond to BRSV in vitro. To test the hypothesis that the vaccine had primed antigen-specific 
CD8+ T cells that required some form of T cell help, anti-MHC class I antibody was used to 
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Table 1. 
BRSV Responses by Fractionated and Nonfractionated T Cells 
BRSV-Driven CD25 Expression a,c 
Cell Phenotvpe Cell Preparation (%CD25 differential ± SEM) 
CD4+ PBMC 53.3 ± 7.9 
CD8 & yô-depleted b 43.8 ± 7.9 
CD8+ PBMC 36.0 ± 5.3 d 
CD4 & y8-depleted b -0.1 ±5.3 
yd TCR+ PBMC 70.5 ± 19.1 
CD4 & CD8-depleted b 29.7 ± 19.1 
a CD25 expression was measured on CD4+, CD8+, and yô TCR+ T cells cultured for five days 
with or without BRSV. Initial preparation of cells was performed in two ways: simple 
isolation of PBMC and PBMC isolation plus magnetic depletion of two T cell subsets to 
isolate the third subset. 
b Depletion efficiencies of CD4+, CD8+, and yô TCR+ T cells were 94-99%, 88-99%, and 90-
95%, respectively. 
c Data represent the percent CD25-positive in BRSV-stimulated cells of a subset minus the 
percent CD25-positive in corresponding nonstimulated control cells (%CD25 differential). 
Values in the table represent the mean ± SEM of two independent assays. SEM uses a pooled 
estimate of error variance for each subset. 
d Denotes a statistically significant difference in A %CD25 between non-fractionated and 
fractionated T cells of a given subset (p < 0.05). 
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Figure 3. 
Influence of blocking antibody against MHC class I upon BRSV-driven CD25 expression in 
vitro. PBMC incubated with and without BRSV antigen were treated with either a 
monoclonal antibody to MHC class I or an isotype control antibody (IgG2a) and analyzed for 
CD25 expression after five days. The difference in CD25 expression by virus-stimulated 
CD4+, CD8+ and yô TCR+ T cells versus non-stimulated controls was calculated. Antigen-
driven CD25 upregulation during treatment with anti-MHC I is expressed as a percentage of 
the corresponding value for cells treated with isotype control antibody. The data represent 
mean values from two assays and error bars represent the standard error of the mean. 
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inhibit or block antigen presentation to CD8+ T cells. Again, the full assay was performed 
twice with cells from one animal. In Figure 3, antigen-driven CD25 upregulation during 
treatment with monoclonal antibody to bovine MHC I is expressed as a percentage of the 
corresponding value for cells treated with isotype control antibody. In the presence of 
increasing anti-MHC I concentrations there were decreasing proportions of CD8+ T cells that 
upregulated CD25 in response to antigen. It should be noted that anti-MHC I antibody also 
diminished the responses of CD4+ and yô T cells to some extent. 
4. Discussion 
Neutralizing antibody responses to MLV and inactivated BRSV vaccines were similar, 
with the exception that titers in the inactivated vaccine group were not detectable until after 
secondary exposure. The SVN antibody response to two doses of MLV was lower than in 
some reports (Ellis et al., 1992b; Ellis et al., 1995; West and Ellis, 1997), but similar to that 
reported in another study where cattle were seronegative at vaccination (West et al., 1999). In 
the latter case, B lymphocytes were primed sufficiently to mount a strong anamnestic SVN 
antibody response following challenge. Researchers have reported widely varying SVN 
responses to inactivated BRSV vaccines. During studies by Ellis and co-workers, eight 
commercial inactivated BRSV vaccines were tested for antibody induction (Ellis et al., 
1992b; Ellis et al., 1995; West and Ellis, 1997; Ellis et al., 2001). Each vaccine induced 
BRSV-specific antibody, detectable by ELIS A, but the levels of neutralizing antibody were 
generally quite low, with a few exceptions. In calves immunized with inactivated BRSV in 
the present study, SVN titers were detected after booster dosage at 28 days, and from that 
point mirrored the response to MLV. This indicates that chemical inactivation of this virus 
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did not denature neutralizing epitopes. Interestingly, the BRSV strain in this vaccine was also 
in one of the polyvalent, inactivated vaccines previously reported to induce significant BRSV 
neutralizing antibody (Ellis et al., 1995), whereas most induced ELIS A antibody but low 
neutralizing activity. 
Both vaccines primed cellular immune responses, and the initiation of T cell priming was 
almost concurrent in the two groups. For individual T cell subsets, significant CD25 
responses to BRSV were observed in both groups within no more than one sampling interval 
of each other. Nonetheless, there were notable differences during the latter stages of the 
experiment. The inactivated vaccine appeared to stimulate a more durable T cell response, 
including elevated CD25 responses after secondary immunization at week four. The T cell 
responses to MLV dropped to statistically insignificant levels by the tenth week. These data 
are consistent with the results of other studies, in which MLV and inactivated, adjuvanted 
BRSV vaccines primed for virus-specific lymphocyte proliferation (Taylor et al., 1987; Ellis 
et al., 1992a; Ellis et al., 1995; Keles et al., 1998; West et al., 1999) and IFN-y production 
(Ellis et al., 2001). In some instances, inactivated vaccines were more effective in priming for 
proliferation than MLV (Taylor et al., 1987; Ellis et al., 1992a). 
In an early study that used light microscopy to analyze CD4 and CD8 expression on 
lymphoblasts from a proliferation assay, CD4+ cells were reported to be the main population 
responding to BRSV after vaccination with MLV or inactivated vaccines (Ellis et al., 1992a). 
Our flow cytometric data indicates that both forms of vaccine primed significant proportions 
of CD4+, CD8+, and y<5 T cells to respond to BRSV, rather than one dominant subset. CD4+ T 
cell responses were lower in the MLV group than in the inactivated vaccine group at the 
latter time points. This may have been due to the fact that inactivated vaccine was formulated 
with an adjuvant, a difference which could have been accentuated if the MLV replicated 
poorly. Yet, CD8+ T cell priming was quite similar in the two treatment groups. 
yô T cell responses developed against BRSV were quite evident in both treatment groups. 
We are not aware of other studies that have examined yô T cell priming by BRSV vaccines. 
The large percentages of the yô T cells that upregulated CD25 during culture with virus 
suggest that they either proliferated very rapidly upon recognition of antigen or were 
stimulated via nonadaptive receptors, such as NKG2D, a receptor for stress-inducible MICA 
(Bauer et al., 1999). The first possibility is more likely because the capacity to respond to 
BRSV was only evident after immunization (Fig. 2C). It is interesting that yô T cells from 
vaccinated animals were activated in the presence of BRSV because lymphocyte studies in 
gnotobiotic calves undergoing mild BRSV infection did not indicate a direct role for 7Ô T 
cells in protective immunity or pathogenesis (Taylor et al., 1995; Thomas et al., 1996; 
Mclnnes et al., 1999). 
Antigen-driven CD25 upregulation was detected on the surface of CD8+ T cells from 
cattle immunized with either the inactivated or MLV vaccines. This phenotypic change is 
consistent with the expected response of memory or effector CD8+ T cells since CTL 
precursors in TCR-transgenic mice respond to antigen in vitro with high CD25 expression 
compared to naïve cells (Cho et al., 1999). Because the classical CD8+ T cell response is 
initiated with endogenous antigen processing and presentation, priming of this subset is 
generally attributed to intracellular replication of a pathogen. Therefore, it was somewhat 
unexpected that the inactivated vaccine would prime CD8+ T cells for a strong in vitro 
response to BRSV. To address the nature of this response in recipients of the inactivated 
BRSV vaccine, two further experiments were carried out. First, the antigen was added to 
negatively selected PBMC samples such that CD4+, CD8+, and 70 T cell responses could 
each be evaluated in the near absence of other T cells. While the CD4 response was not 
changed significantly, responses by the other two subsets were inhibited, particularly that of 
the CD8+ T cells. Thus, the antigen-driven in vitro CDS response was dependent on help 
from other T cells, presumably CD4+ cells. One possible explanation is that cytokines 
produced by class II-restricted T cells might activate CD8+ T cells without any TCR 
engagement (bystander activation). Another possibility is that help from CD4+ T cells was an 
essential co-factor with peptide-class I ligand for the activation of CD8+ T cells. This 
requirement has been reported previously in cattle (Taracha et al., 1997; Walravens et al., 
2002). In order to distinguish between these possibilities, another method was used to 
determine if MHC class I recognition was required for the recall CDS response. Anti-MHC 
class I monoclonal antibody added to PBMC at the beginning of culture with BRSV inhibited 
the upregulation of CD25 on CD8+ T cells in a dose-dependent manner. The meaning of this 
result is somewhat obscured because anti-MHC I also inhibited the in vitro activation of 
CD4+ T cells, to a lesser extent, for unknown reasons. Perhaps impeding the CDS response 
dampens the responses of CD4+ T cells, or the IgG may have nonspecific inhibitory effects 
on cells. Nonetheless, anti-MHC I was more suppressive toward the CDS recall response 
than toward the CD4 recall response. This suggests that the inactivated vaccine did prime 
MHC class I-restricted, BRSV-specific CD8+ T cells. BRSV-induced stimulation of yô T 
cells was inhibited by anti-MHC I at a level intermediate between the other two subsets. 
This observation is difficult to interpret, but the possibility that some bovine yô T cells might 
be class I-restricted is noteworthy. A minor proportion of bovine yô T cells express CDS, 
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which is also consistent with the possibility that some 7Ô T cells may recognize antigen in the 
context of MHC I (Howard et al., 1999). 
CD8+ T cell priming by this inactivated BRSV vaccine is consistent with some previous 
reports. Keles et al detected BRSV-specific CTL in the peripheral blood of lambs that had 
been immunized with a glutaraldehyde-fixed, whole-cell vaccine with adjuvant (Keles et al., 
1998). Heat-inactivated Sendai virus (another paramyxovirus) primed for an MHC class I-
restricted CTL response in mice (Liu et al., 1995). Further studies in cell lines (Liu et al., 
1997b) and splenic antigen presenting cells (Liu et al., 1997a) showed that inactivated Sendai 
virus antigen was processed independently of LMP2/7 proteosome subunits and TAP 1/2 
peptide transporters, which are elements of the classical MHC I antigen presentation 
pathway. 
There are several potential reasons for CD8+ T cell priming in response to inactivated 
virus. Antigen cross-presentation is a special activity of professional APCs that allows them 
to present epitopes from microbes that do not infect APCs (Kurts, 2000). By this 
mechanism, an APC ingests exogenous antigens in peripheral tissues and presents them on 
MHC class I to naïve CD8+ T cells in secondary lymphoid tissues. In our scenario, the 
inactivated BRSV might have been taken up by APC and processed into CD8+ T cell ligands 
in this manner. The Sendai virus studies in mice pointed instead to an endosomal pathway in 
which peptides were loaded onto class I molecules recycling from the cell surface (Liu et al., 
1997a, 1997b). Alternatively, it is plausible that unique characteristics of paramyxoviruses 
make them accessible to the endogenous antigen presentation pathway. If functional 
attachment (G) and fusion (F) proteins remain intact after virus inactivation, they might 
mediate virion entry into the cytoplasm of host cells. Finally, the inactivated vaccine tested in 
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our study contained a proprietary adjuvant that also could have mediated direct entry of 
antigen into the endogenous antigen presenting pathway, a role which some adjuvants are 
designed to play (Vogel, 2000). 
In conclusion, the MLV and inactivated vaccines examined in this study appear to have 
distinct stimulatory effects upon the humoral and cell-mediated immune response to BRSV. 
With respect to cell-mediated immunity, the inactivated vaccine was more effective in 
priming CD4+ and yô T cell subsets to respond in vitro to BRSV antigen. Most notably, 
CD8+ T cells from cattle in the inactivated vaccine group responded to BRSV as well as 
those from MLV vaccinates. These findings provide new insight into the cell-mediated 
immune responses stimulated by conventional BRSV vaccines and support the idea that 
inactivated BRSV vaccines can induce effective cell-mediated immunity in cattle. 
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Chapter 6. T Cells from a High Proportion of Apparently Naïve Cattle 
Can Be Activated by Modified Vaccinia Virus Ankara (MVA) 
A paper submitted to Viral Immunology 
Matthew R. Sandbulte, Ratree Piatt, and James A. Roth 
ABSTRACT 
Modified vaccinia virus Ankara (MVA) was used as a vector to express genes from 
bovine respiratory syncytial virus (BRSV). Using these recombinant viruses as recall 
antigens for cells from BRSV-immune cattle proved to be problematic because non-
recombinant MVA itself frequently stimulated high levels of T lymphocyte activation. This 
phenomenon was observed in a high percentage of cattle from multiple herds. Gamma delta 
T cells were more sensitive to activation by MVA than other classes of T cells. A serological 
assay for MVA neutralization detected low, fluctuating titers of serum virus neutralizing 
(SVN) activity toward MVA in some cattle, but these were lower titers than those observed 
in cattle that underwent MVA vaccination. T cell reactivity in non-vaccinated cattle did not 
correlate significantly (p > 0.05) with SVN activity, undermining the notion that any adaptive 
immune response was responsible for the observed T cell sensitivity. More probable 
explanations are that MVA has autogenic or superantigenic properties, or that the virus 
induces 76 T cell activation through interactions with innate pattern recognition receptors. 
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INTRODUCTION 
Modified vaccinia virus Ankara (MVA), a highly attenuated vaccinia virus strain, is one 
of several poxviruses that have been used as vaccine vectors for pathogen-derived genes. 
Recombinant MVA constructs have been used experimentally to immunize against a number 
of important pathogens, including Dengue virus (13), human immunodeficiency virus (7), 
measles virus (21), Mycobacterium tuberculosis (5), and Plasmodium falciparum (18). The , 
original vaccinia virus isolate from Ankara, Turkey, was attenuated by over 570 passages in 
chick embryo fibroblast culture (15). The genome of MVA has six major deletions, which 
correspond with at least 31 kb of wild type vaccinia virus DNA (14). In mammalian cells the 
MVA replication cycle is blocked at a late stage, but viral genes can be expressed, as can 
heterologous genes placed under MVA promoters (22). 
In at least two studies, recombinant vaccinia vimses have been used in vitro to deliver 
recall antigens for human peripheral blood lymphocytes (10,20). In one of these studies 
(20), non-recombinant MVA stimulated lymphocytes from some individual donors to release 
varying amounts of interferon gamma (IFN-7). It has also been reported that MVA and other 
poxviruses could stimulate lymphocytes from domestic animals that presumably had no 
previous exposure to such agents (2,4). For instance, inactivated parapox ovis virus 
(PPOV), fowlpox virus, vaccinia virus Lister, and MVA all induced responses by porcine 
lymphocytes (4). These responses included cell proliferation and the production of 
cytokines. Activities like these might explain the known immunostimulatory properties of 
inactivated PPOV in vivo. PPOV is the main component in a commercial therapeutic product 
(Baypamun, Bayer AG, Leverkusen, Germany) that reportedly enhances resistance to a 
number of animal infections (3, 9,24). 
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We pursued the possibility of using MVA as a vector for genes of bovine respiratory 
syncytial virus (BRSV). One of the aims was to use several recombinant MVAs as in vitro 
recall antigens to determine the dominant target antigens through the course of an immune 
response to BRSV. During these experiments, we observed that non-recombinant MVA has 
stimulatory properties toward T cells from some cattle, despite the animals' lack of known 
exposure to poxviruses. This posed a major problem for using recombinant MVAs to express 
in vitro recall antigens, because background responses to MVA alone were often nearly as 
high as responses to recombinant MVAs encoding BRSV genes. We performed more in-
depth studies of the interactions between MVA and the immune system of immunized and 
non-immunized cattle. 
MATERIALS AND METHODS 
Animals and experimental design. Cattle used in this study originated from several 
Iowa dairy and beef herds. Most were calves less than one year of age. Groups of cattle are 
named in this section in the order that they were obtained. Fifteen Holstein calves (Group A) 
were housed in a biosafety level 2 animal facility. Twelve of them were inoculated with live 
recombinant MVAs that encoded BRSV genes F, G, or N. MVA-F, MVA-G, MVA-N, and 
non-recombinant MVA were each used to immunize three calves. Three control calves were 
not inoculated with MVA or recombinant MVA. Two doses of 5xl08 TCID50 were 
administered subcutaneously, seven weeks apart. Blood was collected at several time points 
prior to and after inoculation so that serological and cellular responses to MVA and BRSV 
could be analyzed. Blood samples were also obtained from a group of 34 Holstein calves 
(Group B), a group of 18 Holstein calves (Group C), and a group of 24 Angus calves (Group 
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D) during different phases of the work. Calves in groups B, C, and D were kept in 
conventional housing at Iowa State University, and were not inoculated with MVA or 
recombinant MVA. 
Media and reagents. DMEM-F12++ growth medium was prepared from DMEM-F12 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. RPMI++ growth medium consisted of RPMI1640 with 2 mM L-
glutamine and 25 mM HEPES buffer (Mediatech, Inc., Herndon, VA); 10% fetal bovine 
serum (bovine viral diarrhea virus-free, Atlanta Biologicals, Norcross, GA); and 1% 
penicillin / streptomycin solution (Mediatech), providing final concentrations of 100IU 
penicillin/ml and 100 fig streptomycin/ml. 
Primary antibodies to bovine lymphocyte markers were purchased from VMRD (Pullman, 
WA). These murine immunoglobulins included anti-CD4 IgGl (CACTI38A), anti-CD8a 
IgGl (CACT80C), anti-CD8a IgM (BAQ111A), anti-^6 TCR IgG2b (GB21A), and anti-
CD25 IgG2a (CACTI08A). Anti-mouse IgGl-FITC and anti-mouse IgG2a-PE secondary 
antibodies were purchased from Southern Biotechnology Associates (Birmingham, AL). 
Anti-mouse IgG2b-Tri-Color® and anti-mouse IgM-AlexaFluor® 647 secondary antibodies 
were purchased from Caltag Laboratories (Burlingame, CA) and Molecular Probes (Eugene, 
OR), respectively. 
Viruses. MVA was provided by Dr. Bernard Moss (Laboratory of Viral Diseases, 
National Institute of Allergy and Infectious Diseases, Bethesda, MD). The virus was 
amplified by infecting a chicken embryo fibroblast (CEF) cell line (ATCC CRL-1590). CEF 
were grown in D-MEM/F-12++. Virus was isolated after extensive cytopathic effects were 
visible. This was accomplished by freezing and thawing the washed, infected cells; 
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resuspending the contents in a small volume of PBS or DMEM-F12++; and sonicating the 
suspension to liberate virus. After the suspension was centrifuged 10 minutes at 400 x g, the 
clarified supernatant was aliquotted and stored at -70°C. Mock antigen was prepared by 
identical treatment of non-infected CEF cultures. High-titer virus suspensions intended for 
the inoculation of cattle or for density gradient purification were prepared by lysing infected 
cell layers in the medium in which they were grown, which already contained free virus. 
Partially purified virus was obtained by density gradient separation. MVA was isolated by 
the initial steps listed above, then concentrated by ultracentrifugation of the material onto a 
cushion of 50% OptiPrep (Sigma, St. Louis, MO). This spin was performed in a SW 28 rotor 
(Beckman Coulter, Fullerton, CA) for 3 hours at 27,000 rpm (average RCF = 96000 x g). 
Bands collected from these tubes were further concentrated by spinning in a Beckman MLS 
50 rotor (Beckman Coulter) for 2 hours at 40,000 rpm (average RCF = 128000 x g), with the 
same type of cushion as before. The resulting virus suspension was layered onto a 
discontinuous OptiPrep gradient containing adjacent layers of 22% and 32% OptiPrep in 
lOmM Tris-Cl, pH 9.0. This design was adapted from another study in which vaccinia virus 
was purified over a continuous gradient with the same minimum and maximum 
concentrations of OptiPrep (11). The tubes were ultracentrifuged at 25,000 rpm for 3 hours 
(average RCF = 50000 x g), and the band found between the two gradient layers was 
collected and stored at -70°C. The titer of virus inactivity was 3xl07 TCIDso/ml. 
T cell stimulation. Cattle were bled by jugular venipuncture, and blood was collected in 
acid citrate dextrose or sodium heparin solutions. Samples were centrifuged at 800 x g for 25 
minutes. Buffy coat layers were aspirated, and the remaining erythrocytes were treated with 
two rounds of hypotonic lysis by adding two volumes of buffered water for 1 minute and 
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then restoring the suspension to normal osmolality with one volume of triple strength PBS 
(16). Two different systems were used for culturing peripheral blood mononuclear cells 
(PBMC) with MVA in vitro. For cells analyzed by two-color flow cytometry, each well of a 
round-bottom 96-well microtiter plate received 200 fû RPMI++ growth media, 4 x 105 
PBMC, and 2.5 x 102 TCID50 of MVA. Plates were incubated for five days at 37°C in a 
humidified 5% CO2 atmosphere. For cells analyzed by three- and four-color flow cytometry, 
each well of a flat-bottom 96-well microtiter plate received 1 x 106 PBMC in 200 fû 
RPMI++. Plates were incubated for four days at 39°C in a humidified 5% CO2 atmosphere. 
The quantity of MVA added was 2.5 x 103 TCID50 per well, except in titration experiments 
where dose effects were tested. In the first such experiment, cells from 34 cattle (Group B) 
were stimulated by the original MVA preparation at three five-fold dilutions: 5.0 x 102 
TCDD50 / well, 2.5 x 103 TCID50 / well, and 1.25 x 104 TCDD50 / well. In the second titration 
experiment, PBMC from five cattle (Group C) were stimulated by the original MVA 
preparation and by semi-purified MVA at three ten-fold dilutions: 2.5 x 102 TCED50 / well, 
2.5 x 103 TCDD50 / well, and 2.5 x 104 TCID50 / well. Control wells received plain media or 
mock-infected CEF lysate / sonicate instead of virus suspension. 
Flow cytometry. Following the incubation period, flow cytometry was used to analyze 
the sensitivity of CD4, CDS, and 7Ô T cells to MVA antigen. T cell activation was assessed 
by measuring CD25 upregulation upon in vitro exposure to the virus. Because we developed 
improvements to the flow cytometry protocol during the course of these studies, three 
versions of the CD25 assay were used at different stages. In the initial two-color flow 
cytometry assay, triplicate samples were used to analyze the CD4+, CD8+, and y<5 TCR+ 
subsets in parallel, as described previously (17). Briefly, all three received anti-CD25 
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primary antibody (IgG2a) and individual samples received either anti-CD4 (IgGl), anti-
CD8a(IgGl), or anti-70 ICR (IgG2b). Then FITC- and PE-labeled secondary antibodies 
were used to detect subset markers and CD25, respectively. In the three-color technique, 
which used the same primary antibodies, anti-CD8a, anti-70 TCR, and anti-CD25 were 
combined to label one sample. Secondary antibody conjugates used in this format were anti-
IgGl-FITC, anti-IgG2a-PE, and anti-IgG2b-Tri-Color. This allowed CD8+ 76 TCR" cells, 
CD8+ 7Ô TCR+ cells, and CD8" 76 TCR+ cells to be distinguished from one another. CD4 T 
cell analysis in the other sample was unchanged from the two-color assay. Finally, the four-
color assay allowed CD25 expression to be analyzed on all three T-cell subsets in a single 
test sample. In this technique, CD8 was labeled with anti-CD8a IgM primary antibody and 
anti-IgM-AlexaFluor 647 secondary antibody. 
Two- and three-color flow cytometric analysis of FITC, PE, and TriColor fluorescence 
signals were performed on a FACScan cytometer (Becton-Dickinson). Four-color analysis 
was performed on an Epics Altra cytometer (Beckman-Coulter). FITC, PE, and TriColor 
dyes were excited by a 488 nm krypton laser, and AlexaFluor 647 was excited by a spatially 
separated 633 nm helium-neon laser. A gated amplifier was used to differentiate TriColor 
and AlexaFluor 647 signals, which were detected in the same PMT. Analysis of data from 
both flow cytometry methods was performed using CellQuest or FlowJo software. Live 
lymphocytes were gated according to forward- and side-scatter distribution. Data from CD4+ 
T cells was plotted directly from this gate. Plots of CD8 versus 76 TCR were used to draw 
gates that delineated three separate T-cell subsets: CD8 single-positive, 7Ô TCR single-
positive, and CD8 / 76 TCR double-positive. For each of the four subsets, two CD25 
parameters were tabulated: the percentage of cells expressing CD25 (%CD25+) and the 
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geometric mean fluorescence intensity (MFI) of CD25 signal among positive cells. The 
CD25 expression index (EI) was calculated according to the following formula: [(%CD25+) 
x (CD25 MFI) of MVA-stimulated cells] / [(%CD25+) x (CD25 MFI) of non-stimulated cells 
of the same animal)]. 
Serum virus neutralization (SVN) assay. Serum samples collected from cattle were 
stored at -20°C. Before performing the assay, samples were inactivated by heating in a 56°C 
water bath for 30 minutes. For each sample, two-fold serial dilutions were made from 1/4 to 
1/4096 in duplicate rows of a microtiter plate. DMEM-F12++ culture media was used as 
diluent, and the volume of diluted serum was 100 fi\ per well. In addition, each well received 
1.0 x 101 TCID50 of MVA suspended in 100 fil of DMEM-F12++. Serum and virus were 
allowed to incubate for 1 hour at 37°C. Then each well received 100 /tl of cells freshly 
subcultured from 3-5 day-old CEF culture. This combination of serum, virus, and cells was 
incubated in a humidified 5% CO2 atmosphere for 6 days at 37°C. Plates were read for the 
presence of cytopathic effects (CPE) by observation under an inverted microscope. CPE was 
present in 100% of control wells that were set up in each plate with MVA but no serum. The 
SVN titer was defined as the inverse of the highest serum dilution that neutralized MVA in at 
least 1 of 2 wells. Serum samples that did not neutralize MVA at the lowest dilution (1:4) 
were assigned a titer of 2. When non-immunized cattle were tested for SVN activity, two 
serum samples were collected within two months of each other, and the mean of the two 
results was the final titer. 
Statistics. Statistical analyses were performed with IMP 5 software (SAS Institute Inc., 
Cary, NC). Student's T test was used to test for differences in group means. Bivariate 
analysis of SVN titer versus CD25 expression index was performed for each T cell subset. 
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Coefficient of determination (R2) values were computed for these relationships, and the 
statistical significance of each R2 value was determined by analysis of variance. For multiple 
comparisons among three treatments, the Tukey-Kramer HSD test was used. In the 
experiment where calves received MVA inoculations, SVN and CD25 data points collected 
at weeks 0, 7, and 11 were handled as distinct from one another. In the experiment where 
non-immunized calves were tested, mean SVN values from two bleedings were plotted 
versus mean CD25 expression index values from three bleedings; all samples were taken 
within a two-month period. 
RESULTS 
MVA-induced activation was frequently observed in T cells from conventionally reared 
Iowa cattle. This effect was quantified in a large number of animals when we carried out 
repeated four-color flow cytometry assays on MVÂ-stimulated PBMC from groups of 18 
Holstein calves (Group C) and 24 Angus calves (Group D). Data from Group C, which is 
representative of both groups, is displayed in Figure 1. Activation of CD4+ T cells in 
response to the virus was rare, and the level of CD25 expression induced in those cases was 
modest. Activation of CD8+ yô TCR T cells by MVA was observed somewhat more 
frequently, and in a few instances the magnitude of their CD25 expression was high. Both 
subsets of yô T cells (CD8+ and CD8") were more responsive than CD4+ T cells or CD8+ yô 
TCR" T cells. In particular, there was a high frequency of responses among the CD8" yô 
TCR+ T cell subset, with varying levels of CD25 expression. Responses by individual 
animals were rather variable among the four repeated assays, but there was a trend that 
FIGURE 1. T cell activation in response to MVA. PBMC from non-immunized cattle in 
Group C were incubated with MVA for four days. CD25 expression was measured in the 
major T cell subsets: CD4+ (A), CD8+ yô TCR" (B), CD8+ yô TCR+ (C), and CD8" yô TCR+ 
(D), by four-color flow cytometry. CD25 expression index values > 30 are plotted as 30 in 
the graphs. 
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responders could be distinguished from non-responders. 
MVA concentrations were titrated to examine dose dependency in PBMC from 34 calves. 
Three five-fold dilutions of MVA were tested: 5 x 102, 2.5 x 103, and 1.25 x 104 TCID50 / 
well. In all four T cell subsets, which were analyzed by three-color flow cytometry, CD25 
expression was elevated at the highest concentration of viral stimulus (Figure 2). In the CDS" 
yô TCR+ subset, which make up most of the yô T cells, this increase was particularly large. 
Apparently there is a rather narrow threshold of MVA concentration for the activation of yô 
T cells. There was variation among individuals with respect to reactivity, as some responded 
readily to virus at the two lower concentrations, whereas others only responded to the highest 
concentration. 
MVA viral antigen had been prepared from infected CEF. To help assess the virus 
specificity of T cell responses, stimulation by MVA was compared with stimulation by mock 
MVA prepared from uninfected CEF. PBMC from 27 calves (three from Group C and 24 
from Group D) were incubated with equal dilutions of the two stimuli and analyzed by four-
color flow cytometry (Table 1). The mean CD25 expression indices in response to mock 
antigen were less than 2.0 for all four subsets. Cells belonging to the CD4+, CD8+ yô TCR", 
and CD8+ yô TCR+ subsets had significantly higher mean CD25 expression in response to 
MVA stimulation (p < 0.01). The CD8" yô TCR+ T cells had a mean CD25 expression index 
greater than 10 in response to MVA, the highest among the four subsets. 
To further test for virus specificity, we compared the stimulatory effects of original MVA 
and semi-purified MVA (Figure 3). PBMC from five cattle were used in the assay, and both 
virus preparations were dosed at three ten-fold dilutions. Results from four-color flow 
cytometry showed that the two preparations had similar dose-dependent effects toward each 
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FIGURE 2. Dose response of bovine T cells to MVA. PBMC were isolated from 34 calves 
and incubated with three five-fold dilutions of MVA for four days. CD25 expression in each 
of the T cell subsets (CD4+, CD8+ yô TCR-, CD8+ yô TCR+, and CDS' 76 TCR+) was then 
analyzed by three-color flow cytometry. Error bars represent the standard error of the mean. 
Statistical differences were tested by Tukey-Kramer HSD test:a CD25 expression induced by 
virus at high titer (1.25 x 104 TGD50 / well) is significantly greater than by virus at low titer 
(5 x 102 TCID50 / well), p < 0.05. b CD25 expression induced by virus at high titer is 
significantly greater than by virus at medium titer (2.5 x 103 TCID50 / ml), p < 0.05. 
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TABLE 1. Virus specificity of T cell responses to MVA grown in CEF. 
CD25 Expression Indices Within Each T Cell Subset2 
Stimulus CD4+ CD8+ yô TCR" CD8+ yô TCR+ CD8" yô TCR+ 
MVA1 1.71 ±0.22 2.40 ± 0.40 4.80 ±1.09 10.41 ±2.04 
Mock MVA 1 0.93 ± 0.09 1.18 ±0.14 1.45 ±0.26 1.57 ±0.32 
1 MVA and mock MVA were used to stimulate PBMC isolated from 27 cattle. The two 
stimuli were added to PBMC cultures at equal dilutions. 
2 PBMC were analyzed by flow cytometry for CD25 expression in the four main T-cell 
subsets after four days of incubation. In each of the four subsets there was a statistically 
significant difference between stimulation with MVA virus and stimulation with mock MVA 
(Student's /-test, p < 0.01). 
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FIGURE 3. Effects of MVA virus purity on T cell stimulation. Original MVA lysate / 
sonicate was compared with MVA that was partially purified by ultacentrifugation on a 
density gradient. PBMC from five cattle were incubated with each virus preparation, or with 
no antigen, for four days. Error bars represent the standard error of the mean. 
subset of T cells, and the semi-purified MVA appeared somewhat more stimulatory. This 
suggests that the reactivity is not due to factors released by infected tissue culture cells 
during propagation of the virus. 
A serum virus neutralization (SVN) assay was designed to measure serological reactivity 
with MVA. MVA-positive sera were archived from the experiment in which calves (Group 
A) were inoculated with live MVA. Those calves were also tested for MVA-specific CD4+, 
CD8+, and 7Ô TCR+ T cell activation, using two-color flow cytometric analysis of CD25 
expression. Sera from all twelve inoculated calves, as well as three control calves, were 
tested one week before immunization, seven weeks after primary immunization (the day of 
secondary immunization), and eleven weeks after primary immunization. The humoral 
response to MVA inoculation resulted in geometric mean SVN titers of approximately 27 
and 256 at weeks 7 and 11, respectively (Figure 4). In control calves, SVN titers against 
MVA remained low or undetectable (data not shown). The seroconversion of the vaccinated 
animals corresponded with CD4+, CD8+, and 7Ô TCR+ T cell responses to MVA, which also 
increased substantially after immunization with the virus (Figure 4). CD4+ T cells showed 
evidence of a secondary response at week 11, which fits well with the apparent secondary 
SVN antibody response. The range of SVN titers measured by the assay was quite broad, 
with readings extending from 4 to 1024, which suggested high assay sensitivity. Bivariate 
analysis was performed to model linear fit between the log: transformed CD25 expression 
indices for CD4+, CD8+, and yô TCR+ T cells versus the corresponding log% transformed 
SVN titers. R2 values obtained for each of these models were modest: 0.25, 0.19, and 0.31, 
respectively. However, these correlations were statistically significant (p < 0.01). 
Next, the SVN assay was used to test 42 normal (non-MVA-inoculated) calves (Group C 
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FIGURE 4. Immune responses induced in calves following subcutaneous inoculation with 
MVA. Twelve calves each received 5xl08 TCID50 MVA. Booster doses of vaccine were 
administered at week 7. PBMC were incubated with MVA in vitro for five days and analyzed 
for CD25 upregulation on CD4+, CD8+, and yô TCR+ T cells by two-color flow cytometry. 
Serum samples were frozen and later tested for MVA neutralizing activity in CEF culture. 
Error bars represent the standard error of the mean. 
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and Group D) for serological reactivity with MVA. T cells from the same calves were also 
tested by four-color flow cytometry for responses to MVA (Figure 1). Therefore, any 
potential correlations between serological reactivity and T cell reactivity could be identified. 
The two sets of normal sera were collected two weeks apart, and in that low range of SVN 
titers there was not great consistency for individual animals from the first assay to the 
second. Most of the normal cattle (41/42) had a detectable level of serological reactivity with 
MVA in at least one of two serum samples. However, 17 of the normal cattle had 
undetectable reactivity in one of two samples. The mean log2 SVN titer for normal calves 
overall was 3.05, which is less than the titer present in calves after primary vaccination with 
MVA (Figure 4). With regard to normal cattle, no statistically significant correlation was 
found between SVN activity and CD25 responses by any subset of T cells. 
DISCUSSION 
It has been hypothesized that the complexity and large size of poxviruses tends to make 
them highly immunogenic or mitogenic, but that the wild-type poxviruses have adapted by 
encoding genes to interfere with the host immune response (4). These suppressive factors 
include soluble receptors for tumor necrosis factor-#, interleukin-1, and interferon-^; 
chemokine binding proteins, and vaccinia virus complement control protein (19). The 
attenuation of MVA is partly attributed to the loss of several soluble cytokine receptor genes 
(1). It is possible that some intrinsic immunostimulatory properties of pox viruses are 
"unveiled" in attenuated strains like MVA or in inactivated poxviruses. The results of a 
study examining the immunostimulatory properties of several viable and inactivated 
poxviruses were consistent with this notion (2). There it was shown that viable MVA 
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induced significant IFN-a production by PBMC from humans, sheep, and swine. In contrast, 
no detectable IFN-a was induced by equivalent doses of the less attenuated Elstree, Bern, and 
Copenhagen vaccinia strains. However, when Elstree strain vaccinia was inactivated with |8-
propiolactone it became a strong inducer of IFN-a It appears likely that a non-structural 
product (or set of products) from replicating, wild type poxviruses is able to suppress that 
host response. 
Fachinger et al. tested several inactivated poxvirus strains for a wider range of 
immunostimulatory properties toward porcine lymphocytes (4). They showed that 
chemically inactivated fowl poxvirus, parapox ovis virus, and MVA could all induce 
lymphocyte proliferation and the secretion of IL-2, IFN-a, and IFN-y. Flow cytometric 
analysis of lymphocytes demonstrated virus-induced CD25 and MHC class II upregulation, 
predominantly in the CD4+ subset of T cells. 
The results of our experiments with lymphocytes from young cattle indicate that bovine T 
cells are also responsive to stimulation by MVA. Responses by yô T cells were the greatest 
and most frequent. Most individuals upregulated CD25 expression on the surface of yô T 
cells in an MVA dose-dependent manner. Gamma delta T cells of cattle reportedly fall into 
two main phenotypes: a CD8+WC1" subset and a CD8"WC1+ subset that predominates in the 
periphery (12). We also observed CD8+ and CD8" subpopulations of yô T cells after 
incubation with or without MVA. The CDS" yô TCR+ subpopulation was much greater in 
number and generally more responsive to MVA. Gamma delta T cells make up a large 
proportion of the lymphocyte population in the blood in calves and other young ruminants (8, 
23). It is important to understand the interactions of yô T cells with MVA if the virus is to be 
used as a vector for bovine vaccines. The MVA dose-response curve of T cells from 
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presumably naïve cattle was interesting for at least two reasons. First, T cells belonging to 
the CD4+ and CD8+ yô TCR" subsets generally did not respond in parallel with the responses 
by 7Ô TCR+ T cells. In certain animals, CD4+ and CD8+ 7Ô TCR" T cells were activated upon 
incubation with MVA, but this was a fairly rare occurrence. Second, the multiplicity of 
infection (MOI) required to optimize T cell reactivity for these non-immunized animals 
(1.25x10"2) was more than an order of magnitude higher than the MOI that activated T cells 
from vaccinated calves (6.25x10"4). 
It was unclear whether the reactivity of bovine T cells with MVA was a result of adaptive 
immunity to some cross-reactive antigen or an innate response to the virus. An adaptive 
response seemed questionable because there are no recognized poxviruses circulating among 
North American cattle. We reasoned that serological reactivity with MVA would correlate 
with T cell reactivity if cattle had acquired antigen-specific immunity. Using a SVN assay 
that was developed and validated with sera from MVA-vaccinated cattle, we tested two sets 
of serum samples from 42 calves that had no known previous exposure to poxviruses. High 
sensitivity in the assay was achieved partly by using 10 TCID50 per well rather than the 
standard 100 TCID50. SVN titers were relatively low in these cattle, and they appeared 
somewhat unstable from the first assay to the second. These data might reflect fluctuations in 
non-antigen-specific serum contents, such as type 1 interferons or tumor necrosis factor-o. If 
the MVA-responsive T cells had been primed by exposure to a poxvirus or other cross-
reactive antigen, greater corresponding SVN titers would have been likely. 
Cross-reactivity with another virus (or viruses) is a potential explanation for the MVA-
reactive T cells and SVN titers observed in a high proportion of non-vaccinated cattle. It is 
possible that such cross-reactivity arises from exposure to papular stomatitis virus or 
pseudocowpoxviras. These are parapoxviruses with minor clinical significance that occur 
commonly in cattle worldwide (6). However, our observations of low serological reactivity 
with MVA and a general lack of reactivity by CD4+ and CD8+ 7Ô TCR" T cells suggest that 
the M V A-responsi veness of yô T cells is innate rather than acquired. There are several 
plausible mechanisms for this. One possibility is that the virus has mitogenic or 
superantigenic properties, causing polyclonal activation of lymphocytes. Another possibility 
is that pattern recognition receptors on lymphocytes bind to conserved poxvirus motifs and 
mediate activation. Alternatively, the virus could cause stress-induced molecules, such as 
heat-shock proteins, to be expressed on some subset of the PBMC. In this case, lymphocyte 
activation may result from pattern recognition receptors binding to those stress-induced 
molecules. Cells from some individual calves appeared more MVA-sensitive than others. 
Similarly, it was shown previously that inactivated parapox ovis virus stimulated varying 
degrees of proliferation by PBMC from different pigs (4). These results could be due to 
differences in the genetic makeup of individual animals, such as heterogeneity in major 
histocompatibility complex (MHC) types. For instance, if MVA has superantigenic activity, 
it is logical that cattle with different MHC types could have different levels of sensitivity to 
the virus. In conclusion, the use of MVA as a vector for genes from bovine pathogens is 
complicated by that virus' unexplained reactivity with host lymphocytes. While this 
reactivity hampers the use of recombinant MVA viruses as in vitro recall antigens, it is 
possible that it can provide a useful adjuvant effect in vivo. 
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Chapter 7. In Vitro Analysis of BRSV-Specific T Cell Priming in 
Vaccinated Cattle by a Multi-Parameter Flow Cytometry Assay for 
Activation and by ELIS A for Interferon-7 Production 
A paper to be submitted to Veterinary Immunology and Immunopathology 
Matthew R. Sandbulte and James A. Roth 
Abstract 
Immune responses to bovine respiratory syncytial virus (BRSV) were analyzed in calves 
that were inoculated with polyvalent modified-live and inactivated virus vaccines from 
commercial sources. In addition to standard serological assays for virus neutralization, 
antigen-specific T cell responses were monitored before, during, and after the vaccine 
regimen. The priming of T cells against BRSV was tested by a flow cytometry-based assay 
for CD25 upregulation in response to viral antigens in vitro. In this assay, the expression of 
CD4, CDS, 7Ô TCR, and CD25 were analyzed simultaneously on T cells from antigen-
stimulated peripheral blood mononuclear cell suspensions. Four phenotypes of T cells were 
analyzed: CD4+, CD8+ yô TCR", CD8+ yô TCR+, and CDS" yô TCR+. In addition, an ELISA 
was used to quantify the production of interferon-^ (IFN-7) in response to antigen. One 
treatment group received two doses of inactivated virus vaccine with adjuvant (n=6). A 
second treatment group received two doses of modified-live virus (MLV) vaccine. A control 
group was inoculated with saline solution (n=6). At the time of vaccination, calves were all 
seropositive to BRSV by virus neutralization, but naïve according to T cell responses, 
suggesting that the BRSV-specific antibody was of maternal origin. Both the inactivated 
virus and MLV vaccines primed T cells of all four subsets for BRSV-specific activation, and 
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inactivated vaccine induced a stronger T cell activation response and IFN-7 production than 
the MLV vaccine after the booster dose was administered. 
1. Introduction 
BRSV is a Paramyxovirus that causes mild to severe respiratory disease in cattle. It is one 
of several infectious agents of the bovine respiratory disease complex in young calves, which 
causes substantial economic losses. Replication of the virus is largely restricted to 
respiratory epithelial cells (Viuff et al., 1996). The cell-mediated branch of the bovine 
immune system plays a large part in recovery and protection from BRSV infection. During 
experimental infection of young calves, there was an influx of CD8+ T cells into the lungs, 
and pulmonary CD4+ and CD8+ T cells had increased expression of activation markers 
(Mclnnes et al., 1999). Under similar experimental conditions, MHC-restricted, BRSV-
specific cytotoxic T lymphocytes (CTL) were observed in the peripheral blood and lungs of 
infected calves (Gaddum et al., 1996). The depletion of T cell subsets from gnotobiotic 
calves prior to experimental BRSV challenge indicated that CD8+ T cells have an important 
role in the clearance of virus (Taylor et al., 1995). Pneumonic lesions were more extensive 
in individuals lacking CD4+ or CD8+ T cells. With regard to humoral immunity, there are 
data indicating that passive maternal antibody to BRSV can lessen the severity of infection 
(Kimman et al., 1988), as can BRSV-neutralizing monoclonal antibodies (Thomas et al., 
1998). 
Numerous efforts have been made to characterize the ability of MLV and inactivated 
vaccines to elicit antibody, cell-mediated immunity (CMI), and protection against BRSV 
challenge. Vaccines representing both forms have been shown to induce neutralizing 
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antibody to BRSV, but inactivated viruses often result in lower ratios of neutralizing 
antibody titer to ELISA-detectable IgG titer (Ellis et al., 1992b; Ellis et al., 1995; West and 
Ellis, 1997; Ellis et al., 2001). It has been known for some time that both categories of 
vaccine can prime lymphocytes for proliferative responses to BRSV (Ellis et al., 1992a; Ellis 
et al., 1995). A study that monitored in vitro correlates of CMI after vaccination with 
modified-live BRSV and after subsequent challenge indicated that protection was correlated 
with enhanced antigen-specific lymphocyte proliferation and EFN-7production (West et al., 
1999). One inactivated BRSV vaccine conferred significant clinical protection that 
corresponded with the priming of antigen-specific IFN-y production (Ellis et al., 2001). 
In a previous study, we partially characterized the in vitro T cell responses to BRSV that 
were primed by commercially available MLV and inactivated vaccines given to seronegative 
calves (Sandbulte and Roth, in press). Following vaccination, CD4+, CD8+, and y<5 TCR+ 
lymphocytes all upregulated activation marker CD25 during in vitro incubation with the 
virus. Results from an MHC class I blocking experiment suggested that the CD8+ T cell 
response was class I-restricted. There was no attempt to differentiate CD8+ 7Ô TCR~ T cells 
from CD8+ 76 TCR+ T cells. The latter phenotype occurs in a small proportion of bovine 
PBMC (MacHugh et al., 1997). Because responses by 78 TCR+ T cells tended to be high, it 
was uncertain whether any BRSV-responsive CD8+ T cells belonged to the cqS T cell 
category. 
In this study, we again analyzed cell-mediated and humoral responses to BRSV following 
immunization with two polyvalent vaccines. These were a MLV vaccine and an inactivated 
virus vaccine with adjuvant. One aim of the present study was to evaluate a different pair of 
commercial MLV and inactivated vaccines for efficacy in priming antibody and T cell 
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responses to BRSV in calves with pre-existing antibody titers. Other aims were to 
characterize the phenotypes of responding T cells more precisely and to monitor antigen-
specific DFN-y production as a parallel measure of T cell function. 
2. Materials and Methods 
2.1. Animals and Experimental Design 
Eighteen beef calves weighing approximately 300 kg were included in the study. At the 
time of vaccination they were approximately ten months of age. Calves were assigned 
randomly to three treatment groups (n=6). On day zero, commercial polyvalent vaccines 
were administered to two treatment groups. One group was inoculated with Triangle 4 + 
Type IIBVD, an inactivated virus vaccine containing BHV-1, BVDV type 1 and 2 strains, 
bovine respiratory syncytial virus (BRSV), parainfluenza virus 3, and a proprietary adjuvant 
(Fort Dodge Animal Health, Overland Park, KS). Another group was inoculated with 
Titanium™ 5, which is a MLV vaccine also consisting of BHV-1, BVDV types 1 and 2, 
BRSV, and PI-3 (Agri Laboratories, St. Joseph, MO). The control group received 
inoculations of saline solution. All inoculations were 2 ml given subcutaneously, in 
accordance with manufacturers' instructions. Three weeks later, booster doses of both 
vaccines were given to the respective treatment groups, and the control group received 
second doses of saline solution. All cattle were bled on six occasions, which included two 
times prior to primary vaccination (week -1 and week 0), the day of secondary vaccination 
(week 3), and three times after secondary vaccination (week 5, week 7, and week 9). Cattle 
were bled by jugular venipuncture, and blood for cell isolation was collected in acid citrate 
dextrose, while an additional sample was collected in serum separation tubes. Three adult 
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Holstein cattle that had received multiple vaccinations with Titanium 5 and demonstrated 
strong T cell responses to BRSV were used as positive control animals. 
2.2. Media and reagents. 
RPMI++ growth medium consisted ofRPMI 1640 with 2 mM L-glutamine and 25 mM 
HEPES buffer (Mediatech, Inc., Herndon, VA); 10% fetal bovine serum (bovine viral 
diarrhea virus-free, Atlanta Biologicals, Norcross, GA); and 1% penicillin / streptomycin 
solution (Mediatech), providing final concentrations of 100IU penicillin/ml and 100 /tg 
streptomycin/ml. PBS++ solution consisted of phosphate buffered saline (PBS) plus 0.5% 
bovine serum albumin and 0.1% sodium azide. Primary antibodies to bovine lymphocyte 
markers were purchased from VMRD (Pullman, WA). These murine immunoglobulins 
included anti-CD4 IgGl (CACTI38A), anti-CD8a IgM (BAQ111A), anti-yÔ TCR IgG2b 
(GB21A), and anti-CD25 IgG2a (CACTI08A). Goat anti-mouse IgGl-FITC and goat anti-
mouse IgG2a-PE secondary antibodies were purchased from Southern Biotechnology 
Associates (Birmingham, AL). Goat anti-mouse IgG2b-Tri-Color® and goat anti-mouse 
IgM-AlexaFluor® 647 secondary antibodies were purchased from Caltag Laboratories 
(Burlingame, CA) and Molecular Probes (Eugene, OR), respectively. 
2.3. Virus 
Live BRSV was used as the recall antigen for in vitro T cell response assays. It was 
obtained in the form of a monovalent modified-live BRSV vaccine (Bovi-Shield™ BRSV, 
Pfizer Animal Health, Exton, PA). Virus was reconstituted with manufacturer's diluent, 
aliquotted, and stored at -70° C. The virus was titrated prior to the experiment to determine 
the optimal dilution for in vitro activation of T cells from BRSV-immune cattle. 
2.4. In vitro T cell stimulation 
Peripheral blood samples were centrifuged at 800 x g for 20 minutes. Buffy coat layers 
were collected, and remaining erythrocytes were lysed by adding two volumes of buffered 
water for 1 minute and then restoring the suspension to normal osmolarity with one volume 
of triple strength PBS (Roth et al., 1982). The resulting suspension of peripheral blood 
mononuclear cells (PBMC) was pelleted by slow speed centrifugation (250 x g for 10 
minutes), resuspended in PBS, and treated with a second round of lysis. Then the PBMC 
were resuspended to 5 x 106 cells/ml in RPMI++ culture medium. In each well of a 96-well, 
flat-bottomed microtiter plate, 106 PBMC (200 fi\ of suspension) were combined with either 
50 [û of BRSV antigen diluted in Hanks balanced salt solution, 50 gl concanavalin A (ConA) 
solution (0.6 jug/well), or 50 /xl of plain diluent. Plates were incubated for four days at 39 °C 
in a humidified 5% CO2 atmosphere. After incubation, cells were transferred to round-
bottomed microtiter plates and centrifuged at 200 x g for 1 minute, allowing supernatants to 
be collected and stored at -20 °C. 
2.5. Flow cytometry 
Following the incubation period, four-color flow cytometry was used to analyze the 
reactivity of T cells with BRSV antigen or ConA. CD4, CD8a, and 7ÔTCR surface markers 
were detected simultaneously with CD25, a marker of activation. First, plates were chilled 
on ice 15 minutes. Then cells were washed three times with PBS++ before being labeled via 
an indirect antibody protocol. The primary antibodies were diluted together in PBS++, with 
anti-CD4 and -CD 8a diluted to 10 /xg/ml, and anti-yô TCR and -CD25 diluted to 1.3 fig/ml. 
Each well of a microtiter plate received 50 /-tl primary antibody mixture, and plates were 
incubated 30 minutes on ice, followed by three washes with PBS++. In the secondary 
antibody mixture, anti-IgGl, anti-IgG2a, anti-IgG2b, and anti-IgM were diluted to 2.5 /xg/ml, 
0.6 jug/ml, 0.5 fig/ml, and 10 fig/ml, respectively, in PBS++. Each well received 50 [Û 
secondary antibody mixture, and plates were incubated 30 minutes on ice, followed by three 
washes with plain PBS. Cells were fixed in a PBS solution with 1% formaldehyde. Four-
color analysis was performed using an Epics Altra cytometer (Beckman-Coulter). FITC, PE, 
and Tricolor dyes were excited by a 488 nm krypton laser, and AlexaFluor 647 was excited 
by a spatially separated 633 nm helium-neon laser. A gated amplifier was used to 
differentiate Tricolor and AlexaFluor 647 signals, which were detected in the same photo 
multiplier tube. Approximately 10,000 live lymphocyte events were analyzed per sample. 
Analysis of flow cytometry data was performed using Flow Jo software. The first step in 
analysis was gating out doublet events (clumps) according to their distribution in plots of 
peak forward scatter versus linear forward scatter. Then live lymphocytes were gated 
according to linear forward scatter and side scatter properties. Histograms for CD4 
expression were plotted directly from this gate. Plots of CD8 versus yô TCR were used to 
draw gates that delineated three separate T-cell subsets: CD8 single-positive, yô TCR single-
positive, and CD8 / yô TCR double-positive. Histograms of CD25 expression were drawn 
for each of the four subsets, and the percentage of cells expressing CD25 (%CD25+) was 
determined. Antigen-driven CD25 upregulation was calculated for each of the T cell subsets 
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using the A%CD25+ formula, which equals [(%CD25+ for cells incubated in the presence of 
stimulant) - (%CD25+ for control cells incubated in the absence of stimulant)]. 
2.6. Measurement of in vitro IFN-yproduction 
Supernatant samples collected from PBMC incubated with and without BRSV were 
thawed and mixed well. IFN-y concentrations in the supernatants were quantified with the 
Bovigam™ ELIS A test kit (Biocor Animal Health, Omaha, NE). The manufacturer's 
recommended protocol was followed, except that sample volumes were 25 fil instead of 50 
[il. A Vmax Microplate Reader (Molecular Devices, Sunnyvale, CA) was used to analyze 
optical density at a wavelength of 450 nm. A two-fold serial dilution of recombinant bovine 
IFN-y (Serotec, Oxford, UK) was used to calculate a linear standard curve for each ELISA 
plate. Data reported here are IFN-y protein concentrations derived from those curves. 
2.7. Serology 
Blood samples in serum separation tubes were centrifuged for 30 minutes at 1200 x g. 
Serum samples were removed and submitted to the Iowa State University Veterinary 
Diagnostic Laboratory where a routine serum virus neutralization (SVN) assay against BRSV 
was conducted. Each SVN titer was the reciprocal of the highest dilution that inhibited 100% 
of cytopathic effects in cell culture. 
2.8. Statistical analysis 
CD25 expression data from the six tests were expressed as A%CD25+ and grouped into 
three periods during the vaccination regimen. Period 1 included both pre-vaccination assays 
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(week -1 and week 0). Period 2 included only the week 3 assay, which was representative of 
responses to one dose of vaccine. Period 3 included all three assays performed after 
secondary vaccinations were administered: week 5, week 7, and week 9. Analysis of 
variance was performed using the general linear models (glm) procedure in SAS software 
(SAS Institute Inc., Cary, NC). For the first and third period, which included multiple 
assays, repeated measures analysis was performed by assigning "animal within treatment 
group" as the error term. Tests for differences in CD25 expression index among treatment 
groups were performed by the least squares means method. SVN data was log^-transfbrmed 
and analyzed by week, using standard ANOVA. In all statistical tests, significant differences 
between means were declared when P < 0.05. 
3. Results 
3.1. Serology 
Serum virus neutralization (SVN) titers were thus far obtained for three post-vaccination 
time points, at weeks 3, 5, and 7. Across the three assays, all calves in the non-vaccinated 
control group had antibody to BRSV (Figure 1). Since the calves were randomly distributed 
into treatment groups, it may be concluded that all of them were seropositive to BRSV prior 
to vaccination. Data from week 3 suggest that primary immunization with MLV versus 
inactivated virus vaccines caused similar increases in SVN titers. Data from weeks 5 and 7 
indicate that there was no increase in antibody titer after secondary vaccination. 
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Figure 1. Serum virus neutralization titers against BRSV. Control calves were inoculated 
with saline solution, whereas experimental groups were inoculated with two doses (weeks 0 
and 3) of inactivated virus vaccine or two doses of MLV vaccine. Error bars represent the 
standard error of the mean log2 SVN titer within a treatment group (n=6). Statistically 
significant differences between groups (P < 0.05) are denoted as follows: f MLV > Control; 
* Inactivated virus > Control. Double symbols denote P < 0.01. 
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3.2. T Cell Responses 
The four main subsets of T cells identified within cultured PBMC have the following 
phenotypes: CD4+, CD8+ yô TCR-, CD8+ yô TCR+, and CD8~ 7Ô TCR+. In PBMC cultures 
that were incubated in the absence of virus, the mean proportions of these subsets were 
27.8%, 11.9%, 1.9%, and 38.2%, respectively, during a representative assay of all 18 cattle. 
PBMC from positive control cattle were sampled and tested throughout the study for recall 
responses to live BRSV. CD25 expression was upregulated in all four subsets, as CD4+, 
CD8+ yô TCR", CD8+ 7Ô TCR+, and CD8" yô TCR+ T cells had A%CD25+ values across the 
study of 16.6 ± 3.0, 7.8 ± 1.6, 34.5 ± 5.3, and 35.0 ± 5.3 (mean ± standard error, n = 18), 
respectively. Each T cell subset, in each treatment group, had strong CD25 responses to 
ConA (A%CD25+ > 40) during each period (data not shown). 
T cell responsiveness to BRSV before, during, and after the vaccination regimens are 
illustrated by the CD25 expression data in Figure 2. Despite the fact that all calves were 
seropositive to BRSV, no significant T cell responses against the virus were detectable in any 
of the treatment groups before vaccination. After primary vaccination (Period 2), there were 
no significant differences between the MLV and inactivated virus vaccine groups in terms of 
T cell responses to BRSV, but one or both vaccine groups had higher responses than controls 
in the CD4+, CD8+ yô TCR-, and CD8+ 70 TCR+ subsets (P < 0.05). There was an apparent 
trend for T cell responses to increase in the inactivated virus vaccine group after secondary 
vaccination, but not in the MLV vaccine group. This led to statistically significant 
differences between the two vaccine groups in all subsets except CD8+ yô TCR" in Period 3 
(P < 0.05). Data on the capacity of PBMC for in vitro IFN-7 production in response to 
BRSV is presented in Figure 3. Increased IFN-7 production was apparent in BRSV-
Figure 2. 
T cell responsiveness to BRSV before, during, and after vaccination regimens. PBMC from 
control calves, calves inoculated with MLV vaccine, and calves inoculated with inactivated 
virus vaccine were incubated with and without BRSV antigen. After four days, CD25 
expression on the major T cell subsets was measured by four-color flow cytometry. 
A%CD25 was the difference in frequency of CD25 expression between BRSV-stimulated 
and non-stimulated samples. Period 1 of the experiment consisted of the week -1 and week 0 
timepoints. Period 2 consisted of the week 3 timepoint, representing the primary response to 
vaccines. Period 3 consisted of weeks 5, 7, and 9 - all timepoints after secondary 
immunization. Error bars represent the standard error of the mean within a treatment group. 
Statistically significant differences in CD25 expression between groups (P < 0.05, n = 6) are 
denoted as follows: j MLV > Control; * Inactivated virus > Control; $ Inactivated virus > 
MLV. Double symbols denote f < 0.01. 
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Figure 3. 
IFN-y production by BRSV-stimulated PBMC sampled before, during, and after vaccination 
regimens. Supematants collected from PBMC samples that were incubated with and without 
BRSV were later assayed by ELISA for levels of IFN-y The background IFN-y level 
observed in non-virus-stimulated samples was subtracted from the level observed in 
corresponding samples that were incubated with BRSV. Error bars represent the standard 
error of the mean within a treatment group. Statistically significant differences between 
groups (P < 0.05, n = 6) are denoted as follows: f MLV > Control; * Inactivated virus > 
Control; $ Inactivated virus > MLV. Double symbols denote f < 0.01. 
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stimulated cultures from the MLV and inactivated virus vaccine groups after primary 
vaccination, though not to levels significantly different from the controls (P > 0.05). After 
secondary vaccination, there was no indication of a further increase for the MLV group. In 
contrast, elevated IFN-7 was measured for the inactivated virus group, and this level was 
significantly greater than in either the MLV group or the controls (P < 0.05). 
4. Discussion 
The calves in this experiment had neutralizing antibodies to BRSV before vaccines were 
given. Since the calves lacked detectable BRSV-specific T cell immunity before 
immunization, it is likely that the antibodies were of maternal origin. The calves were 
approximately ten months of age at the time of vaccination. It is generally thought that 
maternal antibodies wane by the time calves reach that age, but there is little data in the 
literature addressing this issue for cattle. Interfering levels of maternal antibody to measles 
virus have been reported in human infants at nine months of age (Gans et al., 2001). An 
alternative explanation is that previous exposure to BRSV primed an active antibody 
response without leaving evidence of a CMI response. This scenario would complicate the 
interpretation of subsequent T cell responses, but mechanistically, it seems unlikely. We 
reported evidence of T cell priming against BRSV despite the lack of an antibody response in 
calves that were apparently exposed to BRSV in the face of maternal antibody (Sandbulte 
and Roth, 2002). 
For immunization against BRSV, both the MLV and inactivated virus vaccines are 
recommended by their manufacturers to be administered in two doses, two to four weeks 
apart. These are typical guidelines for BRSV immunization using commercial MLV and 
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inactivated virus vaccines. In contrast, only one dose of MLV is typically recommended for 
immunization against bovine viral diarrhea virus, bovine herpesvirus 1, and parainfluenza 
virus 3. Since the calves in this study were seropositive to BRSV, pre-existing antibodies 
might have inhibited the replication of modified-live BRSV. 
After primary immunization, increased responsiveness to BRSV was observed in T cells 
from calves that received either of the vaccines. Both vaccine treatments led to statistically 
significant responses by CD8+ yô TCR- T cells, and significant CD4+ and CD8+ yô TCR+ T 
cell responses were also induced by the inactivated virus vaccine (P < 0.05). In Period 3, 
which encompassed the three timepoints after secondary immunization, CD25 expression 
levels were higher in the inactivated virus vaccine group than the MLV vaccine group for all 
four T cell subsets. Secondary immunization with inactivated virus vaccine led to elevated 
BRSV-responsiveness in all T cell subsets except CD8+ yô TCR- T cells. In contrast, there 
was no evidence of a booster effect by the second dose of MLV. As a result, there were 
statistically significant differences between the inactivated virus and MLV treatments groups 
in all T cell subsets except CD8+ yô TCR- T cells during Period 3. The second dose of MLV 
also failed to increase the capacity of PBMC for IFN-y production. The lack of a booster 
effect by MLV contradicts results from another study, in which two doses of modified-live 
BRSV induced higher levels of virus specific lymphocyte proliferation and IFN-y production 
than one dose (West et al., 1999), though statistical significance was not indicated in those 
comparisons. 
The trend for inactivated BRSV to induce stronger cellular immunity than MLV supports 
findings from our earlier vaccine study with BRSV-naïve calves (Sandbulte and Roth, in 
press), even though different adjuvanted, inactivated vaccines were used in the two studies. 
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In the earlier study, CD8+ T cell responses to BRSV were among the T cell responses 
detected, and there was evidence that responding CD8+ T cells were MHC I-restricted. This 
went against the concept that MHC I-restricted T cells are only primed by endogenous 
antigens. One drawback with our earlier findings was that CD8+ ot@ T cells were not 
differentiated from CD8+ y<5 T cells, leaving doubt as to whether the responding CD8+ T cells 
belonged to the subset normally associated with CTL activity. In the present study, 
activation assays were performed by four-color flow cytometry, which allowed CD8+ yô 
TCR" cells to be distinguished from CD8+ yô TCR+ cells. Results from this assay confirmed 
significant recall responses by CD8+ yô TCR- (presumably oj3 TCR+) cells after 
immunization with inactivated BRSV. 
Also in this study, we examined IFN-y production as an in vitro indicator of T cell 
priming. This property was shown to correlate statistically with clinical protection from 
BRSV challenge in another vaccine study (West et al., 1999). In the present experiment, 
BRSV-induced IFN-y production followed a kinetic course similar to CD25 expression in 
CD4+ and other T cells. The data not only shows that this inactivated BRSV vaccine is 
capable of priming for IFN-y production, which was reported for a similar commercial 
vaccine (Ellis et al., 2001), but indicated that it may in fact be superior to a particular MLV 
vaccine in that regard. Formalin-inactivated human RSV (FI-HRSV) and BRSV (FI-BRSV) 
vaccines, both with alum adjuvant, have been shown to exacerbate disease upon subsequent 
infection (Kim et al., 1969; Gershwin et al., 1998). It has been theorized that such vaccines 
skew the immune response toward a T helper 2 (Th2) bias, thus undermining the important 
CTL response and promoting the recruitment of granulocytes to the lung (Graham et al., 
2000). An older theory proposes that non-neutralizing antibodies elicited by formalin-
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inactivated RSV is a root cause because they are non-protective yet favor type III 
hypersensitivity reactions (Murphy et al., 1986). Calves that received a FI-BRSV vaccine 
developed non-neutralizing antibody to the virus and weak IFN-7 responses during 
subsequent virus challenge, results which appear to fit both theories (Gershwin et al., 1998; 
Woolums et al., 1999). The strong IFN-7 response observed after vaccination with 
inactivated BRSV vaccine in the present study, combined with the fact that CD8+ T cells 
were primed against the virus, suggests that this commercial vaccine does not have Th2-
biasing properties. SVN antibody responses in this study are complicated by the fact that 
calves were seropositive at vaccination, but our earlier study indicated that an inactivated 
BRSV vaccine could induce SVN titers as high as a MLV vaccine (Sandbulte and Roth, in 
press). Taken together, these findings offer assurance that some commercial inactivated 
BRSV vaccines are low risks for disease enhancement. 
The effectiveness of an inactivated BRSV vaccine in driving T cell responses, particularly 
by CD8+ 70 TCR" T cells that potentially correspond with CTL, is contrary to dogma. It is 
generally understood that CD8+ T cells are only primed by an antigen that is processed and 
presented through the endogenous pathway, as with components of intracellular pathogens. 
The antigen cross presentation mechanism attributed to professional antigen presenting cells 
offers one potential way for inactivated BRSV to access the endogenous pathway (Kurts, 
2000). Certain adjuvants may have properties that facilitate antigen crossing into the 
cytoplasm (Vogel, 2000). Aside from these general possibilities, it is possible that 
Paramyxoviruses have unique properties that favor their antigen presentation to naïve T cells, 
even when inactivated. Heat-inactivated Sendai virus, which is also a member of this virus 
family, was shown to prime for CTL responses in mice (Liu et al., 1995). One could 
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speculate that the fusion (F) and attachment (G) glycoproteins retain a conformation, even 
when virions are inactivated, that mediates entry across the plasma membrane of a host cell. 
A different line of thought was opened by a recent study that compared the effects of live and 
inactivated BRSV on bovine monocyte-derived dendritic cells in vitro (Werling et al., 2002). 
Incubating live BRSV with the dendritic cells led to greater IL-10 gene transcription, but less 
transcription of IL-12p40 and IL-15 genes than inactivated virus. If such a scenario is also 
true in vivo, it is conceivable that inactivated BRSV antigen creates a microenvironment that 
is more favorable to priming Thl-type T cell responses than live BRSV. 
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Chapter 8. General Conclusions 
Discussion. 
The studies described in this dissertation have generated several novel findings about 
immune responses to bovine respiratory syncytial virus (BRSV) in calves. New knowledge 
has been gained about the immunostimulatory effects of several vaccines and about the 
influence of pre-existing antibody upon immune responses to BRSV vaccines and natural 
BRSV exposure. Progress was also made in understanding interactions between bovine 
lymphocytes and modified vaccinia virus Ankara (MVA), which is a potential vector for 
BRSV vaccines. 
In the first project, which is described in Chapter 4, it was learned that T cells could be 
primed against BRSV independently of an antibody response. In certain calves, CD4+, 
CD8+, and yô TCR+ T cells were sensitive to activation by in vitro exposure to BRSV, even 
though no neutralizing antibody or IgG specific for the virus were detectable. Furthermore, 
upon vaccinating calves with modified-live BRSV, individuals with primed T cells were able 
to mount anamnestic virus neutralizing antibody responses. It would be consistent with these 
results that a natural BRSV infection had occurred in those calves in the face of maternal 
antibody, leading to suppressed antibody production but normal T cell priming. An 
important implication of this work is that seronegative calves should not be considered to be 
immunologically naïve to BRSV. Another potentially important impact of this discovery is 
that seroconversion may not need to be seen as a necessary correlate for effective 
immunization. Functional immunity to BRSV might be achievable by vaccinating calves at 
younger ages, while maternal antibody to BRSV is still predominant. 
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The priming of CD4+, CD8+, and 7Ô TCR+ T cells by modified-live and inactivated virus 
vaccines given to BRSV -seronegative calves was investigated in the second major project, 
which is described in Chapter 5. This work showed that commercial BRSV vaccines 
belonging to both categories are capable of priming all three phenotypes of T cells for in 
vitro recall responses. The data indicated that T cell responses to an adjuvanted, inactivated 
BRSV vaccine can in fact be higher and longer-lasting than responses to modified-live virus 
(MLV). Of particular interest was the priming of CD8+ T cells, because the inactivated virus 
vaccine induced at least as strong a response in that subset as MLV. Data obtained with cells 
from an animal in the inactivated virus vaccine group indicated that the in vitro recall 
response by CD8+ T cells was MHC class I dependent. Data demonstrating yô TCR+ T cell 
responses to the vaccines tested in this experiment (and others within the dissertation) 
provide new knowledge to the field, as well. The author is not aware of other studies that 
monitored the priming of bovine yô TCR+ T cells in response to BRSV vaccines or infection. 
Whether these cells contribute to protective immunity against BRSV is uncertain, but these 
results suggest that previously reported lymphocyte blastogenesis data for CMI responses to 
BRSV probably reflected a considerable amount of yô T cell activity. 
The interactions of MVA with bovine lymphocytes were the focus of studies in the third 
project, which is described in Chapter 6. MVA could potentially be used as a vaccine vector 
for BRSV genes, as it has been used to vector genes from many pathogens. It was learned 
that young calves inoculated with recombinant MVA constructs would develop CD4+, CD8+, 
and yô TCR+ T cell responses and neutralizing antibody titers to the MVA backbone. More 
surprisingly, it was also learned that T cells from many normal (non-MVA-immunized) cattle 
are activated by incubation with a relatively high level of MVA. This phenomenon was most 
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often observed in y5 TCR+ T cells. Low, fluctuating titers of MVA neutralizing activity were 
measured in sera from some normal cattle, but it was not clear that this was due to antibody 
from a previous exposure to a poxvirus. No statistical correlation was found between T cell 
sensitivity and serum neutralizing activity to MVA. The observations of seemingly "innate" 
reactivity by bovine T cells with MVA may have practical importance. This reactivity might 
lend an adjuvant effect to recombinant vaccines for BRSV or other targets. However, it is 
also a drawback to experiments in which recombinant MVAs would be used as in vitro recall 
antigens to probe for recall responses to individually vectored proteins. Our experience 
indicated that the vector-specific T cell response tends to create a background that causes 
difficulty in detecting responses to the heterologous protein. 
The fourth project, which is described in chapter 7, expanded upon the earlier study of T 
cell responses to modified-live and inactivated BRSV vaccines. Whereas the calves tested in 
the prior study were seronegative to BRSV, the ones tested this time had low to moderate 
levels of serum virus neutralizing antibody, presumably of maternal origin, at the time of 
vaccination. As before, a modified-live and an adjuvanted, inactivated BRSV vaccine were 
evaluated in this experiment, but both of them were obtained from different commercial 
sources than in the previous experiment. Using a flow cytometry system that could measure 
overlap in the expression of CD8 and yô TCR, it was possible to discern the two single-
positive subsets from each other and from the double-positive subset. It was determined that 
vaccines could prime for in vitro activation of CD4+, CD8+ yô TCR-, CD8+ yô TCR+, and 
CD8- yô TCR+ T cells in response to BRSV in the presence of pre-existing antibody. 
Statistically significant responses by the latter three subsets were measured in calves 
receiving either form of vaccine. It is valuable to know that in vitro CD8+ T cell responses to 
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BRSV following immunization with inactivated virus are representative of both the CD8+ yd 
TCR" and CD8+ y5 TCR+ phenotypes. If all of the response had been attributable to CD8+ 76 
TCR+ T cells, then it would have been doubtful that any classical cytotoxic T lymphocyte 
precursors were primed by the vaccine. Another key finding from this study was that 
vaccines prime for BRSV-specific IFN-7 production, and this activity corresponded rather 
closely with in vitro CD25 expression in T cells. 
Recommendations for further research. 
Quantifying the reactivity of various types of T cells with BRSV at the in vitro level, as 
was done in the studies of this dissertation, is a promising approach to monitoring immune 
responses. The techniques that my colleagues and I have developed and reported upon 
should be adequate to follow up with some useful and interesting experiments. The concept 
of T cell priming in the presence of passive antibody should be pursued in more depth. The 
studies described in Chapter 4 offered circumstantial evidence that infection in the face of 
maternal antibody had led to T cell priming without antibody production, but the concept was 
not proven. A good experimental design would be to feed newborn calves defined amounts 
of pooled colostrum from seropositive and seronegative dams before vaccination at an early 
age. Modified-live and inactivated BRSV vaccines should both be tested, since the latter is 
thought to be less sensitive to passive antibody interference. Antibody titers and in vitro T 
cell responses should be monitored until the point when passive antibody has waned. B cell 
priming should also be monitored by a flow cytometry-based assay similar to that used for T 
cells. Then a challenge infection or secondary immunization can be administered to test the 
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hypothesis that CMI and anamnestic antibody responses to BRSV can be primed in calves 
with high maternal antibody titers. 
In terms of making long term progress in understanding BRSV immunity, more in-depth 
methods will be important. It will be very difficult to draw firm conclusions about vaccine 
effectiveness until there have been more comprehensive studies that draw associations 
between T cell activation, T cell effector functions, and protection from challenge infection. 
Challenge studies have demonstrated fairly conclusively that CD8+ cytotoxic T 
lymphocytes (CTL) are a vital part of protective immunity, and that aspect of immunity 
should be a major focus of research to come. Traditional CTL assays are cumbersome for 
monitoring immunity in large numbers of cattle. It would be worthwhile to invest in studies 
to link CTL activity with parameters that can be tested more efficiently. Ideally, the assay 
we already developed for CD25 expression on CD8+ T cells would be sufficient. However, 
other antigen-driven responses by CD8+ T cells may correlate better. Good candidates would 
be IFN-y or granzyme production, which could be analyzed by flow cytometry. 
At this point, the literature is lacking in studies that tested the roles of CD4+ helper T cells 
and yd T cells in protecting cattle from virulent challenge. An area of particular interest for 
studying these cells would be the production of cytokines, such as IL-4, IL-5, EL-10, and 
IFN-y. The cytokines produced by helper T cells and yô T cells might reflect shifts in the 
Thl-Th2 balance and help to predict the development of protective versus pathogenic 
immune responses. An attractive method for analyzing cytokine production within the 
distinct T cell subsets would be with intracellular staining and flow cytometry. 
Innate immune cells are likely to be important in the induction of immune responses to 
BRSV infection or vaccination. The potency of adjuvanted, inactivated BRSV vaccines in 
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priming for T cell responses, as described in parts of this dissertation, is indirect evidence 
that early stimulation of innate immune cells might be highly influential. Studying the 
dendritic cells (DC) and natural killer (NK) cells immediately following exposure to BRSV 
could lead to a better understanding of their roles, and help to predict development of 
protective immunity. Sampling these cells would probably be most successful in lymph or 
draining lymph nodes. Useful in vitro parameters for testing DC might include the uptake of 
viral antigen, modulation of co-stimulatory molecules, and production of IL-12 or 
chemokines. Useful parameters for testing NK cells might include upregulation of activation 
markers, production of DFN-7, and cytotoxicity. 
Given successful methods for testing some of these additional parameters, a series of 
powerful experiments could follow. Modified-live and inactivated virus vaccines, plus any 
number of new-generation recombinant vaccines could be administered to cattle and 
followed up with challenge infection. A few experimental models of BRSV infection were 
reported in recent years to cause virulent infection in calves, and would be ideal tools for this 
purpose. Presumably, there would be differences between vaccine treatments in terms of the 
in vitro immune responses that they prime for. Discovering which of those parameters 
correlate positively and negatively with the severity of disease would greatly facilitate 
continuing progress in the design and evaluation of new BRSV vaccines. 
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